5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide
| Title | Journal |
|---|---|
| The synthetic cannabinoid XLR-11 induces in vitro nephrotoxicity by impairment of endocannabinoid-mediated regulation of mitochondrial function homeostasis and triggering of apoptosis. | Toxicology letters 20180501 |
| WWL70 attenuates PGE(2) production derived from 2-arachidonoylglycerol in microglia by ABHD6-independent mechanism. | Journal of neuroinflammation 20170101 |
| Parabens inhibit fatty acid amide hydrolase: A potential role in paraben-enhanced 3T3-L1 adipocyte differentiation. | Toxicology letters 20161116 |
| Cannabinoid receptor interacting protein suppresses agonist-driven CB(1) receptor internalization and regulates receptor replenishment in an agonist-biased manner. | Journal of neurochemistry 20161101 |
| In Vivo Characterization of the Ultrapotent Monoacylglycerol Lipase Inhibitor {4-[bis-(benzo[d][1,3]dioxol-5-yl)methyl]-piperidin-1-yl}(1H-1,2,4-triazol-1-yl)methanone (JJKK-048). | The Journal of pharmacology and experimental therapeutics 20161001 |
| Endogenous 2-Arachidonoylglycerol Alleviates Cyclooxygenases-2 Elevation-Mediated Neuronal Injury From SO2 Inhalation via PPARγ Pathway. | Toxicological sciences : an official journal of the Society of Toxicology 20151001 |
| Pharmacological modulation of the endocannabinoid signalling alters binge-type eating behaviour in female rats. | British journal of pharmacology 20130601 |
| Modeling alcohol self-administration in the human laboratory. | Current topics in behavioral neurosciences 20130101 |
| Qualitative screening for adulterants in weight-loss supplements by ion mobility spectrometry. | Journal of pharmaceutical and biomedical analysis 20121201 |
| Structural analogs of pyrazole and sulfonamide cannabinoids: effects on acute food intake in mice. | European journal of pharmacology 20121115 |
| Rimonabant improves obesity but not the overall cardiovascular risk and quality of life; results from CARDIO-REDUSE (CArdiometabolic Risk reDuctIOn by Rimonabant: the Effectiveness in Daily practice and its USE). | Family practice 20121001 |
| Recent advances in the pathophysiology and pharmacological treatment of obesity. | Journal of clinical pharmacy and therapeutics 20121001 |
| The effects of fasting duration on gastric emptying in man, an exploration of the role of the endocannabinoid system and inter-individual responsiveness. | Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society 20121001 |
| AM-251 and rimonabant act as direct antagonists at mu-opioid receptors: implications for opioid/cannabinoid interaction studies. | Neuropharmacology 20121001 |
| NESS038C6, a novel selective CB1 antagonist agent with anti-obesity activity and improved molecular profile. | Behavioural brain research 20121001 |
| Acute myocardial infarction inhibits the neurogenic tachycardic and vasopressor response in rats via presynaptic cannabinoid type 1 receptor. | The Journal of pharmacology and experimental therapeutics 20121001 |
| Evaluation of the endogenous cannabinoid system in mediating the behavioral effects of dipyrone (metamizol) in mice. | Behavioural pharmacology 20121001 |
| JD-5006 and JD-5037: peripherally restricted (PR) cannabinoid-1 receptor blockers related to SLV-319 (Ibipinabant) as metabolic disorder therapeutics devoid of CNS liabilities. | Bioorganic & medicinal chemistry letters 20121001 |
| [Effect of metabolic drugs on the secretion of acylation stimulating protein in 3T3-L1 adipocytes]. | Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology 20121001 |
| 7-Alkyl-3-benzylcoumarins: a versatile scaffold for the development of potent and selective cannabinoid receptor agonists and antagonists. | Journal of medicinal chemistry 20120927 |
| Angiotensin II induces vascular endocannabinoid release, which attenuates its vasoconstrictor effect via CB1 cannabinoid receptors. | The Journal of biological chemistry 20120907 |
| Fatty acid flux and oxidation are increased by rimonabant in obese women. | Metabolism: clinical and experimental 20120901 |
| Cannabinol and cannabidiol exert opposing effects on rat feeding patterns. | Psychopharmacology 20120901 |
| Cannabinoid receptors mediate methamphetamine induction of high frequency gamma oscillations in the nucleus accumbens. | Neuropharmacology 20120901 |
| Reports of the death of CB1 antagonists have been greatly exaggerated: recent preclinical findings predict improved safety in the treatment of obesity. | Behavioural pharmacology 20120901 |
| Selective cannabinoid-1 receptor blockade benefits fatty acid and triglyceride metabolism significantly in weight-stable nonhuman primates. | American journal of physiology. Endocrinology and metabolism 20120901 |
| Contrasting effects of different cannabinoid receptor ligands on mouse ingestive behaviour. | Behavioural pharmacology 20120901 |
| Hypothalamic CB1 cannabinoid receptors regulate energy balance in mice. | Endocrinology 20120901 |
| Second generation CB1 receptor blockers and other inhibitors of peripheral endocannabinoid overactivity and the rationale of their use against metabolic disorders. | Expert opinion on investigational drugs 20120901 |
| Anandamide regulates the expression of GnRH1, GnRH2, and GnRH-Rs in frog testis. | American journal of physiology. Endocrinology and metabolism 20120815 |
| Effect of CB1 receptor blockade on food-reinforced responding and associated nucleus accumbens neuronal activity in rats. | The Journal of neuroscience : the official journal of the Society for Neuroscience 20120815 |
| Interactions between dopamine transporter and cannabinoid receptor ligands in rhesus monkeys. | Psychopharmacology 20120801 |
| In silico investigation of interactions between human cannabinoid receptor-1 and its antagonists. | Journal of molecular modeling 20120801 |
| Inhibition of forebrain μ-opioid receptor signaling by low concentrations of rimonabant does not require cannabinoid receptors and directly involves μ-opioid receptors. | Neurochemistry international 20120801 |
| Antidepressant-like effects of Δ⁹-tetrahydrocannabinol and rimonabant in the olfactory bulbectomised rat model of depression. | Pharmacology, biochemistry, and behavior 20120801 |
| Inhibition of fatty acid amide hydrolase by URB597 attenuates the anxiolytic-like effect of acetaminophen in the mouse elevated plus-maze test. | Behavioural pharmacology 20120801 |
| Cannabinoid receptor 1 in the vagus nerve is dispensable for body weight homeostasis but required for normal gastrointestinal motility. | The Journal of neuroscience : the official journal of the Society for Neuroscience 20120725 |
| Activation of type 5 metabotropic glutamate receptors and diacylglycerol lipase-α initiates 2-arachidonoylglycerol formation and endocannabinoid-mediated analgesia. | The Journal of neuroscience : the official journal of the Society for Neuroscience 20120711 |
| Effects induced by cannabinoids on monoaminergic systems in the brain and their implications for psychiatric disorders. | Progress in neuro-psychopharmacology & biological psychiatry 20120702 |
| Effect of delta-9-tetrahydrocannabinol on behavioral despair and on pre- and postsynaptic serotonergic transmission. | Progress in neuro-psychopharmacology & biological psychiatry 20120702 |
| Cannabinoid CB₁ receptor restrains accentuated activity of hypothalamic corticotropin-releasing factor and brainstem tyrosine hydroxylase neurons in endotoxemia-induced hypophagia in rats. | Neuropharmacology 20120701 |
| Photoperiodic changes in endocannabinoid levels and energetic responses to altered signalling at CB1 receptors in Siberian hamsters. | Journal of neuroendocrinology 20120701 |
| Genetic dissection of the role of cannabinoid type-1 receptors in the emotional consequences of repeated social stress in mice. | Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20120701 |
| Hyperalgesia by low doses of the local anesthetic lidocaine involves cannabinoid signaling: an fMRI study in mice. | Pain 20120701 |
| Involvement of a non-CB1/CB2 cannabinoid receptor in the aqueous humor outflow-enhancing effects of abnormal-cannabidiol. | Experimental eye research 20120701 |
| Effects of palmitoylethanolamide on aqueous humor outflow. | Investigative ophthalmology & visual science 20120701 |
| Presynaptic CB(1) cannabinoid receptors control frontocortical serotonin and glutamate release--species differences. | Neurochemistry international 20120701 |
| Long-term depression of nociceptive synapses by non-nociceptive afferent activity: role of endocannabinoids, Ca²+, and calcineurin. | Brain research 20120615 |
| Design, synthesis, and pharmacological characterization of indol-3-ylacetamides, indol-3-yloxoacetamides, and indol-3-ylcarboxamides: potent and selective CB2 cannabinoid receptor inverse agonists. | Journal of medicinal chemistry 20120614 |
| Association study of cannabinoid receptor 1 (CNR1) gene in tardive dyskinesia. | The pharmacogenomics journal 20120601 |
| Molecular mechanisms of diabetes and atherosclerosis: role of adiponectin. | Endocrine, metabolic & immune disorders drug targets 20120601 |
| Ibipinabant attenuates β-cell loss in male Zucker diabetic fatty rats independently of its effects on body weight. | Diabetes, obesity & metabolism 20120601 |
| Cannabinoids and atherosclerotic coronary heart disease. | Clinical cardiology 20120601 |
| A systematic review and mixed treatment comparison of pharmacological interventions for the treatment of obesity. | Obesity reviews : an official journal of the International Association for the Study of Obesity 20120601 |
| Methamphetamine-induced dopamine terminal deficits in the nucleus accumbens are exacerbated by reward-associated cues and attenuated by CB1 receptor antagonism. | Neuropharmacology 20120601 |
| Cannabinoids ameliorate disease progression in a model of multiple sclerosis in mice, acting preferentially through CB1 receptor-mediated anti-inflammatory effects. | Neuropharmacology 20120601 |
| Rimonabant abolishes sensitivity to workload changes in a progressive ratio procedure. | Pharmacology, biochemistry, and behavior 20120601 |
| Addition of a low dose of rimonabant to orlistat therapy decreases weight gain and reduces adiposity in dietary obese rats. | Clinical and experimental pharmacology & physiology 20120601 |
| Pleiotropic effects of rimonabant and simvastatin on obesity associated multiple metabolic risk factors in rats. | European review for medical and pharmacological sciences 20120601 |
| Dual fatty acid amide hydrolase and monoacylglycerol lipase blockade produces THC-like Morris water maze deficits in mice. | ACS chemical neuroscience 20120516 |
| CB(1) antagonism restores hepatic insulin sensitivity without normalization of adiposity in diet-induced obese dogs. | American journal of physiology. Endocrinology and metabolism 20120515 |
| Exploiting transport activity of p-glycoprotein at the blood-brain barrier for the development of peripheral cannabinoid type 1 receptor antagonists. | Molecular pharmaceutics 20120507 |
| Endocannabinoids stimulate human melanogenesis via type-1 cannabinoid receptor. | The Journal of biological chemistry 20120504 |
| Effects of chronic oral rimonabant administration on energy budgets of diet-induced obese C57BL/6 mice. | Obesity (Silver Spring, Md.) 20120501 |
| Anti-obesity drugs: a review about their effects and their safety. | Expert opinion on drug safety 20120501 |
| CB1 receptor antagonists: new discoveries leading to new perspectives. | Acta physiologica (Oxford, England) 20120501 |
| Food and Drug Administration's Obesity Drug Guidance Document: a short history. | Circulation 20120501 |
| Allosteric modulator ORG27569 induces CB1 cannabinoid receptor high affinity agonist binding state, receptor internalization, and Gi protein-independent ERK1/2 kinase activation. | The Journal of biological chemistry 20120406 |
| The cannabinoid CB1 receptor antagonists rimonabant (SR141716) and AM251 directly potentiate GABA(A) receptors. | British journal of pharmacology 20120401 |
| The endocannabinoid system in the rat dorsolateral periaqueductal grey mediates fear-conditioned analgesia and controls fear expression in the presence of nociceptive tone. | British journal of pharmacology 20120401 |
| Clozapine impairs insulin action by up-regulating Akt phosphorylation and Ped/Pea-15 protein abundance. | Journal of cellular physiology 20120401 |
| The GPCR-associated sorting protein 1 regulates ligand-induced down-regulation of GPR55. | British journal of pharmacology 20120401 |
| Tonic regulation of GABAergic synaptic activity on vasopressin neurones by cannabinoids. | Journal of neuroendocrinology 20120401 |
| Exogenous and endogenous cannabinoids suppress inhibitory neurotransmission in the human neocortex. | Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20120401 |
| Inhibitory inputs from rostromedial tegmental neurons regulate spontaneous activity of midbrain dopamine cells and their responses to drugs of abuse. | Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20120401 |
| Cannabinoid CB1 receptor activation, pharmacological blockade, or genetic ablation affects the function of the muscarinic auto- and heteroreceptor. | Naunyn-Schmiedeberg's archives of pharmacology 20120401 |
| [The potential use of cannabidiol in the therapy of metabolic syndrome]. | Orvosi hetilap 20120401 |
| Design and synthesis of cannabinoid receptor 1 antagonists for peripheral selectivity. | Journal of medicinal chemistry 20120322 |
| [The pharmacological treatment of obesity: past, present and future]. | Orvosi hetilap 20120311 |
| FAT SIGNALS--lipases and lipolysis in lipid metabolism and signaling. | Cell metabolism 20120307 |
| Antagonism of peripheral hepatic cannabinoid receptor-1 improves liver lipid metabolism in mice: evidence from cultured explants. | Hepatology (Baltimore, Md.) 20120301 |
| The CB1 receptor antagonist rimonabant controls cell viability and ascitic tumour growth in mice. | Pharmacological research 20120301 |
| Effects of the anandamide uptake blocker AM404 on food intake depend on feeding status and route of administration. | Pharmacology, biochemistry, and behavior 20120301 |
| Endogenous cannabinoid system regulates intestinal barrier function in vivo through cannabinoid type 1 receptor activation. | American journal of physiology. Gastrointestinal and liver physiology 20120301 |
| Some cannabinoid receptor ligands and their distomers are direct-acting openers of SUR1 K(ATP) channels. | American journal of physiology. Endocrinology and metabolism 20120301 |
| Does rimonabant independently affect free fatty acid and glucose metabolism? | The Journal of clinical endocrinology and metabolism 20120301 |
| Sex differences in cannabinoid 1 vs. cannabinoid 2 receptor-selective antagonism of antinociception produced by delta9-tetrahydrocannabinol and CP55,940 in the rat. | The Journal of pharmacology and experimental therapeutics 20120301 |
| Reversal of liver fibrosis by the antagonism of endocannabinoid CB1 receptor in a rat model of CCl(4)-induced advanced cirrhosis. | Laboratory investigation; a journal of technical methods and pathology 20120301 |
| Blockade of cannabinoid receptor 1 improves insulin resistance, lipid metabolism, and diabetic nephropathy in db/db mice. | Endocrinology 20120301 |
| Changes in cannabinoid receptor subtype 1 activity and interaction with metabotropic glutamate subtype 5 receptors in the periaqueductal gray-rostral ventromedial medulla pathway in a rodent neuropathic pain model. | CNS & neurological disorders drug targets 20120301 |
| The serine hydrolases MAGL, ABHD6 and ABHD12 as guardians of 2-arachidonoylglycerol signalling through cannabinoid receptors. | Acta physiologica (Oxford, England) 20120201 |
| Involvement of the endocannabinoid system in reward processing in the human brain. | Psychopharmacology 20120201 |
| Involvement of opioid system in cognitive deficits induced by ∆⁹-tetrahydrocannabinol in rats. | Psychopharmacology 20120201 |
| Rimonabant reduces the essential value of food in the genetically obese Zucker rat: an exponential demand analysis. | Physiology & behavior 20120201 |
| 3-Substituted pyrazole analogs of the cannabinoid type 1 (CB₁) receptor antagonist rimonabant: cannabinoid agonist-like effects in mice via non-CB₁, non-CB₂ mechanism. | The Journal of pharmacology and experimental therapeutics 20120201 |
| Rimonabant for neurocognition in schizophrenia: a 16-week double blind randomized placebo controlled trial. | Schizophrenia research 20120201 |
| Cannabinoid CB1 receptor mediates glucocorticoid effects on hormone secretion induced by volume and osmotic changes. | Clinical and experimental pharmacology & physiology 20120201 |
| Latest advances in novel cannabinoid CB(2) ligands for drug abuse and their therapeutic potential. | Future medicinal chemistry 20120201 |
| Blurred boundaries: the therapeutics and politics of medical marijuana. | Mayo Clinic proceedings 20120201 |
| Inflammatory cause of metabolic syndrome via brain stress and NF-κB. | Aging 20120201 |
| Anti-Obesity Drugs: A Review about Their Effects and Safety. | Diabetes & metabolism journal 20120201 |
| Blocking the postpartum mouse dam's CB1 receptors impairs maternal behavior as well as offspring development and their adult social-emotional behavior. | Behavioural brain research 20120115 |
| The inverse agonist effect of rimonabant on G protein activation is not mediated by the cannabinoid CB1 receptor: evidence from postmortem human brain. | Biochemical pharmacology 20120115 |
| Δ9-Tetrahydrocannabinol attenuates MDMA-induced hyperthermia in rhesus monkeys. | Neuroscience 20120110 |
| SK channel modulation rescues striatal plasticity and control over habit in cannabinoid tolerance. | Nature neuroscience 20120108 |
| Modulation of L-α-lysophosphatidylinositol/GPR55 mitogen-activated protein kinase (MAPK) signaling by cannabinoids. | The Journal of biological chemistry 20120102 |
| Innate difference in the endocannabinoid signaling and its modulation by alcohol consumption in alcohol-preferring sP rats. | Addiction biology 20120101 |
| Effects of 7 days of treatment with the cannabinoid type 1 receptor antagonist, rimonabant, on emotional processing. | Journal of psychopharmacology (Oxford, England) 20120101 |
| Cannabinoid receptor stimulation increases motivation for nicotine and nicotine seeking. | Addiction biology 20120101 |
| CB1 receptor antagonism/inverse agonism increases motor system excitability in humans. | European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology 20120101 |
| The changes in plasma retinol-binding protein 4 levels are associated with those of the apolipoprotein B-containing lipoproteins during dietary and drug treatment. | Angiology 20120101 |
| The endocannabinoid system in anxiety, fear memory and habituation. | Journal of psychopharmacology (Oxford, England) 20120101 |
| CB1 - cannabinoid receptor antagonist effects on cortisol in cannabis-dependent men. | The American journal of drug and alcohol abuse 20120101 |
| Magnesium deficiency induces anxiety and HPA axis dysregulation: modulation by therapeutic drug treatment. | Neuropharmacology 20120101 |
| Immunoregulation of experimental autoimmune encephalomyelitis by the selective CB1 receptor antagonist. | Journal of neuroscience research 20120101 |
| Rimonabant attenuates amphetamine sensitisation in a CCK2 receptor-dependent manner. | Behavioural brain research 20120101 |
| Expression of fatty acid amide hydrolase (FAAH) in human, mouse, and rat urinary bladder and effects of FAAH inhibition on bladder function in awake rats. | European urology 20120101 |
| JWH-018 and JWH-073: Δ⁹-tetrahydrocannabinol-like discriminative stimulus effects in monkeys. | The Journal of pharmacology and experimental therapeutics 20120101 |
| The effects of chronic administration of tranylcypromine and rimonabant on behaviour and protein expression in brain regions of the rat. | Pharmacology, biochemistry, and behavior 20120101 |
| Detection of hazardous weight-loss substances in adulterated slimming formulations using ultra-high-pressure liquid chromatography with diode-array detection. | Food additives & contaminants. Part A, Chemistry, analysis, control, exposure & risk assessment 20120101 |
| Does innovation in obesity drugs affect stock markets? An event study analysis. | Gaceta sanitaria 20120101 |
| Central and peripheral cannabinoid receptors as therapeutic targets in the control of food intake and body weight. | Handbook of experimental pharmacology 20120101 |
| Stress hormones receptors in the amygdala mediate the effects of stress on the consolidation, but not the retrieval, of a non aversive spatial task. | PloS one 20120101 |
| Pharmacological interventions in the treatment of the acute effects of cannabis: a systematic review of literature. | Harm reduction journal 20120101 |
| Amyloid precursor protein and proinflammatory changes are regulated in brain and adipose tissue in a murine model of high fat diet-induced obesity. | PloS one 20120101 |
| Randomized, double-blind, placebo-controlled, linear dose, crossover study to evaluate the efficacy and safety of a green coffee bean extract in overweight subjects. | Diabetes, metabolic syndrome and obesity : targets and therapy 20120101 |
| Effects of a selective cannabinoid CB2 agonist and antagonist on intravenous nicotine self administration and reinstatement of nicotine seeking. | PloS one 20120101 |
| Lipidomics reveals multiple pathway effects of a multi-components preparation on lipid biochemistry in ApoE*3Leiden.CETP mice. | PloS one 20120101 |
| What is the clinical effectiveness and cost-effectiveness of using drugs in treating obese patients in primary care? A systematic review. | Health technology assessment (Winchester, England) 20120101 |
| Endocannabinoids and the processing of value-related signals. | Frontiers in pharmacology 20120101 |
| Decreased reward sensitivity in rats from the Fischer344 strain compared to Wistar rats is paralleled by differences in endocannabinoid signaling. | PloS one 20120101 |
| Short- and long-term cognitive effects of chronic cannabinoids administration in late-adolescence rats. | PloS one 20120101 |
| Decreased prevalence of diabetes in marijuana users: cross-sectional data from the National Health and Nutrition Examination Survey (NHANES) III. | BMJ open 20120101 |
| Serum contents of endocannabinoids are correlated with blood pressure in depressed women. | Lipids in health and disease 20120101 |
| Gut Hormones and Appetite Control: A Focus on PYY and GLP-1 as Therapeutic Targets in Obesity. | Gut and liver 20120101 |
| Differences in spontaneously avoiding or approaching mice reflect differences in CB1-mediated signaling of dorsal striatal transmission. | PloS one 20120101 |
| Alterations to melanocortinergic, GABAergic and cannabinoid neurotransmission associated with olanzapine-induced weight gain. | PloS one 20120101 |
| The endocannabinoid transport inhibitor AM404 differentially modulates recognition memory in rats depending on environmental aversiveness. | Frontiers in behavioral neuroscience 20120101 |
| The endocannabinoid system: an overview. | Frontiers in behavioral neuroscience 20120101 |
| Do placebo response rates from cessation trials inform on strength of addictions? | International journal of environmental research and public health 20120101 |
| Combination Drug Therapy for Pain following Chronic Spinal Cord Injury. | Pain research and treatment 20120101 |
| Reversible disruption of pre-pulse inhibition in hypomorphic-inducible and reversible CB1-/- mice. | PloS one 20120101 |
| Desipramine inhibits histamine H1 receptor-induced Ca2+ signaling in rat hypothalamic cells. | PloS one 20120101 |
| CNR1 genotype influences HDL-cholesterol response to change in dietary fat intake. | PloS one 20120101 |
| A novel method for determination of drug distribution in rat brain tissue sections by LC/MS/MS: functional tissue microanalysis. | Current topics in medicinal chemistry 20120101 |
| Update on the role of cannabinoid receptors after ischemic stroke. | Mediators of inflammation 20120101 |
| Public health concerns for anti-obesity medicines imported for personal use through the internet: a cross-sectional study. | BMJ open 20120101 |
| Dysfunction in fatty acid amide hydrolase is associated with depressive-like behavior in Wistar Kyoto rats. | PloS one 20120101 |
| Role of Gut-Related Peptides and Other Hormones in the Amelioration of Type 2 Diabetes after Roux-en-Y Gastric Bypass Surgery. | ISRN endocrinology 20120101 |
| RP-HPLC Method Development and Its Validation for Quantitative Determination of Rimonabant in Human Plasma. | Journal of analytical methods in chemistry 20120101 |
| Effects of cannabinoid receptor agonist WIN 55,212-2 on blood-brain barrier disruption in focal cerebral ischemia in rats. | Pharmacology 20120101 |
| Induction of glucose intolerance by acute administration of rimonabant. | Pharmacology 20120101 |
| On the Role of Cannabinoid CB1- and μ-Opioid Receptors in Motor Impulsivity. | Frontiers in pharmacology 20120101 |
| Endocannabinoid modulation of dopaminergic motor circuits. | Frontiers in pharmacology 20120101 |
| Metabolic effects of n-3 PUFA as phospholipids are superior to triglycerides in mice fed a high-fat diet: possible role of endocannabinoids. | PloS one 20120101 |
| Antipsychotic profile of cannabidiol and rimonabant in an animal model of emotional context processing in schizophrenia. | Current pharmaceutical design 20120101 |
| Antipsychotic-like effects of cannabidiol and rimonabant: systematic review of animal and human studies. | Current pharmaceutical design 20120101 |
| The endocannabinoid system and schizophrenia: integration of evidence. | Current pharmaceutical design 20120101 |
| Effect of anti-obesity drug on cardiovascular risk factors: a systematic review and meta-analysis of randomized controlled trials. | PloS one 20120101 |
| Targeted inactivation of GPR26 leads to hyperphagia and adiposity by activating AMPK in the hypothalamus. | PloS one 20120101 |
| Relationships between glucose, energy intake and dietary composition in obese adults with type 2 diabetes receiving the cannabinoid 1 (CB1) receptor antagonist, rimonabant. | Nutrition journal 20120101 |
| Homology modelling of CB1 receptor and selection of potential inhibitor against Obesity. | Bioinformation 20120101 |
| Coordinated improvement in glucose tolerance, liver steatosis and obesity-associated inflammation by cannabinoid 1 receptor antagonism in fat Aussie mice. | International journal of obesity (2005) 20111201 |
| Retinol-binding protein 4 : a possible role in cardiovascular complications. | British journal of pharmacology 20111201 |
| Inhibition of cerebral type 1 cannabinoid receptors is associated with impaired auditory mismatch negativity generation in the ketamine model of schizophrenia. | Psychopharmacology 20111201 |
| Naloxone and rimonabant reduce the reinforcing properties of exercise in rats. | Experimental and clinical psychopharmacology 20111201 |
| Endocannabinoids and prostaglandins both contribute to GnRH neuron-GABAergic afferent local feedback circuits. | Journal of neurophysiology 20111201 |
| Characterization of a novel, brain-penetrating CB1 receptor inverse agonist: metabolic profile in diet-induced obese models and aspects of central activity. | Naunyn-Schmiedeberg's archives of pharmacology 20111201 |
| Centrally mediated antinociceptive effects of cannabinoid receptor ligands in rat models of nociception. | Pharmacology, biochemistry, and behavior 20111201 |
| Cannabinoid receptor 1 (CB1) antagonism enhances glucose utilisation and activates brown adipose tissue in diet-induced obese mice. | Diabetologia 20111201 |
| ANKK1/DRD2 locus variants are associated with rimonabant efficacy in aiding smoking cessation: pilot data. | Journal of investigative medicine : the official publication of the American Federation for Clinical Research 20111201 |
| Positron emission tomographic imaging of the cannabinoid type 1 receptor system with [¹¹C]OMAR ([¹¹C]JHU75528): improvements in image quantification using wild-type and knockout mice. | Molecular imaging 20111201 |
| Prescribed drugs and violence: a case/noncase study in the French PharmacoVigilance Database. | European journal of clinical pharmacology 20111101 |
| Rimonabant, a cannabinoid receptor type 1 inverse agonist, inhibits hepatocyte lipogenesis by activating liver kinase B1 and AMP-activated protein kinase axis downstream of Gα i/o inhibition. | Molecular pharmacology 20111101 |
| Perinatal exposure to Δ9-tetrahydrocannabinol triggers profound defects in T cell differentiation and function in fetal and postnatal stages of life, including decreased responsiveness to HIV antigens. | The Journal of pharmacology and experimental therapeutics 20111101 |
| Large size cells in the visceral adipose depot predict insulin resistance in the canine model. | Obesity (Silver Spring, Md.) 20111101 |
| Effects of the cannabinoid antagonist SR 141716 on sexual and motor behaviour in receptive female rats. | Clinical and experimental pharmacology & physiology 20111101 |
| A role for the ventral hippocampal endocannabinoid system in fear-conditioned analgesia and fear responding in the presence of nociceptive tone in rats. | Pain 20111101 |
| 1-Aryl-5-(1H-pyrrol-1-yl)-1H-pyrazole-3-carboxamide: an effective scaffold for the design of either CB1 or CB2 receptor ligands. | European journal of medicinal chemistry 20111101 |
| Negative inotropic effect of a CB2 agonist A-955840 in isolated rabbit ventricular myocytes is independent of CB1 and CB2 receptors. | Current drug safety 20111101 |
| Genetic deletion of monoacylglycerol lipase alters endocannabinoid-mediated retrograde synaptic depression in the cerebellum. | The Journal of physiology 20111015 |
| The endocannabinoid 2-arachidonoylglycerol mediates D1 and D2 receptor cooperative enhancement of rat nucleus accumbens core neuron firing. | Neuroscience 20111013 |
| CRIP1a switches cannabinoid receptor agonist/antagonist-mediated protection from glutamate excitotoxicity. | Neuroscience letters 20111010 |
| Nonopioid placebo analgesia is mediated by CB1 cannabinoid receptors. | Nature medicine 20111002 |
| delta(9)-Tetrahydrocannabinol-dependent mice undergoing withdrawal display impaired spatial memory. | Psychopharmacology 20111001 |
| Activation by 2-arachidonoylglycerol of platelet p38MAPK/cPLA2 pathway. | Journal of cellular biochemistry 20111001 |
| Cannabinoid CB1 receptor antagonist rimonabant disrupts nicotine reward-associated memory in rats. | Pharmacology, biochemistry, and behavior 20111001 |
| Pro-epileptic effects of the cannabinoid receptor antagonist SR141716 in a model of audiogenic epilepsy. | Epilepsy research 20111001 |
| Bioactivation pathways of the cannabinoid receptor 1 antagonist rimonabant. | Drug metabolism and disposition: the biological fate of chemicals 20111001 |
| Fatty acid amide hydrolase blockade attenuates the development of collagen-induced arthritis and related thermal hyperalgesia in mice. | Pharmacology, biochemistry, and behavior 20111001 |
| The G protein-coupled cannabinoid-1 (CB1) receptor of mammalian brain: inhibition by phthalate esters in vitro. | Neurochemistry international 20111001 |
| The central cannabinoid CB1 receptor is required for diet-induced obesity and rimonabant's antiobesity effects in mice. | Obesity (Silver Spring, Md.) 20111001 |
| CNS opioid signaling separates cannabinoid receptor 1-mediated effects on body weight and mood-related behavior in mice. | Endocrinology 20111001 |
| Antagonist-elicited cannabis withdrawal in humans. | Journal of clinical psychopharmacology 20111001 |
| Towards rational design of cannabinoid receptor 1 (CB1) antagonists for peripheral selectivity. | Bioorganic & medicinal chemistry letters 20111001 |
| Retention and extinction of delay eyeblink conditioning are modulated by central cannabinoids. | Learning & memory (Cold Spring Harbor, N.Y.) 20111001 |
| Neuropsychiatric adverse effects of centrally acting antiobesity drugs. | CNS neuroscience & therapeutics 20111001 |
| Cannabinoid 1 G protein-coupled receptor (periphero-)neutral antagonists: emerging therapeutics for treating obesity-driven metabolic disease and reducing cardiovascular risk. | Expert opinion on drug discovery 20111001 |
| [The role of the cannabinoid system in the pathogenesis and treatment of alcohol dependence]. | Postepy higieny i medycyny doswiadczalnej (Online) 20110916 |
| Activation of spinal and supraspinal cannabinoid-1 receptors leads to antinociception in a rat model of neuropathic spinal cord injury pain. | Brain research 20110915 |
| Fluorinated cannabinoid CB2 receptor ligands: synthesis and in vitro binding characteristics of 2-oxoquinoline derivatives. | Bioorganic & medicinal chemistry 20110915 |
| Hedonic and incentive signals for body weight control. | Reviews in endocrine & metabolic disorders 20110901 |
| The fatty acid amide hydrolase inhibitor URB 597: interactions with anandamide in rhesus monkeys. | British journal of pharmacology 20110901 |
| The D2 antagonist sulpiride modulates the neural processing of both rewarding and aversive stimuli in healthy volunteers. | Psychopharmacology 20110901 |
| Extinction learning of rewards in the rat: is there a role for CB1 receptors? | Psychopharmacology 20110901 |
| Enhancement of endocannabinoid signaling with JZL184, an inhibitor of the 2-arachidonoylglycerol hydrolyzing enzyme monoacylglycerol lipase, produces anxiolytic effects under conditions of high environmental aversiveness in rats. | Pharmacological research 20110901 |
| Dissimilar cannabinoid substitution patterns in mice trained to discriminate Δ(9)-tetrahydrocannabinol or methanandamide from vehicle. | Behavioural pharmacology 20110901 |
| Safety of new medicines in young children. | Archives of disease in childhood 20110901 |
| Cannabinergic aminoalkylindoles, including AM678=JWH018 found in 'Spice', examined using drug (Δ(9)-tetrahydrocannabinol) discrimination for rats. | Behavioural pharmacology 20110901 |
| Direct injection of lipophilic compounds in the organic phase from liquid-liquid extracted plasma samples onto a reversed-phase column. | Bioanalysis 20110901 |
| Structure-activity relationship studies of novel pyrazole and imidazole carboxamides as cannabinoid-1 (CB1) antagonists. | Bioorganic & medicinal chemistry letters 20110815 |
| Investigations on the 4-quinolone-3-carboxylic acid motif. 4. Identification of new potent and selective ligands for the cannabinoid type 2 receptor with diverse substitution patterns and antihyperalgesic effects in mice. | Journal of medicinal chemistry 20110811 |
| Current and future drug targets in weight management. | Pharmaceutical research 20110801 |
| CB1 receptors mediate rimonabant-induced pruritic responses in mice: investigation of locus of action. | Psychopharmacology 20110801 |
| Central mediation and differential blockade by cannabinergics of the discriminative stimulus effects of the cannabinoid CB1 receptor antagonist rimonabant in rats. | Psychopharmacology 20110801 |
| Differential effect of opioid and cannabinoid receptor blockade on heroin-seeking reinstatement and cannabinoid substitution in heroin-abstinent rats. | British journal of pharmacology 20110801 |
| Increasing endogenous 2-arachidonoylglycerol levels counteracts colitis and related systemic inflammation. | FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20110801 |
| Memory encoding in hippocampal ensembles is negatively influenced by cannabinoid CB1 receptors. | Behavioural pharmacology 20110801 |
| [Pharmacological concepts for the treatment of obesity - a therapeutic meander?]. | Deutsche medizinische Wochenschrift (1946) 20110801 |
| Progress in structure based drug design for G protein-coupled receptors. | Journal of medicinal chemistry 20110714 |
| The use of an improved intragastric balloon technique to reduce weight in pre-obese patients--preliminary results. | Obesity surgery 20110701 |
| CB-1 receptors modulate the effect of the selective serotonin reuptake inhibitor, citalopram on extracellular serotonin levels in the rat prefrontal cortex. | Neuroscience research 20110701 |
| Species independence in brain tissue binding using brain homogenates. | Drug metabolism and disposition: the biological fate of chemicals 20110701 |
| Rimonabant redux and strategies to improve the future outlook of CB1 receptor neutral-antagonist/inverse-agonist therapies. | Obesity (Silver Spring, Md.) 20110701 |
| Diacylglycerol lipase-alpha and -beta control neurite outgrowth in neuro-2a cells through distinct molecular mechanisms. | Molecular pharmacology 20110701 |
| Cannabinoid type 1 receptor antagonists modulate transport activity of multidrug resistance-associated proteins MRP1, MRP2, MRP3, and MRP4. | Drug metabolism and disposition: the biological fate of chemicals 20110701 |
| Effect of rimonabant on carotid intima-media thickness (CIMT) progression in patients with abdominal obesity and metabolic syndrome: the AUDITOR Trial. | Heart (British Cardiac Society) 20110701 |
| Tolerance and cross-tolerance to cannabinoids in mice: schedule-controlled responding and hypothermia. | Psychopharmacology 20110601 |
| Effects of morphine on pain-elicited and pain-suppressed behavior in CB1 knockout and wildtype mice. | Psychopharmacology 20110601 |
| Cannabinoid 1 receptor activation contributes to vascular inflammation and cell death in a mouse model of diabetic retinopathy and a human retinal cell line. | Diabetologia 20110601 |
| Disruptive effects of the prototypical cannabinoid Δ⁹-tetrahydrocannabinol and the fatty acid amide inhibitor URB-597 on go/no-go auditory discrimination performance and olfactory reversal learning in rats. | Behavioural pharmacology 20110601 |
| Propofol enhances memory formation via an interaction with the endocannabinoid system. | Anesthesiology 20110601 |
| Rimonabant improves cholesterol, insulin resistance and markers of non-alcoholic fatty liver in morbidly obese patients: a retrospective cohort study. | International journal of clinical practice 20110601 |
| Risk of depressive episodes with rimonabant: a before and after modified prescription event monitoring study conducted in England. | Drug safety 20110601 |
| The development and description of the comparison group in the Look AHEAD trial. | Clinical trials (London, England) 20110601 |
| Leptin potentiates the anti-obesity effects of rimonabant. | European journal of pharmacology 20110511 |
| The endogenous cannabinoid 2-arachidonoylglycerol is intravenously self-administered by squirrel monkeys. | The Journal of neuroscience : the official journal of the Society for Neuroscience 20110511 |
| Cannabinoid receptor activation modifies NMDA receptor mediated release of intracellular calcium: implications for endocannabinoid control of hippocampal neural plasticity. | Neuropharmacology 20110501 |
| Cannabinoid potentiation of glycine receptors contributes to cannabis-induced analgesia. | Nature chemical biology 20110501 |
| The hypothermic response to bacterial lipopolysaccharide critically depends on brain CB1, but not CB2 or TRPV1, receptors. | The Journal of physiology 20110501 |
| Personalized medicine can pave the way for the safe use of CB₁ receptor antagonists. | Trends in pharmacological sciences 20110501 |
| N-(4-cyanotetrahydro-2H-pyran-4-yl) and N-(1-cyanocyclohexyl) derivatives of 1,5-diarylpyrazole-3-carboxamides showing high affinity for 18 kDa translocator protein and/or cannabinoid receptors. | Journal of medicinal chemistry 20110428 |
| Acute treatment with cannabinoid receptor agonist WIN55212.2 improves prepulse inhibition in psychosocially stressed mice. | Behavioural brain research 20110415 |
| The endogenous cannabinoid anandamide shares discriminative stimulus effects with ∆(9)-tetrahydrocannabinol in fatty acid amide hydrolase knockout mice. | European journal of pharmacology 20110410 |
| An straightforward entry to new pyrazolo-fused dibenzo[1,4]diazepines. | Organic & biomolecular chemistry 20110407 |
| Design, synthesis and biological evaluation of CB1 cannabinoid receptor ligands derived from the 1,5-diarylpyrazole scaffold. | Journal of enzyme inhibition and medicinal chemistry 20110401 |
| Binding properties of antagonists to cannabinoid receptors in intact cells. | Fundamental & clinical pharmacology 20110401 |
| Sensitization to cocaine is inhibited after intra-accumbal GR103691 or rimonabant, but it is enhanced after co-infusion indicating functional interaction between accumbens D(3) and CB1 receptors. | Psychopharmacology 20110401 |
| Additive effects of cannabinoid CB1 receptors blockade and cholecystokinin on feeding inhibition. | Pharmacology, biochemistry, and behavior 20110401 |
| Pharmacology of GPR55 in yeast and identification of GSK494581A as a mixed-activity glycine transporter subtype 1 inhibitor and GPR55 agonist. | The Journal of pharmacology and experimental therapeutics 20110401 |
| Pharmacokinetic optimisation of novel indole-2-carboxamide cannabinoid CB1 antagonists. | Bioorganic & medicinal chemistry letters 20110401 |
| Cannabinoids inhibit insulin receptor signaling in pancreatic β-cells. | Diabetes 20110401 |
| Discovery of indole alkaloids with cannabinoid CB1 receptor antagonistic activity. | Bioorganic & medicinal chemistry letters 20110401 |
| Feedback and lessons from the prescription of rimonabant, a drug to be used under strict guidelines, in southeastern France, March 2007 through June 2008. | Revue d'epidemiologie et de sante publique 20110401 |
| Central endocannabinoid signaling regulates hepatic glucose production and systemic lipolysis. | Diabetes 20110401 |
| Investigations of the endocannabinoid system in adipose tissue: effects of obesity/ weight loss and treatment options. | Danish medical bulletin 20110401 |
| Gemcitabine/cannabinoid combination triggers autophagy in pancreatic cancer cells through a ROS-mediated mechanism. | Cell death & disease 20110401 |
| Newer molecules in the treatment of schizophrenia: A clinical update. | Indian journal of pharmacology 20110401 |
| Effect of Argyreia speciosa root extract on cafeteria diet-induced obesity in rats. | Indian journal of pharmacology 20110401 |
| [Anandamide inhibits the growth of colorectal cancer cells through CB1 and lipid rafts]. | Zhonghua zhong liu za zhi [Chinese journal of oncology] 20110401 |
| Endocannabinoid 2-arachidonoylglycerol protects neurons against β-amyloid insults. | Neuroscience 20110331 |
| Cannabinoid type 1 receptor antagonists for smoking cessation. | The Cochrane database of systematic reviews 20110316 |
| Pharmacological activation of kainate receptors drives endocannabinoid mobilization. | The Journal of neuroscience : the official journal of the Society for Neuroscience 20110302 |
| Effect of the cannabinoid receptor-1 antagonist rimonabant on inflammation in mice with diet-induced obesity. | Obesity (Silver Spring, Md.) 20110301 |
| Nigrostriatal denervation changes the effect of cannabinoids on subthalamic neuronal activity in rats. | Psychopharmacology 20110301 |
| Evaluation of the emotional phenotype and serotonergic neurotransmission of fatty acid amide hydrolase-deficient mice. | Psychopharmacology 20110301 |
| Role of the endocannabinoid system in food intake, energy homeostasis and regulation of the endocrine pancreas. | Pharmacology & therapeutics 20110301 |
| Weight loss induced by rimonabant is associated with an altered leptin expression and hypothalamic leptin signaling in diet-induced obese mice. | Behavioural brain research 20110301 |
| Chronic Δ⁹-tetrahydrocannabinol treatment in rhesus monkeys: differential tolerance and cross-tolerance among cannabinoids. | British journal of pharmacology 20110301 |
| Inhibition of endocannabinoid catabolic enzymes elicits anxiolytic-like effects in the marble burying assay. | Pharmacology, biochemistry, and behavior 20110301 |
| Ligand-induced internalization of the orexin OX(1) and cannabinoid CB(1) receptors assessed via N-terminal SNAP and CLIP-tagging. | British journal of pharmacology 20110301 |
| Central and peripheral endocannabinoids and cognate acylethanolamides in humans: association with race, adiposity, and energy expenditure. | The Journal of clinical endocrinology and metabolism 20110301 |
| Effect of rimonabant on oesophageal motor function in man. | Alimentary pharmacology & therapeutics 20110301 |
| Altered Mesolimbic Dopamine System in THC Dependence. | Current neuropharmacology 20110301 |
| Commentary: Functional Neuronal CB2 Cannabinoid Receptors in the CNS. | Current neuropharmacology 20110301 |
| [Long-term effects of weight-reducing drugs in hypertensive patients--a survey of a Cochrane review]. | Ugeskrift for laeger 20110221 |
| Rise and fall of anti-obesity drugs. | World journal of diabetes 20110215 |
| Effects of cannabinoid CB₁ receptor antagonist rimonabant on acquisition and reinstatement of psychostimulant reward memory in mice. | Behavioural brain research 20110202 |
| Conditioned cues for smoking elicit preparatory responses in healthy smokers. | Psychopharmacology 20110201 |
| Effects of drugs of abuse on putative rostromedial tegmental neurons, inhibitory afferents to midbrain dopamine cells. | Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20110201 |
| Purine receptor-mediated endocannabinoid production and retrograde synaptic signalling in the cerebellar cortex. | British journal of pharmacology 20110201 |
| Three-dimensional quantitative structure-selectivity relationships analysis guided rational design of a highly selective ligand for the cannabinoid receptor 2. | European journal of medicinal chemistry 20110201 |
| Effects of the cannabinoid-1 receptor antagonist rimonabant on psychiatric symptoms in overweight people with schizophrenia: a randomized, double-blind, pilot study. | Journal of clinical psychopharmacology 20110201 |
| An overview of the metabolic effects of rimonabant in randomized controlled trials: potential for other cannabinoid 1 receptor blockers in obesity. | Journal of clinical pharmacy and therapeutics 20110201 |
| Pharmacotherapy for obese adolescents. | Pediatric clinics of North America 20110201 |
| IVUS-based imaging modalities for tissue characterization: similarities and differences. | The international journal of cardiovascular imaging 20110201 |
| Assessment of coronary atherosclerosis by IVUS and IVUS-based imaging modalities: progression and regression studies, tissue composition and beyond. | The international journal of cardiovascular imaging 20110201 |
| Structural and pharmacological analysis of O-2050, a putative neutral cannabinoid CB(1) receptor antagonist. | European journal of pharmacology 20110125 |
| The putative cannabinoid receptor GPR55 defines a novel autocrine loop in cancer cell proliferation. | Oncogene 20110113 |
| The identification of rimonabant polymorphs, sibutramine and analogues of both in counterfeit Acomplia bought on the internet. | Journal of pharmaceutical and biomedical analysis 20110105 |
| The CB₁ receptor antagonist SR141716A reverses adult male mice overweight and metabolic alterations induced by early stress. | Obesity (Silver Spring, Md.) 20110101 |
| The CB-1 receptor antagonist rimonabant modulates the interaction between adipocytes and pancreatic beta-cells in vitro. | Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association 20110101 |
| The CB2 cannabinoid receptor-selective agonist O-3223 reduces pain and inflammation without apparent cannabinoid behavioral effects. | Neuropharmacology 20110101 |
| Rimonabant reduces keratinocyte viability by induction of apoptosis and exerts topical anti-inflammatory activity in mice. | British journal of pharmacology 20110101 |
| Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington's disease. | Brain : a journal of neurology 20110101 |
| Anti-inflammatory nutrition as a pharmacological approach to treat obesity. | Journal of obesity 20110101 |
| Upregulation of cannabinoid type 1 receptors in dopamine D2 receptor knockout mice is reversed by chronic forced ethanol consumption. | Alcoholism, clinical and experimental research 20110101 |
| Psychiatric adverse effects of rimonobant in adults with Prader Willi syndrome. | European journal of medical genetics 20110101 |
| Effects of cannabinoid CB1 receptor agonism and antagonism on SKF81297-induced dyskinesia and haloperidol-induced dystonia in Cebus apella monkeys. | Neuropharmacology 20110101 |
| The role of endocannabinoids in visceral hyposensitivity induced by rapid eye movement sleep deprivation in rats: regional differences. | International journal of molecular medicine 20110101 |
| Taking Orlistat: Predicting Weight Loss over 6 Months. | Journal of obesity 20110101 |
| Metformin may maintain weight loss in obese patients with dysglycaemia initially treated with rimonabant. | Diabetic medicine : a journal of the British Diabetic Association 20110101 |
| Pharmacotherapies for obesity: past, current, and future therapies. | Journal of obesity 20110101 |
| Pharmacological treatment of obesity in patients with polycystic ovary syndrome. | Journal of obesity 20110101 |
| Pharmacological treatment of obesity in children and adolescents: present and future. | Journal of obesity 20110101 |
| Perspectives of CB1 Antagonist in Treatment of Obesity: Experience of RIO-Asia. | Journal of obesity 20110101 |
| The use of lorcaserin in the management of obesity: a critical appraisal. | Drug design, development and therapy 20110101 |
| Drug-induced psychosis: how to avoid star gazing in schizophrenia research by looking at more obvious sources of light. | Frontiers in behavioral neuroscience 20110101 |
| Influence of Sleeve Gastrectomy on NASH and Type 2 Diabetes Mellitus. | Journal of obesity 20110101 |
| Pharmacological and non-pharmacological interventions to influence adipose tissue function. | Cardiovascular diabetology 20110101 |
| Krill oil significantly decreases 2-arachidonoylglycerol plasma levels in obese subjects. | Nutrition & metabolism 20110101 |
| Molecular mechanisms for the destabilization and restabilization of reactivated spatial memory in the Morris water maze. | Molecular brain 20110101 |
| Present and future: pharmacologic treatment of obesity. | Journal of obesity 20110101 |
| Regulation of vascular tone by adipocytes. | BMC medicine 20110101 |
| Bioequivalence study of two tablet formulations containing rimonabant 20 mg in healthy Indian subjects. | Arzneimittel-Forschung 20110101 |
| Endocannabinoid system protects against cryptogenic seizures. | Pharmacological reports : PR 20110101 |
| A new perspective of cannabinoid 1 receptor antagonists: approaches toward peripheral CB1R blockers without crossing the blood-brain barrier. | Current topics in medicinal chemistry 20110101 |
| Analysis of in vitro bioactivity data extracted from drug discovery literature and patents: Ranking 1654 human protein targets by assayed compounds and molecular scaffolds. | Journal of cheminformatics 20110101 |
| Predicting drug side-effect profiles: a chemical fragment-based approach. | BMC bioinformatics 20110101 |
| Targeting nicotine addiction: the possibility of a therapeutic vaccine. | Drug design, development and therapy 20110101 |
| Plasma and liver lipidomics response to an intervention of rimonabant in ApoE*3Leiden.CETP transgenic mice. | PloS one 20110101 |
| Longer term effects of very low energy diet on obstructive sleep apnoea in cohort derived from randomised controlled trial: prospective observational follow-up study. | BMJ (Clinical research ed.) 20110101 |
| Evaluation of efficacy and safety of orlistat in obese patients. | Indian journal of endocrinology and metabolism 20110101 |
| The role of cannabinoids in modulating emotional and non-emotional memory processes in the hippocampus. | Frontiers in behavioral neuroscience 20110101 |
| Pharmacological evidence for different populations of postsynaptic adenosine A2A receptors in the rat striatum. | Neuropharmacology 20110101 |
| Dyslipidemia induced by drugs used for the prevention and treatment of vascular diseases. | The open cardiovascular medicine journal 20110101 |
| Rimonabant: From RIO to Ban. | Journal of obesity 20110101 |
| Usage, risk, and benefit of weight-loss drugs in primary care. | Journal of obesity 20110101 |
| Predictors of weight loss and maintenance in patients treated with antiobesity drugs. | Diabetes, metabolic syndrome and obesity : targets and therapy 20110101 |
| AM251, cannabinoids receptors ligand, improves recognition memory in rats. | Pharmacological reports : PR 20110101 |
| Cannabinoid receptor type I modulates alcohol-induced liver fibrosis. | Molecular medicine (Cambridge, Mass.) 20110101 |
| Pharmacological activation/inhibition of the cannabinoid system affects alcohol withdrawal-induced neuronal hypersensitivity to excitotoxic insults. | PloS one 20110101 |
| Effects of cannabinoid agonists on sheep sphincter of oddi in vitro. | Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] 20110101 |
| Effects of endocannabinoid system modulation on cognitive and emotional behavior. | Frontiers in behavioral neuroscience 20110101 |
| Endocannabinoid system in cardiovascular disorders - new pharmacotherapeutic opportunities. | Journal of pharmacy & bioallied sciences 20110101 |
| Market Access Agreements for pharmaceuticals in Europe: diversity of approaches and underlying concepts. | BMC health services research 20110101 |
| Beyond THC: The New Generation of Cannabinoid Designer Drugs. | Frontiers in behavioral neuroscience 20110101 |
| Endocannabinoid system and psychiatry: in search of a neurobiological basis for detrimental and potential therapeutic effects. | Frontiers in behavioral neuroscience 20110101 |
| Cannabinoid CB1 and Dopamine D1 Receptors Partnership in the Modulation of Emotional Neural Processing. | Frontiers in behavioral neuroscience 20110101 |
| Cannabinoid CB1 receptor activation mediates the opposing effects of amphetamine on impulsive action and impulsive choice. | PloS one 20110101 |
| Role of centralized review processes for making reimbursement decisions on new health technologies in Europe. | ClinicoEconomics and outcomes research : CEOR 20110101 |
| Cost-effectiveness of pharmacotherapy to reduce obesity. | PloS one 20110101 |
| Acute overactive endocannabinoid signaling induces glucose intolerance, hepatic steatosis, and novel cannabinoid receptor 1 responsive genes. | PloS one 20110101 |
| Effect of the Cannabinoid Receptor-1 antagonist SR141716A on human adipocyte inflammatory profile and differentiation. | Journal of inflammation (London, England) 20110101 |
| Nicotine dependence and psychological distress: outcomes and clinical implications in smoking cessation. | Psychology research and behavior management 20110101 |
| Endocannabinoid regulation of acute and protracted nicotine withdrawal: effect of FAAH inhibition. | PloS one 20110101 |
| Obesity in arabic-speaking countries. | Journal of obesity 20110101 |
| Resistance to diet-induced adiposity in cannabinoid receptor-1 deficient mice is not due to impaired adipocyte function. | Nutrition & metabolism 20110101 |
| Palatability as an addictive trigger in obesity: a changing paradigm in the past decades. | Frontiers in psychiatry 20110101 |
| Acute myocardial ischemia enhances the vanilloid TRPV1 and serotonin 5-HT3 receptor-mediated Bezold-Jarisch reflex in rats. | Pharmacological reports : PR 20110101 |
| Natural products and body weight control. | North American journal of medical sciences 20110101 |
| Therapeutic prospects of metabolically active brown adipose tissue in humans. | Frontiers in endocrinology 20110101 |
| Systemic cannabinoids produce CB₁-mediated antinociception by activation of descending serotonergic pathways that act upon spinal 5-HT(7) and 5-HT(2A) receptors. | European journal of pharmacology 20101215 |
| Termination of the CRESCENDO trial. | Lancet (London, England) 20101211 |
| Termination of the CRESCENDO trial. | Lancet (London, England) 20101211 |
| The effects of cannabinoid drugs on abnormal involuntary movements in dyskinetic and non-dyskinetic 6-hydroxydopamine lesioned rats. | Brain research 20101202 |
| Reversal of inflammation-induced impairment of glucose uptake in adipocytes by direct effect of CB1 antagonism on adipose tissue macrophages. | Obesity (Silver Spring, Md.) 20101201 |
| Cardiovascular co-medication among users of antiobesity drugs: a population-based study. | Pharmacy world & science : PWS 20101201 |
| Antagonism of ∆⁹-THC induced behavioral effects by rimonabant: time course studies in rats. | European journal of pharmacology 20101201 |
| Synthesis and biological evaluation of new N-alkyl 1-aryl-5-(1H-pyrrol-1-yl)-1H-pyrazole-3-carboxamides as cannabinoid receptor ligands. | European journal of medicinal chemistry 20101201 |
| Energetic metabolism and human sperm motility: impact of CB₁ receptor activation. | Endocrinology 20101201 |
| Cannabinoid receptor activation leads to massive mobilization of myeloid-derived suppressor cells with potent immunosuppressive properties. | European journal of immunology 20101201 |
| Identification of amino-tadalafil and rimonabant in electronic cigarette products using high pressure liquid chromatography with diode array and tandem mass spectrometric detection. | Journal of chromatography. A 20101126 |
| [Rimonabant is associated with serious neuropsychiatric side effects]. | Praxis 20101117 |
| Effect of the cannabinoid receptor-1 antagonist rimonabant on lipolysis in rats. | European journal of pharmacology 20101110 |
| Effects of acute low-dose combined treatment with rimonabant and sibutramine on appetite and weight gain in rats. | Pharmacology, biochemistry, and behavior 20101101 |
| Effect of non-statin lipid lowering and anti-obesity drugs on LDL subfractions in patients with mixed dyslipidaemia. | Current vascular pharmacology 20101101 |
| Pharmacological evaluation of the natural constituent of Cannabis sativa, cannabichromene and its modulation by Δ(9)-tetrahydrocannabinol. | Drug and alcohol dependence 20101101 |
| The incretin pathway as a new therapeutic target for obesity. | Maturitas 20101101 |
| Tuberoinfundibular peptide of 39 residues (TIP39) signaling modulates acute and tonic nociception. | Experimental neurology 20101101 |
| The novel cannabinoid CB1 antagonist AM6545 suppresses food intake and food-reinforced behavior. | Pharmacology, biochemistry, and behavior 20101101 |
| Chronic treatment with the cannabinoid 1 antagonist rimonabant altered vasoactive cyclo-oxygenase-derived products on arteries from obese Zucker rats. | Journal of cardiovascular pharmacology 20101101 |
| Cannabinoid receptor stimulation impairs mitochondrial biogenesis in mouse white adipose tissue, muscle, and liver: the role of eNOS, p38 MAPK, and AMPK pathways. | Diabetes 20101101 |
| Peripheral endocannabinoid system-mediated actions of rimonabant on growth hormone secretion are ghrelin-dependent. | Journal of neuroendocrinology 20101101 |
| Cannabinoids reveal separate controls for whisking amplitude and timing in rats. | Journal of neurophysiology 20101101 |
| Human platelets express authentic CB₁ and CB₂ receptors. | Current neurovascular research 20101101 |
| Rimonabant inhibits TNF-α-induced endothelial IL-6 secretion via CB1 receptor and cAMP-dependent protein kinase pathway. | Acta pharmacologica Sinica 20101101 |
| Central cannabinoid receptors modulate acquisition of eyeblink conditioning. | Learning & memory (Cold Spring Harbor, N.Y.) 20101101 |
| Prevention: Neuropsychiatric adverse effects signal the end of the line for rimonabant. | Nature reviews. Cardiology 20101101 |
| Synthesis and biological evaluation of bivalent ligands for the cannabinoid 1 receptor. | Journal of medicinal chemistry 20101014 |
| Novel 1',1'-chain substituted hexahydrocannabinols: 9β-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol (AM2389) a highly potent cannabinoid receptor 1 (CB1) agonist. | Journal of medicinal chemistry 20101014 |
| Combination of fenofibrate with non-statin drug regimens. | Current pharmaceutical design 20101001 |
| Anandamide suppresses pain initiation through a peripheral endocannabinoid mechanism. | Nature neuroscience 20101001 |
| Relapse prevention in UK Stop Smoking Services: current practice, systematic reviews of effectiveness and cost-effectiveness analysis. | Health technology assessment (Winchester, England) 20101001 |
| Identification and hit-to-lead optimization of a novel class of CB1 antagonists. | Bioorganic & medicinal chemistry letters 20100915 |
| Regulation of subthalamic neuron activity by endocannabinoids. | Synapse (New York, N.Y.) 20100901 |
| Reduced neural response to reward following 7 days treatment with the cannabinoid CB1 antagonist rimonabant in healthy volunteers. | The international journal of neuropsychopharmacology 20100901 |
| Endocannabinoid-mediated synaptically evoked suppression of GABAergic transmission in the cerebellar cortex. | Neuroscience 20100901 |
| Genetic deletion of fatty acid amide hydrolase alters emotional behavior and serotonergic transmission in the dorsal raphe, prefrontal cortex, and hippocampus. | Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20100901 |
| Discovery of 2-(4-((1H-1,2,4-triazol-1-yl)methyl)-5-(4-bromophenyl)-1-(2-chlorophenyl)-1H-pyrazol-3-yl)-5-tert-butyl-1,3,4-thiadiazole (GCC2680) as a potent, selective and orally efficacious cannabinoid-1 receptor antagonist. | Bioorganic & medicinal chemistry 20100901 |
| Regional enhancement of cannabinoid CB₁ receptor desensitization in female adolescent rats following repeated Delta-tetrahydrocannabinol exposure. | British journal of pharmacology 20100901 |
| GPR55-dependent and -independent ion signalling in response to lysophosphatidylinositol in endothelial cells. | British journal of pharmacology 20100901 |
| Cannabinoid receptors as target for treatment of osteoporosis: a tale of two therapies. | Current neuropharmacology 20100901 |
| Investigations on the 4-quinolone-3-carboxylic acid motif. 3. Synthesis, structure-affinity relationships, and pharmacological characterization of 6-substituted 4-quinolone-3-carboxamides as highly selective cannabinoid-2 receptor ligands. | Journal of medicinal chemistry 20100826 |
| Rimonabant: obituary for a wonder drug. | Lancet (London, England) 20100814 |
| Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial. | Lancet (London, England) 20100814 |
| CB1 cannabinoid receptor expression is regulated by glucose and feeding in rat pancreatic islets. | Regulatory peptides 20100809 |
| Rimonabant is a dual inhibitor of acyl CoA:cholesterol acyltransferases 1 and 2. | Biochemical and biophysical research communications 20100806 |
| Rehashing endocannabinoid antagonists: can we selectively target the periphery to safely treat obesity and type 2 diabetes? | The Journal of clinical investigation 20100802 |
| Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity. | The Journal of clinical investigation 20100802 |
| Endocannabinoids, FOXO and the metabolic syndrome: redox, function and tipping point--the view from two systems. | Immunobiology 20100801 |
| Drug reimbursement and GPs' prescribing decisions: a randomized case-vignette study about the pharmacotherapy of obesity associated with type 2 diabetes: how GPs react to drug reimbursement. | Fundamental & clinical pharmacology 20100801 |
| Efficacy and safety of anti-obesity drugs in children and adolescents: systematic review and meta-analysis. | Obesity reviews : an official journal of the International Association for the Study of Obesity 20100801 |
| Δ⁹-Tetrahydrocannabivarin suppresses in vitro epileptiform and in vivo seizure activity in adult rats. | Epilepsia 20100801 |
| Depression-like phenotype following chronic CB1 receptor antagonism. | Neurobiology of disease 20100801 |
| Rimonabant-induced apoptosis in leukemia cell lines: activation of caspase-dependent and -independent pathways. | Biochemical pharmacology 20100801 |
| The endocannabinoid system tonically regulates inhibitory transmission and depresses the effect of ethanol in central amygdala. | Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20100801 |
| Rimonabant-mediated changes in intestinal lipid metabolism and improved renal vascular dysfunction in the JCR:LA-cp rat model of prediabetic metabolic syndrome. | American journal of physiology. Gastrointestinal and liver physiology 20100801 |
| Rational design of a novel peripherally-restricted, orally active CB(1) cannabinoid antagonist containing a 2,3-diarylpyrrole motif. | Bioorganic & medicinal chemistry letters 20100801 |
| Effects of in vitro antagonism of endocannabinoid-1 receptors on the glucose transport system in normal and insulin-resistant rat skeletal muscle. | Diabetes, obesity & metabolism 20100801 |
| A systematic review of the effectiveness of smoking relapse prevention interventions for abstinent smokers. | Addiction (Abingdon, England) 20100801 |
| [Current trends of nicotine dependence]. | Nihon rinsho. Japanese journal of clinical medicine 20100801 |
| Economic evaluation of lifestyle interventions for preventing diabetes and cardiovascular diseases. | International journal of environmental research and public health 20100801 |
| 1-(3,5-Diethyl-1H-pyrazol-1-yl)-3-phenyl-isoquinoline. | Acta crystallographica. Section E, Structure reports online 20100801 |
| Effects of cannabinoids on capsaicin receptor activity following exposure of primary sensory neurons to inflammatory mediators. | Life sciences 20100731 |
| Rimonabant, a cannabinoid CB1 receptor antagonist, attenuates mechanical allodynia and counteracts oxidative stress and nerve growth factor deficit in diabetic mice. | European journal of pharmacology 20100710 |
| Effect of rimonabant, the cannabinoid CB1 receptor antagonist, on peripheral nerve in streptozotocin-induced diabetic rat. | European journal of pharmacology 20100710 |
| Differential effects of CB(1) neutral antagonists and inverse agonists on gastrointestinal motility in mice. | Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society 20100701 |
| CB(1) modulation of hormone secretion, neuronal activation and mRNA expression following extracellular volume expansion. | Experimental neurology 20100701 |
| TrkB agonist antibody dose-dependently raises blood pressure in mice with diet-induced obesity. | American journal of hypertension 20100701 |
| Modulation of the endocannabinoid system: neuroprotection or neurotoxicity? | Experimental neurology 20100701 |
| FAAH-/- mice display differential tolerance, dependence, and cannabinoid receptor adaptation after delta 9-tetrahydrocannabinol and anandamide administration. | Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20100701 |
| CB1 receptor inhibition leads to decreased vascular AT1 receptor expression, inhibition of oxidative stress and improved endothelial function. | Basic research in cardiology 20100701 |
| Rimonabant-induced Delta9-tetrahydrocannabinol withdrawal in rhesus monkeys: discriminative stimulus effects and other withdrawal signs. | The Journal of pharmacology and experimental therapeutics 20100701 |
| Regulation of inflammatory pain by inhibition of fatty acid amide hydrolase. | The Journal of pharmacology and experimental therapeutics 20100701 |
| The effects of the mGluR5 receptor antagonist 6-methyl-2-(phenylethynyl)-pyridine (MPEP) on behavioural responses to nicotine. | Psychopharmacology 20100701 |
| Altered architecture and functional consequences of the mesolimbic dopamine system in cannabis dependence. | Addiction biology 20100701 |
| Additive actions of the cannabinoid and neuropeptide Y systems on adiposity and lipid oxidation. | Diabetes, obesity & metabolism 20100701 |
| Therapeutic approaches to epileptogenesis--hope on the horizon. | Epilepsia 20100701 |
| CB1 receptor antagonism impairs the induction of epileptiform activity by group I metabotropic glutamate receptor activation. | Epilepsia 20100701 |
| The effect of the cannabinoid-receptor antagonist, SR141716, on the early stage of kainate-induced epileptogenesis in the adult rat. | Epilepsia 20100701 |
| The role of peripheral cannabinoid receptors type 1 in rats with visceral hypersensitivity induced by chronic restraint stress. | Journal of neurogastroenterology and motility 20100701 |
| Quantification of rimonabant (SR 141716A) in monkey plasma using HPLC with UV detection. | Journal of chromatographic science 20100701 |
| The novel triple monoamine reuptake inhibitor tesofensine induces sustained weight loss and improves glycemic control in the diet-induced obese rat: comparison to sibutramine and rimonabant. | European journal of pharmacology 20100625 |
| Chronic constriction injury reduces cannabinoid receptor 1 activity in the rostral anterior cingulate cortex of mice. | Brain research 20100621 |
| Falcarinol is a covalent cannabinoid CB1 receptor antagonist and induces pro-allergic effects in skin. | Biochemical pharmacology 20100615 |
| Antinociceptive effects of racemic AM1241 and its chirally synthesized enantiomers: lack of dependence upon opioid receptor activation. | The AAPS journal 20100601 |
| GPR55 ligands promote receptor coupling to multiple signalling pathways. | British journal of pharmacology 20100601 |
| Enhanced cognitive performance of dopamine D3 receptor 'knock-out' mice in the step-through passive-avoidance test: assessing the role of the endocannabinoid/endovanilloid systems. | Pharmacological research 20100601 |
| Cannabinoid 1 receptors modulate intestinal sensory and motor function in rat. | Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society 20100601 |
| Rimonabant during early pregnancy. | International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics 20100601 |
| Direct and indirect effects of cannabinoids on in vitro GABA release in the rat arcuate nucleus. | Journal of neuroendocrinology 20100601 |
| AM 251 differentially effects food-maintained responding depending on food palatability. | Pharmacology, biochemistry, and behavior 20100601 |
| Kappa opioid mediation of cannabinoid effects of the potent hallucinogen, salvinorin A, in rodents. | Psychopharmacology 20100601 |
| How inverse can a neutral antagonist be? Strategic questions after the rimonabant issue. | Drug discovery today 20100601 |
| Diabesity: therapeutic options. | Diabetes, obesity & metabolism 20100601 |
| Pharmacological and non-pharmacological treatment of non-alcoholic fatty liver disease. | International journal of clinical practice 20100601 |
| Evidence for both inverse agonism at the cannabinoid CB1 receptor and the lack of an endogenous cannabinoid tone in the rat and guinea-pig isolated ileum myenteric plexus-longitudinal muscle preparation. | British journal of pharmacology 20100601 |
| CB1 cannabinoid receptors promote oxidative/nitrosative stress, inflammation and cell death in a murine nephropathy model. | British journal of pharmacology 20100601 |
| Cannabinoid-1 receptor activation induces reactive oxygen species-dependent and -independent mitogen-activated protein kinase activation and cell death in human coronary artery endothelial cells. | British journal of pharmacology 20100601 |
| Endocannabinoid modulation of hyperaemia evoked by physiologically relevant stimuli in the rat primary somatosensory cortex. | British journal of pharmacology 20100601 |
| Neuroprotective potential of CB1 receptor agonists in an in vitro model of Huntington's disease. | British journal of pharmacology 20100601 |
| The peptide hemopressin acts through CB1 cannabinoid receptors to reduce food intake in rats and mice. | The Journal of neuroscience : the official journal of the Society for Neuroscience 20100526 |
| Anxiety-like effects of SR141716-precipitated delta9-tetrahydrocannabinol withdrawal in mice in the elevated plus-maze. | Neuroscience letters 20100521 |
| Effects of cannabinoid receptor antagonists on maintenance and reinstatement of methamphetamine self-administration in rhesus monkeys. | European journal of pharmacology 20100510 |
| Intra-accumbens rimonabant is rewarding but induces aversion to cocaine in cocaine-treated rats, as does in vivo accumbal cannabinoid CB1 receptor silencing: critical role for glutamate receptors. | Neuroscience 20100505 |
| Effects of intra-basolateral amygdala administration of rimonabant on nociceptive behaviour and neuronal activity in the presence or absence of contextual fear. | European journal of pain (London, England) 20100501 |
| Effects of rimonabant, as monotherapy and in combination with fenofibrate or ezetimibe, on plasma adipokine levels: a pilot study. | Angiology 20100501 |
| A role for 2-arachidonoylglycerol and endocannabinoid signaling in the locomotor response to novelty induced by olfactory bulbectomy. | Pharmacological research 20100501 |
| A common polymorphism in the cannabinoid receptor 1 (CNR1) gene is associated with antipsychotic-induced weight gain in Schizophrenia. | Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20100501 |
| Mass spectrometry screening reveals widespread diversity in trichome specialized metabolites of tomato chromosomal substitution lines. | The Plant journal : for cell and molecular biology 20100501 |
| Endocannabinoid control of gastric sensorimotor function in man. | Alimentary pharmacology & therapeutics 20100501 |
| Reduction in endocannabinoid tone is a homeostatic mechanism for specific inhibitory synapses. | Nature neuroscience 20100501 |
| Probing the cannabinoid CB1/CB2 receptor subtype selectivity limits of 1,2-diarylimidazole-4-carboxamides by fine-tuning their 5-substitution pattern. | Bioorganic & medicinal chemistry letters 20100501 |
| The role of adiponectin in the pathogenesis and treatment of non-alcoholic fatty liver disease. | Diabetes, obesity & metabolism 20100501 |
| Gestational diabetes mellitus and obesity. | Diabetes care 20100501 |
| [Therapeutical use of the cannabinoids in psychiatry]. | Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999) 20100501 |
| Neural encoding of psychomotor activation in the nucleus accumbens core, but not the shell, requires cannabinoid receptor signaling. | The Journal of neuroscience : the official journal of the Society for Neuroscience 20100407 |
| WIN55,212-2 induced deficits in spatial learning are mediated by cholinergic hypofunction. | Behavioural brain research 20100402 |
| A metabolically stable analogue of anandamide, Met-F-AEA, inhibits human thyroid carcinoma cell lines by activation of apoptosis. | Investigational new drugs 20100401 |
| A case study of ex ante, value-based price and reimbursement decision-making: TLV and rimonabant in Sweden. | The European journal of health economics : HEPAC : health economics in prevention and care 20100401 |
| Unravelling the complex dissociation of [(3)H]-rimonabant from plated CB(1) cannabinoid receptor-expressing cells. | Fundamental & clinical pharmacology 20100401 |
| The prostacyclin analog beraprost sodium ameliorates characteristics of metabolic syndrome in obese Zucker (fatty) rats. | Diabetes 20100401 |
| Cannabinoid receptor 1 blockade ameliorates albuminuria in experimental diabetic nephropathy. | Diabetes 20100401 |
| Hormone and pharmaceutical regulation of ASP production in 3T3-L1 adipocytes. | Journal of cellular biochemistry 20100401 |
| Resistance to epinephrine and hypersensitivity (hyperresponsiveness) to CB1 antagonists in a patient with pseudohypoparathyroidism type Ic. | European journal of endocrinology 20100401 |
| Cannabinoid inhibition of macrophage migration to the trans-activating (Tat) protein of HIV-1 is linked to the CB(2) cannabinoid receptor. | The Journal of pharmacology and experimental therapeutics 20100401 |
| CB1 antagonism exerts specific molecular effects on visceral and subcutaneous fat and reverses liver steatosis in diet-induced obese mice. | Diabetes 20100401 |
| Dopaminergic augmentation of delta-9-tetrahydrocannabinol (THC) discrimination: possible involvement of D(2)-induced formation of anandamide. | Psychopharmacology 20100401 |
| Pharmacological characterization of cannabinoid receptor activity in the rat-isolated ileum myenteric plexus-longitudinal muscle preparation. | British journal of pharmacology 20100401 |
| The antinociceptive effect of acetylsalicylic acid is differently affected by a CB1 agonist or antagonist and involves the serotonergic system in rats. | Life sciences 20100327 |
| Effect of rimonabant and metformin on glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 in obese women with polycystic ovary syndrome. | Clinical endocrinology 20100301 |
| CB1 cannabinoid receptors promote oxidative stress and cell death in murine models of doxorubicin-induced cardiomyopathy and in human cardiomyocytes. | Cardiovascular research 20100301 |
| Effect of rimonabant on glycemic control in insulin-treated type 2 diabetes: the ARPEGGIO trial. | Diabetes care 20100301 |
| Use of psychotropic drugs and analgesics among users of antiobesity drugs--a population based study. | Pharmacoepidemiology and drug safety 20100301 |
| Central and peripheral consequences of the chronic blockade of CB1 cannabinoid receptor with rimonabant or taranabant. | Journal of neurochemistry 20100301 |
| FAAH deficiency promotes energy storage and enhances the motivation for food. | International journal of obesity (2005) 20100301 |
| Peripherally acting CB1-receptor antagonist: the relative importance of central and peripheral CB1 receptors in adiposity control. | International journal of obesity (2005) 20100301 |
| Discovery of benzhydrylpiperazine derivatives as CB1 receptor inverse agonists via privileged structure-based approach. | European journal of medicinal chemistry 20100301 |
| Anandamide potentiation of miniature spontaneous excitatory synaptic transmission is mediated via IP3 pathway. | Neurochemistry international 20100301 |
| Blockade of the cannabinoid CB1 receptor and alcohol dependence: preclinical evidence and preliminary clinical data. | CNS & neurological disorders drug targets 20100301 |
| Potential antipsychotic properties of central cannabinoid (CB1) receptor antagonists. | The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry 20100301 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20100301 |
| Cannabinoid 1 receptor blockade reduces atherosclerosis with enhances reverse cholesterol transport. | Journal of atherosclerosis and thrombosis 20100226 |
| Sibutramine & naloxone: infra-additive interaction in the regulation of appetite? | Behavioural brain research 20100211 |
| Aspirin-triggered lipoxin induces CB1-dependent catalepsy in mice. | Neuroscience letters 20100205 |
| Metabolic responses to long-term pharmacological inhibition of CB1-receptor activity in mice in relation to dietary fat composition. | International journal of obesity (2005) 20100201 |
| Expression and function of endocannabinoid receptors in the human adrenal cortex. | Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme 20100201 |
| Effect of adolescent exposure to WIN 55212-2 on the acquisition and reinstatement of MDMA-induced conditioned place preference. | Progress in neuro-psychopharmacology & biological psychiatry 20100201 |
| Cannabinoid type 1 receptor blockade induces transdifferentiation towards a brown fat phenotype in white adipocytes. | Diabetes, obesity & metabolism 20100201 |
| Reduced expression of glutamate receptors and phosphorylation of CREB are responsible for in vivo Delta9-THC exposure-impaired hippocampal synaptic plasticity. | Journal of neurochemistry 20100201 |
| Regulation of MAP kinase-directed mitogenic and protein kinase B-mediated signaling by cannabinoid receptor type 1 in skeletal muscle cells. | Diabetes 20100201 |
| Human sperm anatomy: ultrastructural localization of the cannabinoid1 receptor and a potential role of anandamide in sperm survival and acrosome reaction. | Anatomical record (Hoboken, N.J. : 2007) 20100201 |
| Synthesis and structure-activity relationship of 1,2,4-triazole-containing diarylpyrazolyl carboxamide as CB1 cannabinoid receptor-ligand. | Bioorganic & medicinal chemistry 20100201 |
| Rimonabant (SR141716) induces metabolism and acquisition of fertilizing ability in human sperm. | British journal of pharmacology 20100201 |
| Cue-conditioned alcohol seeking in rats following abstinence: involvement of metabotropic glutamate 5 receptors. | British journal of pharmacology 20100201 |
| Obesity and preclinical changes of cardiac geometry and function. | Korean circulation journal 20100201 |
| Current treatment options in smoking cessation. | Hospital practice (1995) 20100201 |
| Doppel and PrPC co-immunoprecipitate in detergent-resistant membrane domains of epithelial FRT cells. | The Biochemical journal 20100115 |
| Novel thioamide derivatives as neutral CB1 receptor antagonists. | Bioorganic & medicinal chemistry letters 20100115 |
| Conversion of 4-cyanomethyl-pyrazole-3-carboxamides into CB1 antagonists with lowered propensity to pass the blood-brain-barrier. | Bioorganic & medicinal chemistry letters 20100115 |
| Antinociceptive effect of the cannabinoid agonist, WIN 55,212-2, in the orofacial and temporomandibular formalin tests. | European journal of pain (London, England) 20100101 |
| Two opposite effects of Delta(9)-tetrahydrocannabinol on subthalamic nucleus neuron activity: involvement of GABAergic and glutamatergic neurotransmission. | Synapse (New York, N.Y.) 20100101 |
| Discriminative stimulus functions of methanandamide and delta(9)-THC in rats: tests with aminoalkylindoles (WIN55,212-2 and AM678) and ethanol. | Psychopharmacology 20100101 |
| Rimonabant (SR141716) has no effect on alcohol self-administration or endocrine measures in nontreatment-seeking heavy alcohol drinkers. | Psychopharmacology 20100101 |
| Synergistic inhibition of human colon cancer cell growth by the cannabinoid CB1 receptor antagonist rimonabant and oxaliplatin. | Oncology reports 20100101 |
| Imaging and quantitation of cannabinoid CB1 receptors in human and monkey brains using (18)F-labeled inverse agonist radioligands. | Journal of nuclear medicine : official publication, Society of Nuclear Medicine 20100101 |
| Cannabinoid CB1 receptor facilitation of substance P release in the rat spinal cord, measured as neurokinin 1 receptor internalization. | The European journal of neuroscience 20100101 |
| Anandamide suppresses proliferation and cytokine release from primary human T-lymphocytes mainly via CB2 receptors. | PloS one 20100101 |
| Biomarkers of endocannabinoid system activation in severe obesity. | PloS one 20100101 |
| Safety and efficacy trial of adipose-tissue derived oral preparation V-6 Immunitor (V-6): results of open-label, two-month, follow-up study. | Lipids in health and disease 20100101 |
| Role of platelets in neuroinflammation: a wide-angle perspective. | Journal of neuroinflammation 20100101 |
| The cannabinoid receptor agonist WIN 55,212-2 inhibits antigen-induced plasma extravasation in guinea pig airways. | International archives of allergy and immunology 20100101 |
| Receptors and channels targeted by synthetic cannabinoid receptor agonists and antagonists. | Current medicinal chemistry 20100101 |
| THC Prevents MDMA Neurotoxicity in Mice. | PloS one 20100101 |
| Weight loss in individuals with metabolic syndrome given DASH diet counseling when provided a low sodium vegetable juice: a randomized controlled trial. | Nutrition journal 20100101 |
| The multiple functions of the endocannabinoid system: a focus on the regulation of food intake. | Diabetology & metabolic syndrome 20100101 |
| Effect of the CB1 cannabinoid agonist WIN 55212-2 on the acquisition and reinstatement of MDMA-induced conditioned place preference in mice. | Behavioral and brain functions : BBF 20100101 |
| N-arachidonoyl glycine, an abundant endogenous lipid, potently drives directed cellular migration through GPR18, the putative abnormal cannabidiol receptor. | BMC neuroscience 20100101 |
| Missing the forest (plot) for the trees? A critique of the systematic review in tobacco control. | BMC medical research methodology 20100101 |
| Endocannabinoids differentially modulate synaptic plasticity in rat hippocampal CA1 pyramidal neurons. | PloS one 20100101 |
| Association between repeated unpredictable chronic mild stress (UCMS) procedures with a high fat diet: a model of fluoxetine resistance in mice. | PloS one 20100101 |
| Type 2 diabetes: postprandial hyperglycemia and increased cardiovascular risk. | Vascular health and risk management 20100101 |
| [Simultaneous determination of rimonabant and orlistat illegally added in the weight-loss functional foods by high performance liquid chromatography-tandem mass spectrometry]. | Se pu = Chinese journal of chromatography 20100101 |
| Endocannabinoids and their role in fatty liver disease. | Digestive diseases (Basel, Switzerland) 20100101 |
| Possible Anandamide and Palmitoylethanolamide involvement in human stroke. | Lipids in health and disease 20100101 |
| Anti-obesity effect of an isoflavone fatty acid ester on obese mice induced by high fat diet and its potential mechanism. | Lipids in health and disease 20100101 |
| Motion sickness, stress and the endocannabinoid system. | PloS one 20100101 |
| Cannabinoid receptor CB1 mediates baseline and activity-induced survival of new neurons in adult hippocampal neurogenesis. | Cell communication and signaling : CCS 20100101 |
| The early nutritional environment of mice determines the capacity for adipose tissue expansion by modulating genes of caveolae structure. | PloS one 20100101 |
| Exenatide: a new promising antidiabetic agent. | Indian journal of pharmaceutical sciences 20100101 |
| Adverse events associated with nicotine replacement therapy (NRT) for smoking cessation. A systematic review and meta-analysis of one hundred and twenty studies involving 177,390 individuals. | Tobacco induced diseases 20100101 |
| Validated stability-indicating RP-HPLC method for the determination of rimonabant in a pharmaceutical dosage form. | Journal of AOAC International 20100101 |
| The endocannabinoid system links gut microbiota to adipogenesis. | Molecular systems biology 20100101 |
| Effects of Endogenous PPAR Agonist Nitro-Oleic Acid on Metabolic Syndrome in Obese Zucker Rats. | PPAR research 20100101 |
| Impact of medical therapy on atheroma volume measured by different cardiovascular imaging modalities. | Cardiology research and practice 20100101 |
| Quantitative in vitro and in vivo pharmacological profile of CE-178253, a potent and selective cannabinoid type 1 (CB1) receptor antagonist. | BMC pharmacology 20100101 |
| Self-Reported Psychosocial Health in Obese Patients before and after Weight Loss. | Journal of obesity 20100101 |
| Fatty acid amide hydrolase in prostate cancer: association with disease severity and outcome, CB1 receptor expression and regulation by IL-4. | PloS one 20100101 |
| Selecting GLP-1 agonists in the management of type 2 diabetes: differential pharmacology and therapeutic benefits of liraglutide and exenatide. | Therapeutics and clinical risk management 20100101 |
| Hepatitis C virus induces the cannabinoid receptor 1. | PloS one 20100101 |
| Diet-induced obesity in zebrafish shares common pathophysiological pathways with mammalian obesity. | BMC physiology 20100101 |
| Effects of SR141716A on Cognitive and Depression-Related Behavior in an Animal Model of Premotor Parkinson's Disease. | Parkinson's disease 20100101 |
| A method for parallel solid-phase synthesis of iodinated analogs of the cannabinoid receptor type I (CB₁) inverse agonist rimonabant. | Methods in enzymology 20100101 |
| Abstracts of the 16th Scientific Symposium of the Austrian Pharmacological Society (APHAR). Vienna, Austria. November 25-27, 2010. | BMC pharmacology 20100101 |
| Rimonabant attenuates sensitization, cross-sensitization and cross-reinstatement of place preference induced by nicotine and ethanol. | Pharmacological reports : PR 20100101 |
| Is there evidence for a set point that regulates human body weight? | F1000 medicine reports 20100101 |
| Methamphetamine-induced dopamine-independent alterations in striatal gene expression in the 6-hydroxydopamine hemiparkinsonian rats. | PloS one 20100101 |
| Blood lipids and adipokines concentrations during a 6-month nutritional and physical activity intervention for metabolic syndrome treatment. | Lipids in health and disease 20100101 |
| Tumour Cannabinoid CB(1) receptor and phosphorylated epidermal growth factor receptor expression are additive prognostic markers for prostate cancer. | PloS one 20100101 |
| A common CNR1 (cannabinoid receptor 1) haplotype attenuates the decrease in HDL cholesterol that typically accompanies weight gain. | PloS one 20100101 |
| Weight-gain in psychiatric treatment: risks, implications, and strategies for prevention and management. | Mens sana monographs 20100101 |
| Efficacy, safety and cost-effectiveness of insulin sensitizers as add-on therapy in metabolic syndrome in patients with secondary sulfonylurea failure: A comparative study. | Journal of pharmacology & pharmacotherapeutics 20100101 |
| Tackling obesity: new therapeutic agents for assisted weight loss. | Diabetes, metabolic syndrome and obesity : targets and therapy 20100101 |
| The role of lipid and carbohydrate digestive enzyme inhibitors in the management of obesity: a review of current and emerging therapeutic agents. | Diabetes, metabolic syndrome and obesity : targets and therapy 20100101 |
| Adipocytokines: The pied pipers. | Journal of pharmacology & pharmacotherapeutics 20100101 |
| Sub-chronic administration of rimonabant causes loss of antidepressive activity and decreases doublecortin immunoreactivity in the mouse hippocampus. | Neuroscience letters 20091225 |
| Central cannabinoid 1 receptor antagonist administration prevents endotoxic hypotension affecting norepinephrine release in the preoptic anterior hypothalamic area. | Shock (Augusta, Ga.) 20091201 |
| The CB1 antagonist rimonabant (SR141716) blocks cue-induced reinstatement of cocaine seeking and other context and extinction phenomena predictive of relapse. | Drug and alcohol dependence 20091201 |
| Efficacy and safety of ezetimibe plus orlistat or rimonabant in statin-intolerant nondiabetic overweight/obese patients with dyslipidemia. | Journal of cardiovascular pharmacology and therapeutics 20091201 |
| Signaling pathways from cannabinoid receptor-1 activation to inhibition of N-methyl-D-aspartic acid mediated calcium influx and neurotoxicity in dorsal root ganglion neurons. | The Journal of pharmacology and experimental therapeutics 20091201 |
| Monoacylglycerol lipase limits the duration of endocannabinoid-mediated depolarization-induced suppression of excitation in autaptic hippocampal neurons. | Molecular pharmacology 20091201 |
| Endocannabinoid signalling as an anti-inflammatory therapeutic target in atherosclerosis: does it work? | Cardiovascular research 20091201 |
| Pentacycle derivatives as cannabinoid CB1 receptor ligands. | Bioorganic & medicinal chemistry letters 20091201 |
| The cannabinoid R+ methanandamide induces IL-6 secretion by prostate cancer PC3 cells. | Journal of immunotoxicology 20091201 |
| Pharmacotherapy for obesity. | British journal of clinical pharmacology 20091201 |
| Rise in antiobesity drug prescribing for children and adolescents in the UK: a population-based study. | British journal of clinical pharmacology 20091201 |
| Regulatory challenges for new drugs to treat obesity and comorbid metabolic disorders. | British journal of clinical pharmacology 20091201 |
| Cannabinoids prevent the opposite regulation of astroglial connexin43 hemichannels and gap junction channels induced by pro-inflammatory treatments. | Journal of neurochemistry 20091201 |
| Central cannabinoid signaling mediating food intake: a pharmacological-challenge magnetic resonance imaging and functional histology study in rat. | Neuroscience 20091110 |
| Hyperlocomotion and paw tremors are two highly quantifiable signs of SR141716-precipitated withdrawal from delta9-tetrahydrocannabinol in C57BL/6 mice. | Neuroscience letters 20091106 |
| The CB(1) antagonist rimonabant is adjunctively therapeutic as well as monotherapeutic in an animal model of Parkinson's disease. | Behavioural brain research 20091105 |
| The cannabinoid CB1 receptor antagonist, rimonabant, protects against acute myocardial infarction. | Basic research in cardiology 20091101 |
| Fatty acid amide hydrolase (FAAH) knockout mice exhibit enhanced acquisition of an aversive, but not of an appetitive, Barnes maze task. | Neurobiology of learning and memory 20091101 |
| Endocannabinoid modulation of amphetamine sensitization is disrupted in a rodent model of lesion-induced dopamine dysregulation. | Synapse (New York, N.Y.) 20091101 |
| Effects of cannabinoid drugs on the reinforcing properties of food in gestationally undernourished rats. | Pharmacology, biochemistry, and behavior 20091101 |
| Prosocial effects of nicotine and ethanol in adolescent rats through partially dissociable neurobehavioral mechanisms. | Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20091101 |
| Evaluation of prevalent phytocannabinoids in the acetic acid model of visceral nociception. | Drug and alcohol dependence 20091101 |
| FAAH inhibitor, URB-597, promotes extinction and CB(1) antagonist, SR141716, inhibits extinction of conditioned aversion produced by naloxone-precipitated morphine withdrawal, but not extinction of conditioned preference produced by morphine in rats. | Pharmacology, biochemistry, and behavior 20091101 |
| Effects of the cannabinoid CB1 antagonist rimonabant on hepatic mitochondrial function in rats fed a high-fat diet. | American journal of physiology. Endocrinology and metabolism 20091101 |
| Cannabinoids for clinicians: the rise and fall of the cannabinoid antagonists. | European journal of endocrinology 20091101 |
| Synthesis and in vitro autoradiographic evaluation of a novel high-affinity radioiodinated ligand for imaging brain cannabinoid subtype-1 receptors. | Bioorganic & medicinal chemistry letters 20091101 |
| CB1 antagonists for obesity--what lessons have we learned from rimonabant? | Nature reviews. Endocrinology 20091101 |
| Effect of the CB(1) receptor antagonists rimonabant and AM251 on the firing rate of dorsal raphe nucleus neurons in rat brain slices. | British journal of pharmacology 20091101 |
| Hypertension and diabetes: should we treat early surrogates? What are the cons? | Diabetes care 20091101 |
| Is there evidence that oral hypoglycemic agents reduce cardiovascular morbidity/mortality? Yes. | Diabetes care 20091101 |
| Adipocytokines and insulin resistance: the possible role of lipocalin-2, retinol binding protein-4, and adiponectin. | Diabetes care 20091101 |
| Obesity in the elderly diabetic patient: is weight loss beneficial? No. | Diabetes care 20091101 |
| Involvement of adipokines in rimonabant-mediated insulin sensitivity in ob/ob mice. | The Journal of pharmacy and pharmacology 20091101 |
| Characterization of the endocannabinoid system in human neuronal cells and proteomic analysis of anandamide-induced apoptosis. | The Journal of biological chemistry 20091023 |
| Atypical responsiveness of the orphan receptor GPR55 to cannabinoid ligands. | The Journal of biological chemistry 20091023 |
| A method for parallel solid-phase synthesis of iodinated analogues of the CB1 receptor inverse agonist rimonabant. | Organic letters 20091015 |
| The endocannabinoid system: potential for reducing cardiometabolic risk. | Obesity (Silver Spring, Md.) 20091001 |
| Short-term dynamics and metabolic impact of abdominal fat depots after bariatric surgery. | Diabetes care 20091001 |
| The CB1 antagonist rimonabant decreases insulin hypersecretion in rat pancreatic islets. | Obesity (Silver Spring, Md.) 20091001 |
| Sex and cannabinoid CB1 genotype differentiate palatable food and cocaine self-administration behaviors in mice. | Behavioural pharmacology 20091001 |
| Rimonabant for the treatment of overweight and obese people. | Health technology assessment (Winchester, England) 20091001 |
| Cannabinoid 1 receptor activation inhibits transient receptor potential vanilloid type 1 receptor-mediated cationic influx into rat cultured primary sensory neurons. | Neuroscience 20090915 |
| Bioisosteric replacement of the hydrazide pharmacophore of the cannabinoid-1 receptor antagonist SR141716A. Part I: potent, orally-active 1,4-disubstituted imidazoles. | Bioorganic & medicinal chemistry letters 20090915 |
| Inhibition of human tumour prostate PC-3 cell growth by cannabinoids R(+)-Methanandamide and JWH-015: involvement of CB2. | British journal of cancer 20090915 |
| Effects of rimonabant on the reinstatement of nicotine-conditioned place preference by drug priming in rats. | Behavioural brain research 20090914 |
| Cannabinoid regulation of nitric oxide synthase I (nNOS) in neuronal cells. | Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology 20090901 |
| Cannabinoid receptor 1 signalling dampens activity and mitochondrial transport in networks of enteric neurones. | Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society 20090901 |
| Pre-exposure to environmental cues predictive of food availability elicits hypothalamic-pituitary-adrenal axis activation and increases operant responding for food in female rats. | Addiction biology 20090901 |
| Discontinuation due to adverse events in randomized trials of orlistat, sibutramine and rimonabant: a meta-analysis. | Obesity reviews : an official journal of the International Association for the Study of Obesity 20090901 |
| Rimonabant inhibits human colon cancer cell growth and reduces the formation of precancerous lesions in the mouse colon. | International journal of cancer 20090901 |
| Inhibition of fatty acid amide hydrolase reduces reinstatement of nicotine seeking but not break point for nicotine self-administration--comparison with CB(1) receptor blockade. | Psychopharmacology 20090901 |
| Investigation of endocannabinoid modulation of conditioned responding evoked by a nicotine CS and the Pavlovian stimulus effects of CP 55,940 in adult male rats. | Psychopharmacology 20090901 |
| The use of iontophoresis in the administration of nicotine and new non-nicotine drugs through the skin for smoking cessation. | Current drug discovery technologies 20090901 |
| Age-dependent effects of the cannabinoid CB1 antagonist SR141716A on food intake, body weight change, and pruritus in rats. | Psychopharmacology 20090901 |
| Cannabinoid-1 receptor inverse agonists: current understanding of mechanism of action and unanswered questions. | International journal of obesity (2005) 20090901 |
| Adiposopathy and bariatric surgery: is 'sick fat' a surgical disease? | International journal of clinical practice 20090901 |
| Rimonabant induces partial seizures in a patient with a history of generalized epilepsy. | Epilepsia 20090901 |
| The 6th Annual World Congress on the insulin resistance syndrome. | Diabetes care 20090901 |
| Beneficial effect of a chronic treatment with rimonabant on pancreatic function and beta-cell morphology in Zucker Fatty rats. | European journal of pharmacology 20090815 |
| Substituted pyrimidines as cannabinoid CB1 receptor ligands. | Bioorganic & medicinal chemistry letters 20090815 |
| Spinal endocannabinoids and CB1 receptors mediate C-fiber-induced heterosynaptic pain sensitization. | Science (New York, N.Y.) 20090807 |
| Antagonism of the cannabinoid CB-1 receptor protects rat liver against ischaemia-reperfusion injury complicated by endotoxaemia. | Gut 20090801 |
| Blood, adipose tissue and brain levels of the cannabinoid ligands WIN-55,212 and SR-141716A after their intraperitoneal injection in mice: compound-specific and area-specific distribution within the brain. | European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology 20090801 |
| Hippocampal CB(1) receptors mediate the memory impairing effects of Delta(9)-tetrahydrocannabinol. | Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20090801 |
| Food intake-independent effects of CB1 antagonism on glucose and lipid metabolism. | Obesity (Silver Spring, Md.) 20090801 |
| Depolarizing GABAergic synaptic input triggers endocannabinoid-mediated retrograde synaptic signaling. | Synapse (New York, N.Y.) 20090801 |
| Acute effects of morphine on distinct forms of impulsive behavior in rats. | Psychopharmacology 20090801 |
| CB1 receptor-independent actions of SR141716 on G-protein signaling: coapplication with the mu-opioid agonist Tyr-D-Ala-Gly-(NMe)Phe-Gly-ol unmasks novel, pertussis toxin-insensitive opioid signaling in mu-opioid receptor-Chinese hamster ovary cells. | The Journal of pharmacology and experimental therapeutics 20090801 |
| Discriminative stimulus properties of delta9-tetrahydrocannabinol (THC) in C57Bl/6J mice. | European journal of pharmacology 20090801 |
| Smoking cessation pharmacotherapy. | Therapeutic advances in cardiovascular disease 20090801 |
| Discovery and functional evaluation of diverse novel human CB(1) receptor ligands. | Bioorganic & medicinal chemistry letters 20090801 |
| Endocannabinoids, sperm biology and human fertility. | Pharmacological research 20090801 |
| Synthesis, cannabinoid receptor affinity, molecular modeling studies and in vivo pharmacological evaluation of new substituted 1-aryl-5-(1H-pyrrol-1-yl)-1H-pyrazole-3-carboxamides. 2. Effect of the 3-carboxamide substituent on the affinity and selectivity profile. | Bioorganic & medicinal chemistry 20090801 |
| 1-(3,5-Dimethyl-1H-pyrazol-1-yl)-3-phenyl-isoquinoline. | Acta crystallographica. Section E, Structure reports online 20090801 |
| Chemical and biological investigation of cyclopropyl containing diaryl-pyrazole-3-carboxamides as novel and potent cannabinoid type 1 receptor antagonists. | Journal of medicinal chemistry 20090723 |
| Discovery of 2-[5-(4-chloro-phenyl)-1-(2,4-dichloro-phenyl)-4-ethyl-1H-pyrazol-3-yl]-1,5,5-trimethyl-1,5-dihydro-imidazol-4-thione (BPR-890) via an active metabolite. A novel, potent and selective cannabinoid-1 receptor inverse agonist with high antiobesity efficacy in DIO mice. | Journal of medicinal chemistry 20090723 |
| Long-term effects of weight-reducing drugs in hypertensive patients. | The Cochrane database of systematic reviews 20090708 |
| Cannabinoid type 1 receptor antagonism delays ascites formation in rats with cirrhosis. | Gastroenterology 20090701 |
| Effect of antiobesity medications in patients with type 2 diabetes mellitus. | Diabetes, obesity & metabolism 20090701 |
| CNR1 gene is associated with high neuroticism and low agreeableness and interacts with recent negative life events to predict current depressive symptoms. | Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20090701 |
| The future of endocannabinoid-oriented clinical research after CB1 antagonists. | Psychopharmacology 20090701 |
| Acute administration of the cannabinoid CB1 antagonist rimonabant impairs positive affective memory in healthy volunteers. | Psychopharmacology 20090701 |
| Single application of a CB1 receptor antagonist rapidly following head injury prevents long-term hyperexcitability in a rat model. | Epilepsy research 20090701 |
| Hit-to-lead optimization of pyrrolo[1,2-a]quinoxalines as novel cannabinoid type 1 receptor antagonists. | Bioorganic & medicinal chemistry letters 20090701 |
| Tesofensine--a novel potent weight loss medicine. Evaluation of: Astrup A, Breum L, Jensen TJ, Kroustrup JP, Larsen TM. Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial. Lancet 2008;372:1906-13. | Expert opinion on investigational drugs 20090701 |
| Effects of chronic treatment with the CB1 antagonist, rimonabant on the blood pressure, and vascular reactivity of obese Zucker rats. | Obesity (Silver Spring, Md.) 20090701 |
| End of the line for cannabinoid receptor 1 as an anti-obesity target? An opinion. | Nature reviews. Drug discovery 20090701 |
| Rimonabant may induce atrial fibrillation. | BMJ (Clinical research ed.) 20090612 |
| Modulation of anxiety by acute blockade and genetic deletion of the CB(1) cannabinoid receptor in mice together with biogenic amine changes in the forebrain. | Behavioural brain research 20090608 |
| Effects of cannabinoid CB1 receptor antagonist rimonabant in consolidation and reconsolidation of methamphetamine reward memory in mice. | Psychopharmacology 20090601 |
| Depolarization-induced release of endocannabinoids by murine dorsal motor nucleus of the vagus nerve neurons differentially regulates inhibitory and excitatory neurotransmission. | Neuropharmacology 20090601 |
| Rimonabant prevents additional accumulation of visceral and subcutaneous fat during high-fat feeding in dogs. | American journal of physiology. Endocrinology and metabolism 20090601 |
| Inhibitors of endocannabinoid-metabolizing enzymes reduce precipitated withdrawal responses in THC-dependent mice. | The AAPS journal 20090601 |
| Synthetic delta-9-tetrahydrocannabinol (dronabinol) can improve the symptoms of schizophrenia. | Journal of clinical psychopharmacology 20090601 |
| New therapeutic agents for diabetes mellitus: implications for anesthetic management. | Anesthesia and analgesia 20090601 |
| The endocannabinoid system: a new pharmacological target for obesity treatment? | Neuroscience bulletin 20090601 |
| Involvement of hypothalamic peptides in the anorectic action of the CB receptor antagonist rimonabant (SR 141716). | The European journal of neuroscience 20090601 |
| [Current and future medical drugs for smoking cessation]. | Laryngo- rhino- otologie 20090601 |
| The psychiatric side-effects of rimonabant. | Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999) 20090601 |
| Effects of the cannabinoid receptor ligands on anxiety-related effects of d-amphetamine and nicotine in the mouse elevated plus maze test. | Journal of physiology and pharmacology : an official journal of the Polish Physiological Society 20090601 |
| Discovery of 2-(2-chlorophenyl)-3-(4-chlorophenyl)-7-(2,2-difluoropropyl)-6,7-dihydro-2H-pyrazolo[3,4-f][1,4]oxazepin-8(5H)-one (PF-514273), a novel, bicyclic lactam-based cannabinoid-1 receptor antagonist for the treatment of obesity. | Journal of medicinal chemistry 20090514 |
| The structure of Rimonabant in the solid state and in solution: an experimental and theoretical study. | European journal of medicinal chemistry 20090501 |
| Attenuation of basal and cocaine-enhanced locomotion and nucleus accumbens dopamine in cannabinoid CB1-receptor-knockout mice. | Psychopharmacology 20090501 |
| Cannabinoid CB1 and cholecystokinin CCK2 receptors modulate, in an opposing way, electrically evoked [3H]GABA efflux from rat cerebral cortex cell cultures: possible relevance for cortical GABA transmission and anxiety. | The Journal of pharmacology and experimental therapeutics 20090501 |
| Changes in symptoms of depression with weight loss: results of a randomized trial. | Obesity (Silver Spring, Md.) 20090501 |
| Cannabinoid receptor-1 blockade attenuates acute pancreatitis in obesity by an adiponectin mediated mechanism. | Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract 20090501 |
| Development and validation of a high-performance liquid chromatographic method for bioanalytical application with rimonabant. | Journal of pharmaceutical and biomedical analysis 20090501 |
| Hair growth stimulator property of thienyl substituted pyrazole carboxamide derivatives as a CB1 receptor antagonist with in vivo antiobesity effect. | Bioorganic & medicinal chemistry letters 20090501 |
| Attrition from randomized controlled trials of pharmacological weight loss agents: a systematic review and analysis. | Obesity reviews : an official journal of the International Association for the Study of Obesity 20090501 |
| Neurobiology and systems physiology of the endocannabinoid system. | Pharmacopsychiatry 20090501 |
| [2008: the end of rimonabant's story]. | Annales pharmaceutiques francaises 20090501 |
| Opioid, cannabinoid CB1 and NOP receptors do not mediate APAP-induced hypothermia in rats. | Pharmacology, biochemistry, and behavior 20090501 |
| Rimonabant affects cyclosporine a, but not tacrolimus pharmacokinetics in renal transplant recipients. | Transplantation 20090427 |
| The FAAH inhibitor URB-597 interferes with cisplatin- and nicotine-induced vomiting in the Suncus murinus (house musk shrew). | Physiology & behavior 20090420 |
| CB1 cannabinoid receptor participates in the vascular hyporeactivity resulting from hemorrhagic shock in rats. | Chinese medical journal 20090420 |
| Synthesis and structure-activity relationship of novel diarylpyrazole imide analogues as CB1 cannabinoid receptor ligands. | Bioorganic & medicinal chemistry 20090415 |
| A role for the endocannabinoid system in the increased motivation for cocaine in extended-access conditions. | The Journal of neuroscience : the official journal of the Society for Neuroscience 20090415 |
| Nonlinear turnover models for systems with physiological limits. | European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20090411 |
| Synthesis and evaluation of dibenzothiazepines: a novel class of selective cannabinoid-1 receptor inverse agonists. | Journal of medicinal chemistry 20090409 |
| Discriminative stimulus functions in rats of AM1346, a high-affinity CB1R selective anandamide analog. | Psychopharmacology 20090401 |
| Apparent affinity estimates of rimonabant in combination with anandamide and chemical analogs of anandamide in rhesus monkeys discriminating Delta9-tetrahydrocannabinol. | Psychopharmacology 20090401 |
| Effects of sibutramine and rimonabant in rats trained to discriminate between 22- and 2-h food deprivation. | Psychopharmacology 20090401 |
| Anandamide-induced behavioral disruption through a vanilloid-dependent mechanism in rats. | Psychopharmacology 20090401 |
| Cannabinoid type 1 receptors in human skeletal muscle cells participate in the negative crosstalk between fat and muscle. | Diabetologia 20090401 |
| Synergy between enzyme inhibitors of fatty acid amide hydrolase and cyclooxygenase in visceral nociception. | The Journal of pharmacology and experimental therapeutics 20090401 |
| Adiponectin is required to mediate rimonabant-induced improvement of insulin sensitivity but not body weight loss in diet-induced obese mice. | American journal of physiology. Regulatory, integrative and comparative physiology 20090401 |
| Oxadiazole-diarylpyrazole 4-carboxamides as cannabinoid CB1 receptor ligands. | Bioorganic & medicinal chemistry letters 20090401 |
| Cannabinoid CB1 receptor antagonists as potential pharmacotherapies for drug abuse disorders. | International review of psychiatry (Abingdon, England) 20090401 |
| Rimonabant: marketing authorization suspended... at last: withdrawal. Half-measures. | Prescrire international 20090401 |
| Impairments in endocannabinoid signaling and depressive illness. | JAMA 20090318 |
| Localization and phenotypic characterization of brainstem neurons activated by rimonabant and WIN55,212-2. | Brain research bulletin 20090316 |
| [Effects of central endocannabinoid system on visceral hyposensitivity induced by rapid eye movement sleep deprivation: experiment with rats]. | Zhonghua yi xue za zhi 20090303 |
| CB(1) and CB(2) cannabinoid receptors mediate different aspects of delta-9-tetrahydrocannabinol (THC)-induced T helper cell shift following immune activation by Legionella pneumophila infection. | Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology 20090301 |
| Endocannabinoids mediate acute fear adaptation via glutamatergic neurons independently of corticotropin-releasing hormone signaling. | Genes, brain, and behavior 20090301 |
| Effect of rimonabant on the high-triglyceride/ low-HDL-cholesterol dyslipidemia, intraabdominal adiposity, and liver fat: the ADAGIO-Lipids trial. | Arteriosclerosis, thrombosis, and vascular biology 20090301 |
| CB1 receptor knockout mice are hyporesponsive to the behavior-stimulating actions of d-amphetamine: role of mGlu5 receptors. | European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology 20090301 |
| Sleep deprivation increases oleoylethanolamide in human cerebrospinal fluid. | Journal of neural transmission (Vienna, Austria : 1996) 20090301 |
| ADAGIO-Lipids gives promises but faces the setbacks. | Arteriosclerosis, thrombosis, and vascular biology 20090301 |
| Cannabinoid receptor antagonists: pharmacological opportunities, clinical experience, and translational prognosis. | Expert opinion on emerging drugs 20090301 |
| Emerging drugs for obesity therapy. | Arquivos brasileiros de endocrinologia e metabologia 20090301 |
| A CB(2) receptor agonist, A-836339, modulates wide dynamic range neuronal activity in neuropathic rats: contributions of spinal and peripheral CB(2) receptors. | Neuroscience 20090218 |
| CB1 receptors mediate the analgesic effects of cannabinoids on colorectal distension-induced visceral pain in rodents. | The Journal of neuroscience : the official journal of the Society for Neuroscience 20090204 |
| Analogs of JHU75528, a PET ligand for imaging of cerebral cannabinoid receptors (CB1): development of ligands with optimized lipophilicity and binding affinity. | European journal of medicinal chemistry 20090201 |
| Rimonabant: a rapidly expanding role in the management of metabolic and systemic disorders besides polycystic ovarian syndrome. | Clinical endocrinology 20090201 |
| An algorithm for tailoring pharmacotherapy for smoking cessation: results from a Delphi panel of international experts. | Tobacco control 20090201 |
| Adiponectin normalization: a clue to the anti-metabolic syndrome action of rimonabant. | Drug discovery today 20090201 |
| Blockade of the endocannabinoid system for the reduction of cardiometabolic risk factors. | Obesity (Silver Spring, Md.) 20090201 |
| The effects of rimonabant on brown adipose tissue in rat: implications for energy expenditure. | Obesity (Silver Spring, Md.) 20090201 |
| 1,2,3-Triazole derivatives as new cannabinoid CB1 receptor antagonists. | Bioorganic & medicinal chemistry letters 20090201 |
| Synthesis and characterization of a peripherally restricted CB1 cannabinoid antagonist, URB447, that reduces feeding and body-weight gain in mice. | Bioorganic & medicinal chemistry letters 20090201 |
| Current pharmacotherapeutic concepts for the treatment of obesity in adults. | Therapeutic advances in cardiovascular disease 20090201 |
| A randomized controlled trial of adding the nicotine patch to rimonabant for smoking cessation: efficacy, safety and weight gain. | Addiction (Abingdon, England) 20090201 |
| Trial comes too late as psychiatric side effects end hope for rimonabant. | Addiction (Abingdon, England) 20090201 |
| [Action mechanisms of anti-obesity drugs]. | Nihon rinsho. Japanese journal of clinical medicine 20090201 |
| The endocannabinoid system: a promising target for the management of type 2 diabetes. | Current protein & peptide science 20090201 |
| The role of the endocannabinoid system in lipogenesis and fatty acid metabolism. | Best practice & research. Clinical endocrinology & metabolism 20090201 |
| Use of cannabinoid CB1 receptor antagonists for the treatment of metabolic disorders. | Best practice & research. Clinical endocrinology & metabolism 20090201 |
| Central side-effects of therapies based on CB1 cannabinoid receptor agonists and antagonists: focus on anxiety and depression. | Best practice & research. Clinical endocrinology & metabolism 20090201 |
| Rimonabant: depression and suicide. | Prescrire international 20090201 |
| The endocannabinoid system and cardiometabolic risk: effects of CB1 receptor blockade on lipid metabolism. | International journal of cardiology 20090124 |
| Discovery of 1-[9-(4-chlorophenyl)-8-(2-chlorophenyl)-9H-purin-6-yl]-4-ethylaminopiperidine-4-carboxylic acid amide hydrochloride (CP-945,598), a novel, potent, and selective cannabinoid type 1 receptor antagonist. | Journal of medicinal chemistry 20090122 |
| Interventions for preventing weight gain after smoking cessation. | The Cochrane database of systematic reviews 20090121 |
| Rimonabant ameliorates insulin resistance via both adiponectin-dependent and adiponectin-independent pathways. | The Journal of biological chemistry 20090116 |
| Glucocorticoids regulate glutamate and GABA synapse-specific retrograde transmission via divergent nongenomic signaling pathways. | The Journal of neuroscience : the official journal of the Society for Neuroscience 20090114 |
| [Pharmacovigilance and teratovigilance 2008]. | Revue medicale suisse 20090114 |
| Non-opioid antinociception produced by brain stem injections of improgan: significance of local, but not cross-regional, cannabinoid mechanisms. | Brain research 20090109 |
| [Nutrition-obesity. Rimonabant and cardiovascular risk factors]. | Revue medicale suisse 20090107 |
| Activated endocannabinoid system in coronary artery disease and antiinflammatory effects of cannabinoid 1 receptor blockade on macrophages. | Circulation 20090106 |
| Delta 9-tetrahydrocannabinol suppresses vomiting behavior and Fos expression in both acute and delayed phases of cisplatin-induced emesis in the least shrew. | Behavioural brain research 20090103 |
| Rimonabant induced anorexia in rodents is not mediated by vagal or sympathetic gut afferents. | Neuroscience letters 20090102 |
| Functional interactions between endocannabinoid and CCK neurotransmitter systems may be critical for extinction learning. | Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20090101 |
| Oral bioavailability of the novel cannabinoid CB1 antagonist AM6527: effects on food-reinforced behavior and comparisons with AM4113. | Pharmacology, biochemistry, and behavior 20090101 |
| A critical review of the cannabinoid receptor as a drug target for obesity management. | Obesity reviews : an official journal of the International Association for the Study of Obesity 20090101 |
| Effects of acute low-dose combined treatment with naloxone and AM 251 on food intake, feeding behaviour and weight gain in rats. | Pharmacology, biochemistry, and behavior 20090101 |
| Rimonabant, a selective cannabinoid CB1 receptor antagonist, inhibits atherosclerosis in LDL receptor-deficient mice. | Arteriosclerosis, thrombosis, and vascular biology 20090101 |
| Characterization of a cannabinoid CB2 receptor-selective agonist, A-836339 [2,2,3,3-tetramethyl-cyclopropanecarboxylic acid [3-(2-methoxy-ethyl)-4,5-dimethyl-3H-thiazol-(2Z)-ylidene]-amide], using in vitro pharmacological assays, in vivo pain models, and pharmacological magnetic resonance imaging. | The Journal of pharmacology and experimental therapeutics 20090101 |
| Divergent effects of anandamide transporter inhibitors with different target selectivity on social play behavior in adolescent rats. | The Journal of pharmacology and experimental therapeutics 20090101 |
| Diarylimidazolyl oxadiazole and thiadiazole derivatives as cannabinoid CB1 receptor antagonists. | Bioorganic & medicinal chemistry letters 20090101 |
| Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects. | Nature chemical biology 20090101 |
| Cannabinoid-1 (CB1) receptors regulate colonic propulsion by acting at motor neurons within the ascending motor pathways in mouse colon. | American journal of physiology. Gastrointestinal and liver physiology 20090101 |
| Effect of delta9-tetrahydrocannabinol, a cannabinoid receptor agonist, on the triggering of transient lower oesophageal sphincter relaxations in dogs and humans. | British journal of pharmacology 20090101 |
| Post-ischemic brain damage: the endocannabinoid system in the mechanisms of neuronal death. | The FEBS journal 20090101 |
| Cannabinoid CB1 receptor antagonists for atherosclerosis and cardiometabolic disorders: new hopes, old concerns? | Arteriosclerosis, thrombosis, and vascular biology 20090101 |
| Antiaversive effects of cannabinoids: is the periaqueductal gray involved? | Neural plasticity 20090101 |
| Metformin maintains the weight loss and metabolic benefits following rimonabant treatment in obese women with polycystic ovary syndrome (PCOS). | Clinical endocrinology 20090101 |
| Recent advances in obesity pharmacotherapy. | Current clinical pharmacology 20090101 |
| Chronic mild stress (CMS) in mice: of anhedonia, 'anomalous anxiolysis' and activity. | PloS one 20090101 |
| Pleiotropic effects of rimonabant: clinical implications. | Current pharmaceutical design 20090101 |
| Withdrawal of Rimonabant--walking the tightrope of 21st century pharmaceutical regulation? | Current drug safety 20090101 |
| Effect of blockage of the endocannabinoid system by CB(1) antagonism on cardiovascular risk. | Pharmacological reports : PR 20090101 |
| [From a crisis to another...Pharmaceutical industry--economics]. | Revue medicale de Liege 20090101 |
| Obesity, the endocannabinoid system, and bias arising from pharmaceutical sponsorship. | PloS one 20090101 |
| Lifestyle-induced metabolic inflexibility and accelerated ageing syndrome: insulin resistance, friend or foe? | Nutrition & metabolism 20090101 |
| PPAR and liver injury in HIV-infected patients. | PPAR research 20090101 |
| Rimonabant: an antagonist drug of the endocannabinoid system for the treatment of obesity. | Pharmacological reports : PR 20090101 |
| The use of sibutramine in the management of obesity and related disorders: an update. | Vascular health and risk management 20090101 |
| [Drug treatment of obesity]. | Revue medicale de Bruxelles 20090101 |
| Cannabinoid receptor activation reverses kainate-induced synchronized population burst firing in rat hippocampus. | Frontiers in integrative neuroscience 20090101 |
| The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. | BMJ (Clinical research ed.) 20090101 |
| Role of the endocannabinoid system in abdominal obesity and the implications for cardiovascular risk. | Cardiology 20090101 |
| Cannabinoid receptor CB1 antagonists state of the art and challenges. | Vitamins and hormones 20090101 |
| Endocannabinoid system and fear conditioning. | Vitamins and hormones 20090101 |
| Endocannabinoid system: An overview of its potential in current medical practice. | Neuro endocrinology letters 20090101 |
| Missing data in randomized clinical trials for weight loss: scope of the problem, state of the field, and performance of statistical methods. | PloS one 20090101 |
| The current status and future perspectives of studies of cannabinoid receptor 1 antagonists as anti-obesity agents. | Current topics in medicinal chemistry 20090101 |
| Polymorphisms of serotonin receptor 2A and 2C genes and COMT in relation to obesity and type 2 diabetes. | PloS one 20090101 |
| Endothelial dysfunction and specific inflammation in obesity hypoventilation syndrome. | PloS one 20090101 |
| The potential for automated question answering in the context of genomic medicine: an assessment of existing resources and properties of answers. | BMC bioinformatics 20090101 |
| Drugs associated with more suicidal ideations are also associated with more suicide attempts. | PloS one 20090101 |
| Systematic review and meta-analysis on the adverse events of rimonabant treatment: considerations for its potential use in hepatology. | BMC gastroenterology 20090101 |
| The endocanabinnoid system and diabetes - critical analyses of studies conducted with rimonabant. | Diabetology & metabolic syndrome 20090101 |
| Melancholic features related to rimonabant. | General hospital psychiatry 20090101 |
| Comparison of rimonabant and sibutramine treatment effects on food compulsion in rats. | Acta cirurgica brasileira 20090101 |
| [Adipose tissue inflammation and atherosclerosis]. | Kardiologiia 20090101 |
| The combination of selective inhibition of the cannabinoid CB1 receptor and activation of the cannabinoid CB2 receptor yields improved attenuation of motor and autonomic deficits in a mouse model of spinal cord injury. | Clinical neurosurgery 20090101 |
| Is there an effective therapy available for non-alcoholic fatty liver disease? | F1000 medicine reports 20090101 |
| Drug addiction. | Current topics in behavioral neurosciences 20090101 |
| Feeding disorders and obesity. | Current topics in behavioral neurosciences 20090101 |
| The potential for automated question answering in the context of genomic medicine: An assessment of existing resources and properties of answers. | Summit on translational bioinformatics 20090101 |
| Cannabinoid CB1 receptor inhibition decreases vascular smooth muscle migration and proliferation. | Biochemical and biophysical research communications 20081226 |
| Endogenous fatty acid ethanolamides suppress nicotine-induced activation of mesolimbic dopamine neurons through nuclear receptors. | The Journal of neuroscience : the official journal of the Society for Neuroscience 20081217 |
| Rational design, synthesis and biological evaluation of new 1,5-diarylpyrazole derivatives as CB1 receptor antagonists, structurally related to rimonabant. | European journal of medicinal chemistry 20081201 |
| A comparison between rimonabant and metformin in reducing biochemical hyperandrogenaemia and insulin resistance in patients with polycystic ovary syndrome (PCOS): a randomized open-label parallel study. | Clinical endocrinology 20081201 |
| Smoking and suicide: a brief overview. | Drug and alcohol dependence 20081201 |
| Exploring the binding features of rimonabant analogues and acyclic CB1 antagonists: docking studies and QSAR analysis. | Journal of molecular modeling 20081201 |
| Facilitation of contextual fear memory extinction and anti-anxiogenic effects of AM404 and cannabidiol in conditioned rats. | European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology 20081201 |
| Antipsychotic-induced alterations in CB1 receptor-mediated G-protein signaling and in vivo pharmacology in rats. | Neuropharmacology 20081201 |
| The cannabinoid CB1 receptor antagonist rimonabant stimulates 2-deoxyglucose uptake in skeletal muscle cells by regulating the expression of phosphatidylinositol-3-kinase. | Molecular pharmacology 20081201 |
| Virodhamine relaxes the human pulmonary artery through the endothelial cannabinoid receptor and indirectly through a COX product. | British journal of pharmacology 20081201 |
| Auditory gating in rat hippocampus and medial prefrontal cortex: effect of the cannabinoid agonist WIN55,212-2. | Neuropharmacology 20081201 |
| CB(1) receptor antagonism: biological basis for metabolic effects. | Drug discovery today 20081201 |
| Dietary treatment for obesity. | Nature clinical practice. Gastroenterology & hepatology 20081201 |
| Brain TRPV1: a depressing TR(i)P down memory lane? | Trends in pharmacological sciences 20081201 |
| Cost-effectiveness of pharmacological anti-obesity treatments: a systematic review. | International journal of obesity (2005) 20081201 |
| Differential response to a selective cannabinoid receptor antagonist (SR141716: rimonabant) in female mice from lines selectively bred for high voluntary wheel-running behaviour. | Behavioural pharmacology 20081201 |
| End of the line for cannabinoid receptor 1 as an anti-obesity target? | Nature reviews. Drug discovery 20081201 |
| High on habits. | Frontiers in neuroscience 20081201 |
| General medical with depression drugs associated. | Psychiatry (Edgmont (Pa. : Township)) 20081201 |
| Biarylpyrazolyl oxadiazole as potent, selective, orally bioavailable cannabinoid-1 receptor antagonists for the treatment of obesity. | Journal of medicinal chemistry 20081127 |
| Reciprocal influences of CB1 cannabinoid receptor agonists on ERK and JNK signalling in N1E-115 cells. | FEBS letters 20081126 |
| The cannabinoid CB1 receptor inverse agonist AM 251 and antagonist AM 4113 produce similar effects on the behavioral satiety sequence in rats. | Behavioural brain research 20081121 |
| Delta-9-tetrahydrocannabinol differently affects striatal c-Fos expression following haloperidol or clozapine administration. | European journal of pharmacology 20081119 |
| The anandamide membrane transporter inhibitor, VDM-11, modulates sleep and c-Fos expression in the rat brain. | Neuroscience 20081111 |
| Constitutive activity at the cannabinoid CB1 receptor is required for behavioral response to noxious chemical stimulation of TRPV1: antinociceptive actions of CB1 inverse agonists. | The Journal of neuroscience : the official journal of the Society for Neuroscience 20081105 |
| Blockade of THC-seeking behavior and relapse in monkeys by the cannabinoid CB(1)-receptor antagonist rimonabant. | Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20081101 |
| Enhancement of endocannabinoid neurotransmission through CB1 cannabinoid receptors counteracts the reinforcing and psychostimulant effects of cocaine. | The international journal of neuropsychopharmacology 20081101 |
| Inhibitory effect of salvinorin A, from Salvia divinorum, on ileitis-induced hypermotility: cross-talk between kappa-opioid and cannabinoid CB(1) receptors. | British journal of pharmacology 20081101 |
| Intrinsic effects of AM4113, a putative neutral CB1 receptor selective antagonist, on open-field behaviors in rats. | Pharmacology, biochemistry, and behavior 20081101 |
| Antinociceptive effects of tetrazole inhibitors of endocannabinoid inactivation: cannabinoid and non-cannabinoid receptor-mediated mechanisms. | British journal of pharmacology 20081101 |
| SERENADE: the Study Evaluating Rimonabant Efficacy in Drug-naive Diabetic Patients: effects of monotherapy with rimonabant, the first selective CB1 receptor antagonist, on glycemic control, body weight, and lipid profile in drug-naive type 2 diabetes. | Diabetes care 20081101 |
| N-arachidonyl maleimide potentiates the pharmacological and biochemical effects of the endocannabinoid 2-arachidonylglycerol through inhibition of monoacylglycerol lipase. | The Journal of pharmacology and experimental therapeutics 20081101 |
| Peripheral, but not central, CB1 antagonism provides food intake-independent metabolic benefits in diet-induced obese rats. | Diabetes 20081101 |
| Effects on food intake and blood lipids of cannabinoid receptor 1 antagonist treatment in lean rats. | Obesity (Silver Spring, Md.) 20081101 |
| [New therapies for type 2 diabetes: what place for incretin-based agents and rimonabant compared to the previous ones?]. | La Revue de medecine interne 20081101 |
| Ethanol self-administration is regulated by CB1 receptors in the nucleus accumbens and ventral tegmental area in alcohol-preferring AA rats. | Alcoholism, clinical and experimental research 20081101 |
| Acute ethanol suppresses glutamatergic neurotransmission through endocannabinoids in hippocampal neurons. | Journal of neurochemistry 20081101 |
| The cannabinoid CB1 receptor and the endocannabinoid anandamide: possible antidepressant targets. | Expert opinion on therapeutic targets 20081101 |
| Effect of rimonabant, micronised fenofibrate and their combination on cardiometabolic risk factors in overweight/obese patients: a pilot study. | Expert opinion on pharmacotherapy 20081101 |
| American College of Endocrinology Pre-Diabetes Consensus Conference: part two. | Diabetes care 20081101 |
| Current and emerging therapies in nonalcoholic fatty liver disease. | Seminars in liver disease 20081101 |
| Differential endocannabinoid regulation of extinction in appetitive and aversive Barnes maze tasks. | Learning & memory (Cold Spring Harbor, N.Y.) 20081101 |
| The effects of medications used for the management of diabetes and obesity on postprandial lipid metabolism. | Current diabetes reviews 20081101 |
| Rimonabant for the treatment of obesity. | Recent patents on cardiovascular drug discovery 20081101 |
| Context-specific reversal of cocaine sensitization by the CB1 cannabinoid receptor antagonist rimonabant. | Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20081001 |
| N-arachidonylethanolamide-induced increase in aqueous humor outflow facility. | Investigative ophthalmology & visual science 20081001 |
| An endocannabinoid signaling system modulates anxiety-like behavior in male Syrian hamsters. | Psychopharmacology 20081001 |
| Lifetime body mass index and later atherosclerosis risk in young adults: examining causal links using Mendelian randomization in the Cardiovascular Risk in Young Finns study. | European heart journal 20081001 |
| Contextual renewal of nicotine seeking in rats and its suppression by the cannabinoid-1 receptor antagonist Rimonabant (SR141716A). | Neuropharmacology 20081001 |
| Prejunctional and peripheral effects of the cannabinoid CB(1) receptor inverse agonist rimonabant (SR 141716). | Naunyn-Schmiedeberg's archives of pharmacology 20081001 |
| Play an ADAGIO with a STRADIVARIUS: the right patient for CB1 receptor antagonists? | Nature clinical practice. Cardiovascular medicine 20081001 |
| Prevention of hepatic fibrosis in a murine model of metabolic syndrome with nonalcoholic steatohepatitis. | The American journal of pathology 20081001 |
| Effects of rimonabant on behavior maintained by progressive ratio schedules of sucrose reinforcement in obese Zucker (fa/fa) rats. | Behavioural pharmacology 20081001 |
| Is rimonabant efficacious and safe in the treatment of obesity? | Expert opinion on pharmacotherapy 20081001 |
| [Sleep disorders associated with treatment with rimonabant]. | Revista de neurologia 20081001 |
| Novel aspects of adipocyte-induced skeletal muscle insulin resistance. | Archives of physiology and biochemistry 20081001 |
| The endocannabinoid system: an osteopathic perspective. | The Journal of the American Osteopathic Association 20081001 |
| Recent advances in the management of type 2 diabetes mellitus: a review. | Postgraduate medical journal 20081001 |
| Effect of weight-reducing agents on glycaemic parameters and progression to Type 2 diabetes: a review. | Diabetic medicine : a journal of the British Diabetic Association 20081001 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20081001 |
| Pharmacotherapy for smoking cessation. | Therapeutic advances in respiratory disease 20081001 |
| [Association of obesity and depression]. | Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology 20081001 |
| Endocannabinoid system and cardio-metabolic risk. | The Medical journal of Malaysia 20081001 |
| Prize sessions. | Indian journal of pharmacology 20081001 |
| Discovery and labeling of high-affinity 3,4-diarylpyrazolines as candidate radioligands for in vivo imaging of cannabinoid subtype-1 (CB1) receptors. | Journal of medicinal chemistry 20080925 |
| Synthesis, ex vivo evaluation, and radiolabeling of potent 1,5-diphenylpyrrolidin-2-one cannabinoid subtype-1 receptor ligands as candidates for in vivo imaging. | Journal of medicinal chemistry 20080925 |
| Bioisosteric replacement of the pyrazole 3-carboxamide moiety of rimonabant. A novel series of oxadiazoles as CB1 cannabinoid receptor antagonists. | Organic & biomolecular chemistry 20080921 |
| Bioisosteric replacement of the pyrazole 5-aryl moiety of N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716A). A novel series of alkynylthiophenes as potent and selective cannabinoid-1 receptor antagonists. | Journal of medicinal chemistry 20080911 |
| Attenuation of cue-induced heroin-seeking behavior by cannabinoid CB1 antagonist infusions into the nucleus accumbens core and prefrontal cortex, but not basolateral amygdala. | Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20080901 |
| Head-to-head studies evaluating efficacy of pharmaco-therapy for obesity: a systematic review and meta-analysis. | Obesity reviews : an official journal of the International Association for the Study of Obesity 20080901 |
| The effect of cannabinoid CB(1) receptor antagonist rimonabant (SR-141716) on ethanol drinking in high-preferring rats. | Alcohol (Fayetteville, N.Y.) 20080901 |
| Differential modulation of AP-1- and CRE-driven transcription by cannabinoid agonists emphasizes functional selectivity at the CB1 receptor. | British journal of pharmacology 20080901 |
| Leptin receptor deficiency is associated with upregulation of cannabinoid 1 receptors in limbic brain regions. | Synapse (New York, N.Y.) 20080901 |
| Reversal of visceral adiposity in candy-diet fed female Wistar rats by the CB1 receptor antagonist rimonabant. | International journal of obesity (2005) 20080901 |
| Depression and weight loss: opposite outcome for surgery and rimonabant? | Obesity reviews : an official journal of the International Association for the Study of Obesity 20080901 |
| Determination of rimonabant in human plasma and hair by liquid chromatography-mass spectrometry. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20080901 |
| Rimonabant and depression. | Pharmacopsychiatry 20080901 |
| Critical role of the endocannabinoid system in the regulation of food intake and energy metabolism, with phylogenetic, developmental, and pathophysiological implications. | Endocrine, metabolic & immune disorders drug targets 20080901 |
| Role of endocannabinoids and their analogues in obesity and eating disorders. | Eating and weight disorders : EWD 20080901 |
| Investigations on the 4-quinolone-3-carboxylic acid motif. 2. Synthesis and structure-activity relationship of potent and selective cannabinoid-2 receptor agonists endowed with analgesic activity in vivo. | Journal of medicinal chemistry 20080828 |
| [CB1 receptor inhibition and glucose metabolism: role of rimonabant in type 2 diabetes]. | Revue medicale suisse 20080827 |
| [Rimonabant helps in overweight patients with multiple cardiovascular risk factors such as type 2 diabetes]. | Revue medicale suisse 20080827 |
| The cannabinoid CB(1) receptor antagonist CE prolongs spatial memory duration in a rat delayed radial arm maze memory task. | European journal of pharmacology 20080820 |
| The CB1 receptor antagonist, SR141716A, prevents high-frequency stimulation-induced reduction of feedback inhibition in the rat dentate gyrus following perforant path stimulation in vivo. | Brain research 20080805 |
| Emerging role of cannabinoids in gastrointestinal and liver diseases: basic and clinical aspects. | Gut 20080801 |
| The endogenous cannabinoid system modulates nicotine reward and dependence. | The Journal of pharmacology and experimental therapeutics 20080801 |
| Cannabinoid type 1 receptor blockade promotes mitochondrial biogenesis through endothelial nitric oxide synthase expression in white adipocytes. | Diabetes 20080801 |
| Endocannabinoid- and mGluR5-dependent short-term synaptic depression in an isolated neuron/bouton preparation from the hippocampal CA1 region. | Journal of neurophysiology 20080801 |
| CB(1) cannabinoid receptor activation dose dependently modulates neuronal activity within caudal but not rostral song control regions of adult zebra finch telencephalon. | Psychopharmacology 20080801 |
| Genetic and pharmacological manipulations of the CB(1) receptor alter ethanol preference and dependence in ethanol preferring and nonpreferring mice. | Synapse (New York, N.Y.) 20080801 |
| The CB1 endocannabinoid system modulates adipocyte insulin sensitivity. | Obesity (Silver Spring, Md.) 20080801 |
| Novel sterically hindered cannabinoid CB1 receptor ligands. | Bioorganic & medicinal chemistry 20080801 |
| Aqueous humor outflow effects of 2-arachidonylglycerol. | Experimental eye research 20080801 |
| Endocannabinoid system in food intake and metabolic regulation. | Current opinion in lipidology 20080801 |
| Satiety signalling histaminergic system and brain-gut peptides in regulation of food intake in rats with portocaval anastomosis. | Journal of physiology and pharmacology : an official journal of the Polish Physiological Society 20080801 |
| Cannabinoid CB(1) receptor antagonist rimonabant attenuates reinstatement of ketamine conditioned place preference in rats. | European journal of pharmacology 20080728 |
| Delta(9)-tetrahydrocannabinol prolongs the immobility time in the mouse forced swim test: involvement of cannabinoid CB(1) receptor and serotonergic system. | European journal of pharmacology 20080728 |
| Additive subthreshold dose effects of cannabinoid CB(1) receptor antagonist and selective serotonin reuptake inhibitor in antidepressant behavioral tests. | European journal of pharmacology 20080728 |
| Rimonabant and progression of atherosclerosis in obese persons. | JAMA 20080716 |
| Facile synthesis, ex-vivo and in vitro screening of 3-sulfonamide derivative of 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxylic acid piperidin-1-ylamide (SR141716) a potent CB1 receptor antagonist. | Bioorganic & medicinal chemistry letters 20080715 |
| Cannabinoid agonists differentially substitute for the discriminative stimulus effects of Delta(9)-tetrahydrocannabinol in C57BL/6J mice. | Psychopharmacology 20080701 |
| Rimonabant blocks the expression but not the development of locomotor sensitization to nicotine in rats. | Psychopharmacology 20080701 |
| Cat odour-induced anxiety--a study of the involvement of the endocannabinoid system. | Psychopharmacology 20080701 |
| Hippocampal endocannabinoids inhibit spatial learning and limit spatial memory in rats. | Psychopharmacology 20080701 |
| Endocannabinoids modulate encoding of sequential memory in the rat hippocampus. | Psychopharmacology 20080701 |
| Discriminative stimulus effects of the cannabinoid CB1 receptor antagonist rimonabant in rats. | Psychopharmacology 20080701 |
| Reply to the letter to the editor 'Long-term cannabinoid receptor (CB1) blockade in obesity: implications for the development of colorectal cancer'. | International journal of cancer 20080701 |
| Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe Study. | European heart journal 20080701 |
| Increase of brain endocannabinoid anandamide levels by FAAH inhibition and alcohol abuse behaviours in the rat. | Psychopharmacology 20080701 |
| Cannabinoid-1 receptor antagonists reduce caloric intake by decreasing palatable diet selection in a novel dessert protocol in female rats. | American journal of physiology. Regulatory, integrative and comparative physiology 20080701 |
| Rimonabant in rats with a metabolic syndrome: good news after the depression. | British journal of pharmacology 20080701 |
| Positron emission tomography imaging using an inverse agonist radioligand to assess cannabinoid CB1 receptors in rodents. | NeuroImage 20080701 |
| Cannabidiol, extracted from Cannabis sativa, selectively inhibits inflammatory hypermotility in mice. | British journal of pharmacology 20080701 |
| The cannabinoid receptor-1 antagonist rimonabant inhibits platelet activation and reduces pro-inflammatory chemokines and leukocytes in Zucker rats. | British journal of pharmacology 20080701 |
| Short- and long-term effects of cannabinoids on the extinction of contextual fear memory in rats. | Neurobiology of learning and memory 20080701 |
| Inhibitors of cannabinoid receptors and glucose metabolism. | Current opinion in clinical nutrition and metabolic care 20080701 |
| The cardiometabolic drug rimonabant: after 2 years of RIO-Europe and STRADIVARIUS. | European heart journal 20080701 |
| The discovery of taranabant, a selective cannabinoid-1 receptor inverse agonist for the treatment of obesity. | Archiv der Pharmazie 20080701 |
| Beyond insulin replacement: addressing the additional needs of the diabetes patient. | Diabetes, obesity & metabolism 20080701 |
| Approaches to treatment of pre-diabetes and obesity and promising new approaches to type 2 diabetes. | Diabetes care 20080701 |
| [Pharmacological treatment options for prevention of alcohol relapse]. | Fortschritte der Neurologie-Psychiatrie 20080701 |
| The element of surprise. | Nature medicine 20080701 |
| Soothing the seizures of children. | Nature medicine 20080701 |
| Acute effects of the cannabinoid receptor agonist WIN55212-2 on dopamine release in rat: an in vivo electrochemical study. | The Chinese journal of physiology 20080630 |
| Conformationally constrained analogues of N-(piperidinyl)-5-(4-chlorophenyl)-1-(2,4- dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716): design, synthesis, computational analysis, and biological evaluations. | Journal of medicinal chemistry 20080626 |
| The cannabinoid CB1 receptor antagonist rimonabant dose-dependently inhibits memory recall in the passive avoidance task in domestic chicks (Gallus domesticus). | Brain research bulletin 20080615 |
| Enhanced striatal glutamate release after the administration of rimonabant to 6-hydroxydopamine-lesioned rats. | Neuroscience letters 20080613 |
| Endogenous opioids and cannabinoids: system interactions in the regulation of appetite, grooming and scratching. | Physiology & behavior 20080609 |
| Impaired cannabinoid receptor type 1 signaling interferes with stress-coping behavior in mice. | The pharmacogenomics journal 20080601 |
| Cannabinoid CB1 receptor antagonists attenuate cocaine's rewarding effects: experiments with self-administration and brain-stimulation reward in rats. | Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20080601 |
| Expression and function of CB1 receptor in the rat striatum: localization and effects on D1 and D2 dopamine receptor-mediated motor behaviors. | Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20080601 |
| The cannabinoid delta-9-tetrahydrocannabinol mediates inhibition of macrophage chemotaxis to RANTES/CCL5: linkage to the CB2 receptor. | Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology 20080601 |
| CXCR2 chemokine receptor antagonism enhances DOP opioid receptor function via allosteric regulation of the CXCR2-DOP receptor heterodimer. | The Biochemical journal 20080601 |
| Cannabinoids inhibit network-driven synapse loss between hippocampal neurons in culture. | The Journal of pharmacology and experimental therapeutics 20080601 |
| Aminopyrazine CB1 receptor inverse agonists. | Bioorganic & medicinal chemistry letters 20080601 |
| Cannabinoid receptor 1 blocker rimonabant (SR 141716) for treatment of alcohol dependence: results from a placebo-controlled, double-blind trial. | Journal of clinical psychopharmacology 20080601 |
| The role of CB1 receptors in psychostimulant addiction. | Addiction biology 20080601 |
| Blocking cannabinoid CB1 receptors for the treatment of nicotine dependence: insights from pre-clinical and clinical studies. | Addiction biology 20080601 |
| Pharmacotherapy for obesity in menopausal women. | Menopause international 20080601 |
| Activation of endocannabinoid transmission induces antidepressant-like effects in rats. | Journal of physiology and pharmacology : an official journal of the Polish Physiological Society 20080601 |
| Smoking cessation therapy with varenicline. | International journal of chronic obstructive pulmonary disease 20080601 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20080601 |
| Early vascular aging (EVA): consequences and prevention. | Vascular health and risk management 20080601 |
| Nutrigenomic analysis of diet-gene interactions on functional supplements for weight management. | Current genomics 20080601 |
| Locomotor effects of morphine or alcohol in mice after a repeated treatment with the cannabinoid agonist HU 210. | European journal of pharmacology 20080531 |
| [Positive influence on cardiovascular risk factor by blocking the endocannabinoid system]. | Praxis 20080528 |
| Liquid chromatography tandem mass spectrometry method for the quantification of rimonabant, a CB1 receptor antagonist, in human plasma. | Biomedical chromatography : BMC 20080501 |
| Effects of rimonabant, a cannabinoid CB1 receptor ligand, on energy expenditure in lean rats. | International journal of obesity (2005) 20080501 |
| Effects of a Cannabinoid1 receptor antagonist and Serotonin2C receptor agonist alone and in combination on motivation for palatable food: a dose-addition analysis study in mice. | The Journal of pharmacology and experimental therapeutics 20080501 |
| Increased energy expenditure contributes more to the body weight-reducing effect of rimonabant than reduced food intake in candy-fed wistar rats. | Endocrinology 20080501 |
| First in vivo evidence for a functional interaction between chemokine and cannabinoid systems in the brain. | The Journal of pharmacology and experimental therapeutics 20080501 |
| The phytocannabinoid Delta(9)-tetrahydrocannabivarin modulates inhibitory neurotransmission in the cerebellum. | British journal of pharmacology 20080501 |
| CB1 receptor blockade reduces the anxiogenic-like response and ameliorates the neurochemical imbalances associated with alcohol withdrawal in rats. | Neuropharmacology 20080501 |
| Cytochrome P-450 metabolites of 2-arachidonoylglycerol play a role in Ca2+-induced relaxation of rat mesenteric arteries. | American journal of physiology. Heart and circulatory physiology 20080501 |
| Modulation of sensory neuron potassium conductances by anandamide indicates roles for metabolites. | British journal of pharmacology 20080501 |
| A saturated N-acylethanolamine other than N-palmitoyl ethanolamine with anti-inflammatory properties: a neglected story.. | Journal of neuroendocrinology 20080501 |
| Endocannabinoids, blood pressure and the human heart. | Journal of neuroendocrinology 20080501 |
| Blood pressure lowering effects of rimonabant in obesity-related hypertension. | Journal of neuroendocrinology 20080501 |
| Endocannabinoids: some like it fat (and sweet too). | Journal of neuroendocrinology 20080501 |
| Dysregulation of the endocannabinoid system in obesity. | Journal of neuroendocrinology 20080501 |
| Central versus peripheral antagonism of cannabinoid CB1 receptor in obesity: effects of LH-21, a peripherally acting neutral cannabinoid receptor antagonist, in Zucker rats. | Journal of neuroendocrinology 20080501 |
| Endocannabinoids, adipose tissue and lipid metabolism. | Journal of neuroendocrinology 20080501 |
| Cannabinoid type 1 receptor: another arrow in the adipocytes' bow. | Journal of neuroendocrinology 20080501 |
| CB1 receptor blockade and its impact on cardiometabolic risk factors: overview of the RIO programme with rimonabant. | Journal of neuroendocrinology 20080501 |
| The endocannabinoid system and the control of glucose homeostasis. | Journal of neuroendocrinology 20080501 |
| The challenge of treating obesity: the endocannabinoid system as a potential target. | Journal of the American Dietetic Association 20080501 |
| [Adipocytokines: implications in the prognosis and drug treatment of cardiovascular diseases]. | Revista clinica espanola 20080501 |
| Suppression by the cannabinoid CB1 receptor antagonist, rimonabant, of the reinforcing and motivational properties of a chocolate-flavoured beverage in rats. | Behavioural pharmacology 20080501 |
| [Treatment of type 2 diabetes with new oral antihyperglycaemic drugs]. | MMW Fortschritte der Medizin 20080501 |
| [Rimonabant. Risk of depression has not been finally clarified]. | Medizinische Monatsschrift fur Pharmazeuten 20080501 |
| Constitutive activity of the cannabinoid CB1 receptor regulates the function of co-expressed Mu opioid receptors. | The Journal of biological chemistry 20080425 |
| Identification of novel cannabinoid CB1 receptor antagonists by using virtual screening with a pharmacophore model. | Journal of medicinal chemistry 20080424 |
| Long term cannabinoid receptor (CB1) blockade in obesity: implications for the development of colorectal cancer. | International journal of cancer 20080415 |
| Conformational analysis and receptor docking of N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-{[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (taranabant, MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist. | Journal of medicinal chemistry 20080410 |
| Benzodioxoles: novel cannabinoid-1 receptor inverse agonists for the treatment of obesity. | Journal of medicinal chemistry 20080410 |
| Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial. | JAMA 20080402 |
| The hope and fear of rimonabant. | JAMA 20080402 |
| [The endocannabinoid system]. | Praxis 20080402 |
| Bidirectional cannabinoid modulation of social behavior in adolescent rats. | Psychopharmacology 20080401 |
| Design, synthesis and biological evaluation of piperazine analogues as CB1 cannabinoid receptor ligands. | Bioorganic & medicinal chemistry 20080401 |
| Inhibitory effect of the anorexic compound oleoylethanolamide on gastric emptying in control and overweight mice. | Journal of molecular medicine (Berlin, Germany) 20080401 |
| [New oral antidiabetic agents--clinical perspectives]. | Der Internist 20080401 |
| Tetrazole-biarylpyrazole derivatives as cannabinoid CB1 receptor antagonists. | Bioorganic & medicinal chemistry letters 20080401 |
| Update on pharmacologic options for smoking cessation treatment. | The American journal of medicine 20080401 |
| Smoking cessation 2008. | IDrugs : the investigational drugs journal 20080401 |
| Stress-induced analgesia in mice: evidence for interaction between endocannabinoids and cholecystokinin. | The European journal of neuroscience 20080401 |
| Prevention and noninvasive management of coronary atherosclerosis in patients with diabetes. | Current atherosclerosis reports 20080401 |
| Orlistat in the prevention of diabetes in the obese patient. | Vascular health and risk management 20080401 |
| Varenicline in the treatment of tobacco dependence. | Neuropsychiatric disease and treatment 20080401 |
| [Residual risk in cardiovascular prevention]. | Giornale italiano di cardiologia (2006) 20080401 |
| [Dyslipidemia in visceral obesity: pathophysiological mechanisms, clinical implications and therapy]. | Giornale italiano di cardiologia (2006) 20080401 |
| [Pharmacological therapy of obesity]. | Giornale italiano di cardiologia (2006) 20080401 |
| Synthesis, cannabinoid receptor affinity, and molecular modeling studies of substituted 1-aryl-5-(1H-pyrrol-1-yl)-1H-pyrazole-3-carboxamides. | Journal of medicinal chemistry 20080327 |
| Indol-3-yl-tetramethylcyclopropyl ketones: effects of indole ring substitution on CB2 cannabinoid receptor activity. | Journal of medicinal chemistry 20080327 |
| Some effects of CB1 antagonists with inverse agonist and neutral biochemical properties. | Physiology & behavior 20080318 |
| Pharmacotherapeutic targeting of the endocannabinoid signaling system: drugs for obesity and the metabolic syndrome. | Physiology & behavior 20080318 |
| Cannabinoid CB(1) receptor activation modulates spontaneous contractile activity in mouse ileal longitudinal muscle. | European journal of pharmacology 20080317 |
| Trimethylaluminium mediated amide bond formation in a continuous flow microreactor as key to the synthesis of rimonabant and efaproxiral. | Chemical communications (Cambridge, England) 20080307 |
| Rimonabant (SR141716) exerts anti-proliferative and immunomodulatory effects in human peripheral blood mononuclear cells. | British journal of pharmacology 20080301 |
| Alcohol inhibits spontaneous activity of basolateral amygdala projection neurons in the rat: involvement of the endocannabinoid system. | Alcoholism, clinical and experimental research 20080301 |
| The role of endocannabinoids in the regulation of gastric emptying: alterations in mice fed a high-fat diet. | British journal of pharmacology 20080301 |
| Cannabinoid receptor 2 (CB2) mediates immunoglobulin class switching from IgM to IgE in cultures of murine-purified B lymphocytes. | Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology 20080301 |
| Determination of endocannabinoid receptor antagonist SR141716 (rimonabant) in plasma by liquid chromatograph tandem mass spectrometry. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20080301 |
| Oral administration of the antiobesity drugs, sibutramine and rimonabant, increases acetylcholine efflux selectively in the medial prefrontal cortex of the rat. | Molecular psychiatry 20080301 |
| Cannabinoids provoke alcoholic steatosis through a conspiracy of neighbors. | Cell metabolism 20080301 |
| Paracrine activation of hepatic CB1 receptors by stellate cell-derived endocannabinoids mediates alcoholic fatty liver. | Cell metabolism 20080301 |
| Rimonabant for overweight and 'metabolic syndrome': the attempt to supersize disease and risk by pharmaceutical marketing. | Internal and emergency medicine 20080301 |
| Pharmacotherapy and psychotherapy in cannabis withdrawal and dependence. | Expert review of neurotherapeutics 20080301 |
| [Prescription of rimonabant in the early stage of pregnancy?]. | Medizinische Monatsschrift fur Pharmazeuten 20080301 |
| Identification of a presynaptic cannabinoid CB1 receptor in the guinea-pig atrium and sequencing of the guinea-pig CB1 receptor. | Journal of physiology and pharmacology : an official journal of the Polish Physiological Society 20080301 |
| [Rimonabant (Acomplia)]. | Journal de pharmacie de Belgique 20080301 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20080301 |
| [The endocannabinoid system and treatment of obesity]. | Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke 20080227 |
| Efficacy and safety of the weight-loss drug rimonabant. | Lancet (London, England) 20080216 |
| Efficacy and safety of the weight-loss drug rimonabant. | Lancet (London, England) 20080216 |
| Involvement of subthalamic nucleus in the stimulatory effect of Delta(9)-tetrahydrocannabinol on dopaminergic neurons. | Neuroscience 20080206 |
| [Metabolic syndrome: jumble syndrome of obesity or specific entity? Which treatment: diet or polypill?]. | Revue medicale suisse 20080206 |
| [The endocannabinoid system as a novel target for the treatment of liver fibrosis]. | Pathologie-biologie 20080201 |
| Involvement of kappa-opioid and endocannabinoid system on Salvinorin A-induced reward. | Biological psychiatry 20080201 |
| Co-administration of SR141716 with peptide YY3-36 or oxyntomodulin has additive effects on food intake in mice. | Diabetes, obesity & metabolism 20080201 |
| Cannabinoids stimulate prostaglandin production by human gestational tissues through a tissue- and CB1-receptor-specific mechanism. | American journal of physiology. Endocrinology and metabolism 20080201 |
| The cannabinoid antagonist AM251 attenuates nicotine self-administration and nicotine-seeking behaviour in rats. | Neuropharmacology 20080201 |
| Adiponectin: an update. | Diabetes & metabolism 20080201 |
| Management of type 2 diabetes in the obese patient: current concerns and emerging therapies. | Current medical research and opinion 20080201 |
| Effect of rimonabant on blood pressure in overweight/obese patients with/without co-morbidities: analysis of pooled RIO study results. | Journal of hypertension 20080201 |
| Topical WIN55212-2 alleviates intraocular hypertension in rats through a CB1 receptor mediated mechanism of action. | Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics 20080201 |
| Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: pooled 1-year data from the Rimonabant in Obesity (RIO) program. | Diabetes care 20080201 |
| Is weight loss beneficial for reduction of morbidity and mortality? What is the controversy about? | Diabetes care 20080201 |
| Rimonabant: new data and emerging experience. | Current atherosclerosis reports 20080201 |
| Endocannabinoid system overactivity and the metabolic syndrome: prospects for treatment. | Current diabetes reports 20080201 |
| Local administration of a cannabinoid agonist alters norepinephrine efflux in the rat frontal cortex. | Neuroscience letters 20080124 |
| Delta 9-tetrahydrocannabinol-induced catalepsy-like immobilization is mediated by decreased 5-HT neurotransmission in the nucleus accumbens due to the action of glutamate-containing neurons. | Neuroscience 20080124 |
| Obesity in adults. | BMJ clinical evidence 20080118 |
| [Pharmacovigilance update]. | Revue medicale suisse 20080116 |
| The PET radioligand [11C]MePPEP binds reversibly and with high specific signal to cannabinoid CB1 receptors in nonhuman primate brain. | Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20080101 |
| The cannabinoid CB1 receptor antagonist SR141716A (Rimonabant) enhances the metabolic benefits of long-term treatment with oleoylethanolamide in Zucker rats. | Neuropharmacology 20080101 |
| Methanandamide activation of a novel current in mouse trigeminal ganglion sensory neurons in vitro. | Neuropharmacology 20080101 |
| Regulation of hypothalamic endocannabinoid levels by neuropeptides and hormones involved in food intake and metabolism: insulin and melanocortins. | Neuropharmacology 20080101 |
| Cannabinoid receptor-mediated translocation of NO-sensitive guanylyl cyclase and production of cyclic GMP in neuronal cells. | Neuropharmacology 20080101 |
| Reduced anxiety-like behaviour induced by genetic and pharmacological inhibition of the endocannabinoid-degrading enzyme fatty acid amide hydrolase (FAAH) is mediated by CB1 receptors. | Neuropharmacology 20080101 |
| Cross-sensitization and cross-tolerance between exogenous cannabinoid antinociception and endocannabinoid-mediated stress-induced analgesia. | Neuropharmacology 20080101 |
| Type-1 cannabinoid receptors colocalize with caveolin-1 in neuronal cells. | Neuropharmacology 20080101 |
| CB1-cannabinoid receptors are involved in the modulation of non-synaptic [3H]serotonin release from the rat hippocampus. | Neurochemistry international 20080101 |
| Long-term cognitive deficits induced by a single, extremely low dose of tetrahydrocannabinol (THC): behavioral, pharmacological and biochemical studies in mice. | Pharmacology, biochemistry, and behavior 20080101 |
| Pretreatment with subeffective doses of Rimonabant attenuates orexigenic actions of orexin A-hypocretin 1. | Neuropharmacology 20080101 |
| Antidepressant-like behavioral effects of impaired cannabinoid receptor type 1 signaling coincide with exaggerated corticosterone secretion in mice. | Psychoneuroendocrinology 20080101 |
| Cannabinoid-mediated neuroprotection, not immunosuppression, may be more relevant to multiple sclerosis. | Journal of neuroimmunology 20080101 |
| [Pharmacotherapy of obesity]. | Der Internist 20080101 |
| An update on therapeutics for tobacco dependence. | Expert opinion on pharmacotherapy 20080101 |
| Role of the endocannabinoid system in metabolic control. | Current opinion in nephrology and hypertension 20080101 |
| Cost-utility analysis of rimonabant in the treatment of obesity. | Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 20080101 |
| Obesity: a review of pathogenesis and management strategies. | Canadian journal of gastroenterology = Journal canadien de gastroenterologie 20080101 |
| Pharmacological regulation of dyslipoproteinaemia in insulin resistant states. | Current vascular pharmacology 20080101 |
| Role of the endocannabinoid system in energy balance regulation and obesity. | Frontiers of hormone research 20080101 |
| Emerging concepts in the medical and surgical treatment of obesity. | Frontiers of hormone research 20080101 |
| CB1 cannabinoid antagonists: structure-activity relationships and potential therapeutic applications. | Current topics in medicinal chemistry 20080101 |
| [Correct prescription of Acomplia (rimonabant) is assured by knowledge]. | Lakartidningen 20080101 |
| [Medication of the month. Rimonabant (Acomplia): first CB1 receptor antagonist of the endocannabinoid system]. | Revue medicale de Liege 20080101 |
| Review: orlistat, sibutramine, and rimonabant reduce weight in overweight and obese persons. | ACP journal club 20080101 |
| The orexigenic effect of ghrelin is mediated through central activation of the endogenous cannabinoid system. | PloS one 20080101 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20080101 |
| Characterisation of the cannabinoid receptor system in synovial tissue and fluid in patients with osteoarthritis and rheumatoid arthritis. | Arthritis research & therapy 20080101 |
| Novel pharmacological approaches for treating tobacco dependence and withdrawal: current status. | Drugs 20080101 |
| Feeding induced by cannabinoids is mediated independently of the melanocortin system. | PloS one 20080101 |
| [Cannabinoid system and feeding regulation]. | Adicciones 20080101 |
| Cannabinoid CB1 receptor antagonists in therapeutic and structural perspectives. | Chemical record (New York, N.Y.) 20080101 |
| STRADIVARIUS: a brave trial aimed at clarifying benefits of rimonabant therapy. | Cardiovascular journal of Africa 20080101 |
| [Buerger's disease: current concepts]. | Revista portuguesa de cirurgia cardio-toracica e vascular : orgao oficial da Sociedade Portuguesa de Cirurgia Cardio-Toracica e Vascular 20080101 |
| Modification of cardiometabolic risk through cannabinoid type-1 receptor antagonism. | Angiology 20080101 |
| Neuropharmacology of human appetite expression. | Developmental disabilities research reviews 20080101 |
| [Endocannabinoid system in the brain...and elsewhere]. | Revue medicale de Liege 20080101 |
| [Raising HDL cholesterol: which is the best strategy?]. | Revista da Associacao Medica Brasileira (1992) 20080101 |
| [Role of cannabinoid receptors in regulation of cardiac tolerance to ischemia and reperfusion]. | Izvestiia Akademii nauk. Seriia biologicheskaia 20080101 |
| Loss of cannabinoid receptor CB1 induces preterm birth. | PloS one 20080101 |
| New drugs for type 2 diabetes mellitus: what is their place in therapy? | Drugs 20080101 |
| Modeling transitions in body composition: the approach to steady state for anthropometric measures and physiological functions in the Minnesota human starvation study. | Dynamic medicine : DM 20080101 |
| Gateways to clinical trials. July-August 2008. | Methods and findings in experimental and clinical pharmacology 20080101 |
| The prince and the pauper. A tale of anticancer targeted agents. | Molecular cancer 20080101 |
| Enhancement of a modified Mediterranean-style, low glycemic load diet with specific phytochemicals improves cardiometabolic risk factors in subjects with metabolic syndrome and hypercholesterolemia in a randomized trial. | Nutrition & metabolism 20080101 |
| PPARdelta Agonism for the Treatment of Obesity and Associated Disorders: Challenges and Opportunities. | PPAR research 20080101 |
| Rimonabant improves weight and glycaemic control: first oral antidiabetic therapy in newly diagnosed type 2 diabetics. | Cardiovascular journal of Africa 20080101 |
| Activation instead of blocking mesolimbic dopaminergic reward circuitry is a preferred modality in the long term treatment of reward deficiency syndrome (RDS): a commentary. | Theoretical biology & medical modelling 20080101 |
| Lack of association of genetic variants in genes of the endocannabinoid system with anorexia nervosa. | Child and adolescent psychiatry and mental health 20080101 |
| Different transcriptional control of metabolism and extracellular matrix in visceral and subcutaneous fat of obese and rimonabant treated mice. | PloS one 20080101 |
| Obesity-related cardiometabolic complications. | Clinical cornerstone 20080101 |
| The endocannabinoid system as a target for obesity treatment. | Clinical cornerstone 20080101 |
| [New avenues for pharmacotherapy of type 2 diabetes mellitus]. | Klinicheskaia meditsina 20080101 |
| CB1 cannabinoid receptor inhibition: promising approach for heart failure? | Congestive heart failure (Greenwich, Conn.) 20080101 |
| Smoking cessation in cardiovascular patients. | Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese 20080101 |
| New therapeutic approaches in type 2 diabetes. | Acta clinica Belgica 20080101 |
| Post-graduate CME. | Indian journal of psychiatry 20080101 |
| Psychosis following anti-obesity treatment with rimonabant. | Obesity facts 20080101 |
| Metabolic syndrome and chronic kidney disease. | Indian journal of nephrology 20080101 |
| Behaviour therapy for obesity treatment considering approved drug therapy. | GMS health technology assessment 20080101 |
| Potentiation of electrical and chemical synaptic transmission mediated by endocannabinoids. | Neuron 20071220 |
| [Still questions around the slimming agent rimobant. Not approved in USA because of the risk of mental adverse effects]. | Lakartidningen 20071219 |
| Cannabinoid-1 receptor blockade in cardiometabolic risk reduction: efficacy. | The American journal of cardiology 20071217 |
| Cannabinoid-1 receptor blockade in cardiometabolic risk reduction: safety, tolerability, and therapeutic potential. | The American journal of cardiology 20071217 |
| [A meta-analysis of the efficacy and safety of the anti-obesity agent Rimonabant]. | Ugeskrift for laeger 20071210 |
| Long term pharmacotherapy for obesity and overweight: updated meta-analysis. | BMJ (Clinical research ed.) 20071208 |
| Effect of cannabinoid CB1 receptor antagonist SR141716A and CB1 receptor knockout on cue-induced reinstatement of Ensure and corn-oil seeking in mice. | Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20071201 |
| Cannabinoid CB1 receptor stimulation affords neuroprotection in MPTP-induced neurotoxicity by attenuating S100B up-regulation in vitro. | Journal of molecular medicine (Berlin, Germany) 20071201 |
| The uncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist memantine prolongs spatial memory in a rat delayed radial-arm maze memory task. | European journal of pharmacology 20071201 |
| Discovery of 1,1-dioxo-1,2,6-thiadiazine-5-carboxamide derivatives as cannabinoid-like molecules with agonist and antagonist activity. | Bioorganic & medicinal chemistry 20071201 |
| The orphan receptor GPR55 is a novel cannabinoid receptor. | British journal of pharmacology 20071201 |
| Blockade of cannabinoid CB1 receptors improves renal function, metabolic profile, and increased survival of obese Zucker rats. | Kidney international 20071201 |
| New 1,8-naphthyridine and quinoline derivatives as CB2 selective agonists. | Bioorganic & medicinal chemistry letters 20071201 |
| Functional blockage of the cannabinoid receptor type 1 evokes a kappa-opiate-dependent analgesia. | Journal of neurochemistry 20071201 |
| Increased depressor response to N-arachidonoyl-dopamine during high salt intake: role of the TRPV1 receptor. | Journal of hypertension 20071201 |
| C-terminal truncated cannabinoid receptor 1 coexpressed with G protein trimer in Sf9 cells exists in a precoupled state and shows constitutive activity. | The FEBS journal 20071201 |
| Cannabinoid-induced tolerance is associated with a CB1 receptor G protein coupling switch that is prevented by ultra-low dose rimonabant. | Behavioural pharmacology 20071201 |
| CB1 receptor-mediated control of the release of endocannabinoids (as assessed by microdialysis coupled with LC/MS) in the rat hypothalamus. | The European journal of neuroscience 20071201 |
| Cannabinoid-1 receptor antagonists in type-2 diabetes. | Best practice & research. Clinical endocrinology & metabolism 20071201 |
| Rimonabant: suicide and depression. Depression and suicidal tendencies are about twice as frequent with rimonabant as with placebo. | Prescrire international 20071201 |
| Cannabinoids in health and disease. | Dialogues in clinical neuroscience 20071201 |
| Pharmacogenetic aspects of addictive behaviors. | Dialogues in clinical neuroscience 20071201 |
| Pharmacotherapy for obesity. | Current atherosclerosis reports 20071201 |
| Role of endocannabinoids in regulating drug dependence. | Neuropsychiatric disease and treatment 20071201 |
| Endocannabinoid signaling in midbrain dopamine neurons: more than physiology? | Current neuropharmacology 20071201 |
| Diaryl dihydropyrazole-3-carboxamides with significant in vivo antiobesity activity related to CB1 receptor antagonism: synthesis, biological evaluation, and molecular modeling in the homology model. | Journal of medicinal chemistry 20071129 |
| [Antiobesity drugs--new limitations]. | Revue medicale suisse 20071128 |
| [The endocannabinoid system, overweight, and the CB1-endocannabinoid-receptor antagonist rimonabant]. | Nederlands tijdschrift voor geneeskunde 20071124 |
| [New drugs; rimonabant]. | Nederlands tijdschrift voor geneeskunde 20071124 |
| Depression and anxiety with rimonabant. | Lancet (London, England) 20071117 |
| Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. | Lancet (London, England) 20071117 |
| Cannabinoid CB(2) receptor activation prevents bronchoconstriction and airway oedema in a model of gastro-oesophageal reflux. | European journal of pharmacology 20071114 |
| Cannabinoid CB(1) receptor and gastric acid secretion. | Digestive diseases and sciences 20071101 |
| Activation of cannabinoid CB1 and CB2 receptors suppresses neuropathic nociception evoked by the chemotherapeutic agent vincristine in rats. | British journal of pharmacology 20071101 |
| PSNCBAM-1, a novel allosteric antagonist at cannabinoid CB1 receptors with hypophagic effects in rats. | British journal of pharmacology 20071101 |
| Single and multiple doses of rimonabant antagonize acute effects of smoked cannabis in male cannabis users. | Psychopharmacology 20071101 |
| Grooming, scratching and feeding: role of response competition in acute anorectic response to rimonabant in male rats. | Psychopharmacology 20071101 |
| Significance of cannabinoid CB1 receptors in improgan antinociception. | The journal of pain : official journal of the American Pain Society 20071101 |
| The endogenous cannabinoid anandamide inhibits cromakalim-activated K+ currents in follicle-enclosed Xenopus oocytes. | The Journal of pharmacology and experimental therapeutics 20071101 |
| Management of obesity in patients with peripheral arterial disease. | European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery 20071101 |
| The inhibition of monoacylglycerol lipase by URB602 showed an anti-inflammatory and anti-nociceptive effect in a murine model of acute inflammation. | British journal of pharmacology 20071101 |
| GPR55 and the vascular receptors for cannabinoids. | British journal of pharmacology 20071101 |
| Characterization of the vasorelaxant mechanisms of the endocannabinoid anandamide in rat aorta. | British journal of pharmacology 20071101 |
| Inhibition of milk ingestion and growth after administration of a neutral cannabinoid CB1 receptor antagonist on the first postnatal day in the mouse. | Pediatric research 20071101 |
| Lack of depolarization-induced suppression of inhibition (DSI) in layer 2/3 interneurons that receive cannabinoid-sensitive inhibitory inputs. | Journal of neurophysiology 20071101 |
| The genetic versus pharmacological invalidation of the cannabinoid CB(1) receptor results in differential effects on 'non-associative' memory and forebrain monoamine concentrations in mice. | Neurobiology of learning and memory 20071101 |
| Vascular pharmacology of a novel cannabinoid-like compound, 3-(5-dimethylcarbamoyl-pent-1-enyl)-N-(2-hydroxy-1-methyl-ethyl)benzamide (VSN16) in the rat. | British journal of pharmacology 20071101 |
| Inhibition of 2-arachidonoylglycerol catabolism modulates vasoconstriction of rat middle cerebral artery by the thromboxane mimetic, U-46619. | British journal of pharmacology 20071101 |
| Endocannabinoid system and cardiometabolic risk. | Clinical pharmacology and therapeutics 20071101 |
| Acute anorectic response to cannabinoid CB1 receptor antagonist/inverse agonist AM 251 in rats: indirect behavioural mediation. | Behavioural pharmacology 20071101 |
| Effects of AM1346, a high-affinity CB1 receptor selective anandamide analog, on open-field behavior in rats. | Behavioural pharmacology 20071101 |
| The effect of CB(1) receptor antagonism in the right basolateral amygdala on conditioned fear and associated analgesia in rats. | The European journal of neuroscience 20071101 |
| Rimonabant: the role of endocannabinoid type 1 receptor antagonism in modulating the weight and lipid profile of obese patients. | Current atherosclerosis reports 20071101 |
| The endocannabinoid system: novel pathway for cardiometabolic Risk-factor reduction. | JAAPA : official journal of the American Academy of Physician Assistants 20071101 |
| Cannabinoids elicit antidepressant-like behavior and activate serotonergic neurons through the medial prefrontal cortex. | The Journal of neuroscience : the official journal of the Society for Neuroscience 20071024 |
| [Obesity: a review of currently used antiobesity drugs and new compounds in clinical development]. | Postepy higieny i medycyny doswiadczalnej (Online) 20071019 |
| Cannabinoid type 1 receptor antagonists (rimonabant) for smoking cessation. | The Cochrane database of systematic reviews 20071017 |
| [Obesity in adults]. | Praxis 20071017 |
| Cannabinoid receptor antagonists counteract sensorimotor gating deficits in the phencyclidine model of psychosis. | Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20071001 |
| Effects of SR141716 and WIN 55,212-2 on tolerance to ethanol in rats using the acute and rapid procedures. | Psychopharmacology 20071001 |
| Cortico-limbic circuitry for conditioned nicotine-seeking behavior in rats involves endocannabinoid signaling. | Psychopharmacology 20071001 |
| The endocannabinoid anandamide inhibits the function of alpha4beta2 nicotinic acetylcholine receptors. | Molecular pharmacology 20071001 |
| Rimonabant as a novel therapeutic option for nonalcoholic steatohepatitis. | Liver international : official journal of the International Association for the Study of the Liver 20071001 |
| Mediterranean diet and the metabolic syndrome. | Molecular nutrition & food research 20071001 |
| Drugs in the treatment of obesity: sibutramine, orlistat and rimonabant. | Public health nutrition 20071001 |
| Understanding cannabinoid psychoactivity with mouse genetic models. | PLoS biology 20071001 |
| Adipose tissue and diabetes therapy: do we hit the target? | Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme 20071001 |
| [Prevention of cardiovascular disease by blocking the endocannabinoid system]. | Herz 20071001 |
| Endocannabinoid regulation of matrix metalloproteinases: implications in ischemic stroke. | Cardiovascular & hematological agents in medicinal chemistry 20071001 |
| Strategies to reduce vascular risk associated with obesity. | Current vascular pharmacology 20071001 |
| Does a weight loss medicine make sense for obese type 2 diabetes? New information on endocannabinoid blockers. | Current diabetes reports 20071001 |
| Exenatide and rimonabant: new treatments that may be useful in the management of diabetes and obesity. | Current diabetes reports 20071001 |
| The antinociceptive effect of Delta9-tetrahydrocannabinol in the arthritic rat involves the CB(2) cannabinoid receptor. | European journal of pharmacology 20070910 |
| Delayed treatment with cannabidiol has a cerebroprotective action via a cannabinoid receptor-independent myeloperoxidase-inhibiting mechanism. | Journal of neurochemistry 20070901 |
| Exposure to marijuana smoke impairs memory retrieval in mice. | The Journal of pharmacology and experimental therapeutics 20070901 |
| A call to action: new treatment options provide even more reasons to intervene in tobacco dependence. | Nature clinical practice. Cardiovascular medicine 20070901 |
| Involvement of CB1 and CB2 receptors in the modulation of cholinergic neurotransmission in mouse gastric preparations. | Pharmacological research 20070901 |
| Understanding metabolic homeostasis and imbalance: what is the role of the endocannabinoid system? | The American journal of medicine 20070901 |
| What is the potential role of cannabinoid-1 receptor blockade in glucose and lipid management? | The American journal of medicine 20070901 |
| WIN-55,212-2 chronically implanted into the CA3 region of the dorsal hippocampus impairs learning: a novel method for studying chronic, brain-area-specific effects of cannabinoids. | Behavioural pharmacology 20070901 |
| Short-term memory is modulated by the spontaneous release of endocannabinoids: evidence from hippocampal population codes. | Behavioural pharmacology 20070901 |
| The safety of obesity drugs. | Expert opinion on drug safety 20070901 |
| Rimonabant: a novel approach for the treatment of obesity and cardiometabolic risk by blockade of the endocannabinoid system. | Future cardiology 20070901 |
| Helix 8 Leu in the CB1 cannabinoid receptor contributes to selective signal transduction mechanisms. | The Journal of biological chemistry 20070824 |
| The CB1 cannabinoid receptor mediates excitotoxicity-induced neural progenitor proliferation and neurogenesis. | The Journal of biological chemistry 20070817 |
| Role of cannabinoidergic mechanisms in ethanol self-administration and ethanol seeking in rat adult offspring following perinatal exposure to Delta9-tetrahydrocannabinol. | Toxicology and applied pharmacology 20070815 |
| Emerging pharmacotherapies for smoking cessation. | American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20070815 |
| Differences in the relative potency of SR 141716A and AM 251 as antagonists of various in vivo effects of cannabinoid agonists in C57BL/6J mice. | European journal of pharmacology 20070813 |
| Pharmacological inhibition of CB1 cannabinoid receptor protects against doxorubicin-induced cardiotoxicity. | Journal of the American College of Cardiology 20070807 |
| Endocannabinoid inhibition: a new cardioprotective strategy against doxorubicin cardiotoxicity. | Journal of the American College of Cardiology 20070807 |
| Combination of rimonabant and donepezil prolongs spatial memory duration. | Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20070801 |
| Non-selective cation channels, transient receptor potential channels and ischemic stroke. | Biochimica et biophysica acta 20070801 |
| Regulation of PI3K/Akt/GSK-3 pathway by cannabinoids in the brain. | Journal of neurochemistry 20070801 |
| NOP receptor antagonist, JTC-801, blocks cannabinoid-evoked hypothermia in rats. | Neuropeptides 20070801 |
| The effect of the palmitoylethanolamide analogue, palmitoylallylamide (L-29) on pain behaviour in rodent models of neuropathy. | British journal of pharmacology 20070801 |
| Virodhamine and CP55,940 modulate cAMP production and IL-8 release in human bronchial epithelial cells. | British journal of pharmacology 20070801 |
| Evidence for a modulatory role of cannabinoids on the excitatory NANC neurotransmission in mouse colon. | Pharmacological research 20070801 |
| Fused-core silica column high-performance liquid chromatography/tandem mass spectrometric determination of rimonabant in mouse plasma. | Analytical chemistry 20070801 |
| Evidence for the involvement of cannabinoid CB1 receptors in the bimatoprost-induced contractions on the human isolated ciliary muscle. | Investigative ophthalmology & visual science 20070801 |
| Methoxy- and fluorine-substituted analogs of O-1302: synthesis and in vitro binding affinity for the CB1 cannabinoid receptor. | Chemical & pharmaceutical bulletin 20070801 |
| Blood pressure-lowering drugs not considered as antihypertensives. | Current hypertension reports 20070801 |
| The endocannabinoid signaling system: a potential target for next-generation therapeutics for alcoholism. | Mini reviews in medicinal chemistry 20070801 |
| Blocking the cannabinoid receptors: drug candidates and therapeutic promises. | Chemistry & biodiversity 20070801 |
| The cannabinoid CB1 receptor antagonist, rimonabant, as a promising pharmacotherapy for alcohol dependence: preclinical evidence. | Molecular neurobiology 20070801 |
| Cannabinoids in eating disorders and obesity. | Molecular neurobiology 20070801 |
| The burden of type 2 diabetes: strategies to prevent or delay onset. | Vascular health and risk management 20070801 |
| Cannabinoid CB1 receptor inverse agonists and neutral antagonists: effects on food intake, food-reinforced behavior and food aversions. | Physiology & behavior 20070724 |
| Cannabinoid type 1 receptor antagonists (rimonabant) for smoking cessation. | The Cochrane database of systematic reviews 20070718 |
| Panel advises against rimonabant approval. | American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20070715 |
| A comparison of the effects of the CB(1) receptor antagonist SR141716A, pre-feeding and changed palatability on the microstructure of ingestive behaviour. | Psychopharmacology 20070701 |
| Effects of the cannabinoid CB1 receptor antagonist rimonabant on distinct measures of impulsive behavior in rats. | Psychopharmacology 20070701 |
| MDMA attenuates THC withdrawal syndrome in mice. | Psychopharmacology 20070701 |
| The fatty acid amide hydrolase inhibitor URB597 (cyclohexylcarbamic acid 3'-carbamoylbiphenyl-3-yl ester) reduces neuropathic pain after oral administration in mice. | The Journal of pharmacology and experimental therapeutics 20070701 |
| The synthetic cannabinoid HU210 induces spatial memory deficits and suppresses hippocampal firing rate in rats. | British journal of pharmacology 20070701 |
| Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa rats. | Hepatology (Baltimore, Md.) 20070701 |
| [New concepts in the treatment of type 2 diabetes]. | Der Internist 20070701 |
| Smoking cessation: lessons learned from clinical trial evidence. | Current opinion in cardiology 20070701 |
| Involvement of the endocannabinoid system in retinal damage after high intraocular pressure-induced ischemia in rats. | Investigative ophthalmology & visual science 20070701 |
| Cannabinoids and cardiovascular disease: the outlook for clinical treatments. | Current vascular pharmacology 20070701 |
| [Cannabinoid receptor blocker rimonabant. CNS side effects prevent U.S. approval]. | MMW Fortschritte der Medizin 20070628 |
| Scaffold hopping, synthesis and structure-activity relationships of 5,6-diaryl-pyrazine-2-amide derivatives: a novel series of CB1 receptor antagonists. | Bioorganic & medicinal chemistry 20070615 |
| Cannabinoids inhibit sodium-dependent, high-affinity excitatory amino acid transport in cultured rat cortical astrocytes. | Biochemical pharmacology 20070615 |
| Novel inhibitors of fatty acid amide hydrolase. | Bioorganic & medicinal chemistry letters 20070615 |
| Cannabinoid CB1 receptors in the paraventricular nucleus and central control of penile erection: immunocytochemistry, autoradiography and behavioral studies. | Neuroscience 20070615 |
| Analogs of SR-141716A (Rimonabant) alter d-amphetamine-evoked [3H] dopamine overflow from preloaded striatal slices and amphetamine-induced hyperactivity. | Life sciences 20070613 |
| Attenuation of allergic contact dermatitis through the endocannabinoid system. | Science (New York, N.Y.) 20070608 |
| Improgan-induced hypothermia: a role for cannabinoid receptors in improgan-induced changes in nociceptive threshold and body temperature. | Brain research 20070604 |
| The cannabinoid antagonist SR 141716A (Rimonabant) reduces the increase of extra-cellular dopamine release in the rat nucleus accumbens induced by a novel high palatable food. | Neuroscience letters 20070604 |
| Rimonabant: just an antiobesity drug? Current evidence on its pleiotropic effects. | Molecular pharmacology 20070601 |
| Nicotinic facilitation of delta9-tetrahydrocannabinol discrimination involves endogenous anandamide. | The Journal of pharmacology and experimental therapeutics 20070601 |
| Anandamide-mediated CB1/CB2 cannabinoid receptor--independent nitric oxide production in rabbit aortic endothelial cells. | The Journal of pharmacology and experimental therapeutics 20070601 |
| Persistent synaptic activity produces long-lasting enhancement of endocannabinoid modulation and alters long-term synaptic plasticity. | Journal of neurophysiology 20070601 |
| Genetic variations at the endocannabinoid type 1 receptor gene (CNR1) are associated with obesity phenotypes in men. | The Journal of clinical endocrinology and metabolism 20070601 |
| Cannabinoids as therapeutic agents in cardiovascular disease: a tale of passions and illusions. | British journal of pharmacology 20070601 |
| The endocannabinoid system and rimonabant: a new drug with a novel mechanism of action involving cannabinoid CB1 receptor antagonism--or inverse agonism--as potential obesity treatment and other therapeutic use. | Journal of clinical pharmacy and therapeutics 20070601 |
| Rimonabant as an adjunct therapy in overweight/obese patients with type 2 diabetes. | European heart journal 20070601 |
| Effects of combined oleoyl-estrone and rimonabant on overweight rats. | Journal of pharmacological sciences 20070601 |
| Less weight or more hype with rimonabant? | Drug and therapeutics bulletin 20070601 |
| Rimonabant, obesity and diabetes. | Prescrire international 20070601 |
| The endocannabinoid system: a new target for the regulation of energy balance and metabolism. | Critical pathways in cardiology 20070601 |
| Cardiovascular disease under the influence of excess visceral fat. | Critical pathways in cardiology 20070601 |
| Rimonabant for treating tobacco dependence. | Vascular health and risk management 20070601 |
| Endocannabinoid system--a novel target for cardiometabolic risk. | The Journal of the Association of Physicians of India 20070601 |
| [Three studies in type 2 diabetes: SERENADE the rimonabant (a blocker of the CB 1 receptors) in monotherapy in type 2 diabetes]. | Annales d'endocrinologie 20070601 |
| Status epilepticus causes a long-lasting redistribution of hippocampal cannabinoid type 1 receptor expression and function in the rat pilocarpine model of acquired epilepsy. | Neuroscience 20070525 |
| Optimization of imidazole amide derivatives as cannabinoid-1 receptor antagonists for the treatment of obesity. | Bioorganic & medicinal chemistry letters 20070515 |
| Inhibition of fatty-acid amide hydrolase accelerates acquisition and extinction rates in a spatial memory task. | Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20070501 |
| The link between abdominal obesity, metabolic syndrome and cardiovascular disease. | Nutrition, metabolism, and cardiovascular diseases : NMCD 20070501 |
| Depolarization-induced rapid generation of 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand, in rat brain synaptosomes. | Journal of biochemistry 20070501 |
| Is rimonabant a safe and effective treatment for obesity? | Nature clinical practice. Endocrinology & metabolism 20070501 |
| Continuous infusion of the cannabinoid WIN 55,212-2 to the site of a peripheral nerve injury reduces mechanical and cold hypersensitivity. | British journal of pharmacology 20070501 |
| The role of endocannabinoid system blockade in the treatment of the metabolic syndrome. | Journal of clinical pharmacology 20070501 |
| Cannabinoid and vanilloid effects of R(+)-methanandamide in the hemisected meningeal preparation. | Cephalalgia : an international journal of headache 20070501 |
| Rimonabant as potential treatment for the neglected epidemic of diabetes in the Middle East and Arabian Peninsula. Implication for prevention. | Saudi medical journal 20070501 |
| Drug treatment of the overweight patient. | Gastroenterology 20070501 |
| Interactions between endocannabinoids and stress-induced decreased sensitivity to natural reward. | Progress in neuro-psychopharmacology & biological psychiatry 20070413 |
| [New therapeutic aspects for the control of risk factors in obesity]. | Medicina clinica 20070407 |
| The endogenous cannabinoid anandamide produces delta-9-tetrahydrocannabinol-like discriminative and neurochemical effects that are enhanced by inhibition of fatty acid amide hydrolase but not by inhibition of anandamide transport. | The Journal of pharmacology and experimental therapeutics 20070401 |
| The disruptive effects of the CB1 receptor antagonist rimonabant on extinction learning in mice are task-specific. | Psychopharmacology 20070401 |
| Medial forebrain bundle stimulation evokes endocannabinoid-mediated modulation of ventral tegmental area dopamine neuron firing in vivo. | Psychopharmacology 20070401 |
| Effects of CB1 antagonist on the control of metabolic functions in obese type 2 diabetic patients. | Diabetes & metabolism 20070401 |
| Correlated species differences in the effects of cannabinoid ligands on anxiety and on GABAergic and glutamatergic synaptic transmission. | The European journal of neuroscience 20070401 |
| Effects of the cannabinoid antagonist SR141716 (rimonabant) and d-amphetamine on palatable food and food pellet intake in non-human primates. | Pharmacology, biochemistry, and behavior 20070401 |
| New oral agents for type 2 diabetes. | Clinical medicine (London, England) 20070401 |
| Potential role of the endocannabinoid receptor antagonist rimonabant in the management of cardiometabolic risk: a narrative review of available data. | Vascular health and risk management 20070401 |
| The endocannabinoid system as a novel approach for managing obesity. | The Journal of the American Osteopathic Association 20070401 |
| Modulation of morphine and alcohol motor stimulant effects by cannabinoid receptors ligands. | Behavioural brain research 20070328 |
| Delta9-tetrahydrocannabinol (Delta9-THC) prevents cerebral infarction via hypothalamic-independent hypothermia. | Life sciences 20070327 |
| Cannabinoid CB1 receptor antagonism markedly increases dopamine receptor-mediated stereotypies. | European journal of pharmacology 20070322 |
| 2-Arachidonylglyceryl ether and abnormal cannabidiol-induced vascular smooth muscle relaxation in rabbit pulmonary arteries via receptor-pertussis toxin sensitive G proteins-ERK1/2 signaling. | European journal of pharmacology 20070322 |
| [Internal medicine--update 2006]. | Praxis 20070314 |
| Exercise reduces adipose tissue via cannabinoid receptor type 1 which is regulated by peroxisome proliferator-activated receptor-delta. | Biochemical and biophysical research communications 20070309 |
| Chronic use of marijuana decreases cannabinoid receptor binding and mRNA expression in the human brain. | Neuroscience 20070302 |
| Adolescent cannabis exposure alters opiate intake and opioid limbic neuronal populations in adult rats. | Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20070301 |
| A novel role of cannabinoids: implication in the fever induced by bacterial lipopolysaccharide. | The Journal of pharmacology and experimental therapeutics 20070301 |
| Hallucinatory and rewarding effect of salvinorin A in zebrafish: kappa-opioid and CB1-cannabinoid receptor involvement. | Psychopharmacology 20070301 |
| Rimonabant: more than an anti-obesity drug? | British journal of pharmacology 20070301 |
| Effect of the cannabinoid CB1 receptor antagonist rimonabant on nociceptive responses and adjuvant-induced arthritis in obese and lean rats. | British journal of pharmacology 20070301 |
| Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro. | British journal of pharmacology 20070301 |
| Genetic and pharmacological approaches to evaluate the interaction between the cannabinoid and cholinergic systems in cognitive processes. | British journal of pharmacology 20070301 |
| Antagonism of type-1 cannabinoid receptors: good for obesity, but is it safe for fertility? | Clinical endocrinology 20070301 |
| Repeated treatment with cannabidiol but not Delta9-tetrahydrocannabinol has a neuroprotective effect without the development of tolerance. | Neuropharmacology 20070301 |
| Role of the endocannabinoid system in regulating cardiovascular and metabolic risk factors. | The American journal of medicine 20070301 |
| Therapeutic options for modifying cardiometabolic risk factors. | The American journal of medicine 20070301 |
| Rimonabant: a novel selective cannabinoid-1 receptor antagonist for treatment of obesity. | American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20070301 |
| [Cannabis and cannabinoids as drugs]. | Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke 20070301 |
| [Endocannabinoids: therapeutic perspectives in chronic liver diseases]. | Gastroenterologie clinique et biologique 20070301 |
| Chronic cocaine sensitizes striatal GABAergic synapses to the stimulation of cannabinoid CB1 receptors. | The European journal of neuroscience 20070301 |
| Weight management for type 2 diabetes mellitus: global cardiovascular risk reduction. | The American journal of cardiology 20070219 |
| Rimonabant in obese patients with type 2 diabetes. | Lancet (London, England) 20070217 |
| Rimonabant in obese patients with type 2 diabetes. | Lancet (London, England) 20070217 |
| Rimonabant in obese patients with type 2 diabetes. | Lancet (London, England) 20070217 |
| Rimonabant in obese patients with type 2 diabetes. | Lancet (London, England) 20070217 |
| The CB1 cannabinoid receptor antagonist rimonabant chronically prevents the nicotine-induced relapse to alcohol. | Neurobiology of disease 20070201 |
| Cannabimimetic properties of ajulemic acid. | The Journal of pharmacology and experimental therapeutics 20070201 |
| Constrained analogs of CB-1 antagonists: 1,5,6,7-Tetrahydro-4H-pyrrolo[3,2-c]pyridine-4-one derivatives. | Bioorganic & medicinal chemistry letters 20070201 |
| The effects of anorexic drugs on free-fed rats responding under a second-order FI15-min (FR10:S) schedule for high incentive foods. | Behavioural pharmacology 20070201 |
| Endocannabinoid antagonism: blocking the excess in the treatment of high-risk abdominal obesity. | Trends in cardiovascular medicine 20070201 |
| Endocannabinoid blockade for improving glycemic control and lipids in patients with type 2 diabetes mellitus. | The American journal of medicine 20070201 |
| CB2 cannabinoid receptors promote mouse neural stem cell proliferation. | The European journal of neuroscience 20070201 |
| [Cardiometabolic effects of rimonabant in obese/overweight subjects with dyslipidaemia or type 2 diabetes]. | Revue medicale de Liege 20070201 |
| Phasic dopamine release evoked by abused substances requires cannabinoid receptor activation. | The Journal of neuroscience : the official journal of the Society for Neuroscience 20070124 |
| Antidepressant-induced undesirable weight gain: prevention with rimonabant without interference with behavioral effectiveness. | European journal of pharmacology 20070112 |
| Drug treatments for obesity: orlistat, sibutramine, and rimonabant. | Lancet (London, England) 20070106 |
| Cannabinoid CB1 receptor antagonists cause status epilepticus-like activity in the hippocampal neuronal culture model of acquired epilepsy. | Neuroscience letters 20070103 |
| WIN-55,212-2 and SR-141716A alter nicotine-induced changes in locomotor activity, but do not alter nicotine-evoked [3H]dopamine release. | Life sciences 20070102 |
| Genetic impairment of frontocortical endocannabinoid degradation and high alcohol preference. | Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20070101 |
| An endocannabinoid mechanism in relapse to drug seeking: a review of animal studies and clinical perspectives. | Brain research reviews 20070101 |
| The obesity epidemic: current and future pharmacological treatments. | Annual review of pharmacology and toxicology 20070101 |
| Cannabinoid (CB1) receptor activation inhibits trigeminovascular neurons. | The Journal of pharmacology and experimental therapeutics 20070101 |
| Anandamide inhibits endothelin-1 production by human cultured endothelial cells: a new vascular action of this endocannabinoid. | Pharmacology 20070101 |
| Activation of peripheral cannabinoid CB1 and CB2 receptors suppresses the maintenance of inflammatory nociception: a comparative analysis. | British journal of pharmacology 20070101 |
| Non-nicotinic therapies for smoking cessation. | Annual review of pharmacology and toxicology 20070101 |
| [Rimonabant actions on cardiometabolic risk factors]. | Medizinische Monatsschrift fur Pharmazeuten 20070101 |
| Cannabinoid receptor antagonists and the metabolic syndrome: Novel promising therapeutical approaches. | Mini reviews in medicinal chemistry 20070101 |
| High reinforcing efficacy of nicotine in non-human primates. | PloS one 20070101 |
| [The role of the endocannabinoid system in the regulation of endocrine function and in the control of energy balance in humans]. | Postepy higieny i medycyny doswiadczalnej (Online) 20070101 |
| Smoking cessation pharmacotherapy--nicotine and non-nicotine preparations. | Preventive cardiology 20070101 |
| Oleamide: a fatty acid amide signaling molecule in the cardiovascular system? | Cardiovascular drug reviews 20070101 |
| Retrograde endocannabinoid inhibition of goldfish retinal cones is mediated by 2-arachidonoyl glycerol. | Visual neuroscience 20070101 |
| [What do we know about obesity?]. | La Clinica terapeutica 20070101 |
| Special report on the Sanofi-Aventis cardiometabolic symposium. | Cardiovascular journal of Africa 20070101 |
| Endocannabinoid system and synaptic plasticity: implications for emotional responses. | Neural plasticity 20070101 |
| The Effect of PPARalpha, PPARdelta, PPARgamma, and PPARpan Agonists on Body Weight, Body Mass, and Serum Lipid Profiles in Diet-Induced Obese AKR/J Mice. | PPAR research 20070101 |
| [Recent advances in the management of obesity]. | Revue medicale de Liege 20070101 |
| Evidence of accelerated ageing in clinical drug addiction from immune, hepatic and metabolic biomarkers. | Immunity & ageing : I & A 20070101 |
| Novel therapies for cardiometabolic risk reduction and implications for clinical practice. | Reviews in cardiovascular medicine 20070101 |
| Treatment of dyslipidemia to reduce cardiovascular risk in patients with multiple risk factors. | Clinical cornerstone 20070101 |
| High-density lipoprotein cholesterol and residual cardiometabolic risk in metabolic syndrome. | Clinical cornerstone 20070101 |
| Reducing cardiometabolic risk through selective antagonism of CB1 receptors. | Clinical cornerstone 20070101 |
| Effect of a weight loss intervention on anthropometric measures and metabolic risk factors in pre- versus postmenopausal women. | Nutrition journal 20070101 |
| Multiple impacts of rimonabant on cardiometabolic risk and safety addressed at ESC congress, Vienna. | Cardiovascular journal of Africa 20070101 |
| A possible role for the endocannabinoid system in the neurobiology of depression. | Clinical practice and epidemiology in mental health : CP & EMH 20070101 |
| Role of the endocannabinoid system in management of patients with type 2 diabetes mellitus and cardiovascular risk factors. | Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 20070101 |
| [Pharmacology of cannabinoid receptors]. | Bulletin de l'Academie nationale de medecine 20070101 |
| Altered gene expression and functional activity of opioid receptors in the cerebellum of CB1 cannabinoid receptor knockout mice after acute treatments with cannabinoids. | Acta biologica Hungarica 20070101 |
| Overweight and obesity: key components of cardiometabolic risk. | Clinical cornerstone 20070101 |
| Rimonabant: the evidence for its use in the treatment of obesity and the metabolic syndrome. | Core evidence 20070101 |
| Endocannabinoids and cardiovascular prevention: real progress? | Heart international 20070101 |
| Discovery of N-[(1S,2S)-3-(4-Chlorophenyl)-2- (3-cyanophenyl)-1-methylpropyl]-2-methyl-2- {[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist for the treatment of obesity. | Journal of medicinal chemistry 20061228 |
| Evaluation of the role of the arachidonic acid cascade in anandamide's in vivo effects in mice. | Life sciences 20061203 |
| Cannabinoid CB1 receptor antagonism modulates plasma corticosterone in rodents. | European journal of pharmacology 20061203 |
| Anxiolytic-like properties of the anandamide transport inhibitor AM404. | Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20061201 |
| The agonists for nociceptors are ubiquitous, but the modulators are specific: P2X receptors in the sensory neurons are modulated by cannabinoids. | Pflugers Archiv : European journal of physiology 20061201 |
| Effects of a cannabinoid agonist on spinal nociceptive neurons in a rodent model of neuropathic pain. | Journal of neurophysiology 20061201 |
| In vivo modulation of LPS-induced alterations in brain and peripheral cytokines and HPA axis activity by cannabinoids. | Journal of neuroimmunology 20061201 |
| Rimonabant: endocannabinoid inhibition for the metabolic syndrome. | International journal of clinical practice 20061201 |
| Metabolic syndrome treatment strategies. | Pharmacotherapy 20061201 |
| Emerging strategies for increasing high-density lipoprotein. | The American journal of cardiology 20061201 |
| Effects of rimonabant (SR141716) on fasting-induced hypothalamic-pituitary-adrenal axis and neuronal activation in lean and obese Zucker rats. | Diabetes 20061201 |
| [Pharmacotherapy of obesity]. | Medizinische Monatsschrift fur Pharmazeuten 20061201 |
| Conformational characteristics of the interaction of SR141716A with the CB1 cannabinoid receptor as determined through the use of conformationally constrained analogs. | The AAPS journal 20061201 |
| Cardiometabolic risk modification: current trends and emerging therapies. | JAAPA : official journal of the American Academy of Physician Assistants 20061201 |
| 6-(4-chlorophenyl)-3-substituted-thieno[3,2-d]pyrimidin-4(3H)-one-based melanin-concentrating hormone receptor 1 antagonist. | Journal of medicinal chemistry 20061130 |
| Involvement of 5-hydroxytryptamine1A receptors in Delta9-tetrahydrocannabinol-induced catalepsy-like immobilization in mice. | European journal of pharmacology 20061121 |
| The cannabinoid receptor agonist, WIN 55,212-2, inhibits cool-specific lamina I medullary dorsal horn neurons. | Neuroscience 20061117 |
| [A drug for therapy of obesity: really only life style? (interview by Dirk Einecke)]. | MMW Fortschritte der Medizin 20061116 |
| Does rimonabant pull its weight for type 2 diabetes? | Lancet (London, England) 20061111 |
| Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. | Lancet (London, England) 20061111 |
| Prenatal exposure to the cannabinoid receptor agonist WIN 55,212-2 and carbon monoxide reduces extracellular glutamate levels in primary rat cerebral cortex cell cultures. | Neurochemistry international 20061101 |
| Differential involvement of the endocannabinoid system in short- and long-term expression of incentive learning supported by nicotine in rats. | Psychopharmacology 20061101 |
| Rimonabant as a potential new treatment for an emerging epidemic of obesity-related glomerulopathy? | Expert opinion on emerging drugs 20061101 |
| [Acomplia, an essential medication or a 'comfort' product?]. | Revue medicale suisse 20061101 |
| The endocannabinoid system as a target for the treatment of visceral obesity and metabolic syndrome. | Annals of the New York Academy of Sciences 20061101 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20061101 |
| Role of cannabinoid receptors in the regulation of cardiac contractility during ischemia/reperfusion. | Bulletin of experimental biology and medicine 20061101 |
| Rimonabant for overweight or obesity. | The Cochrane database of systematic reviews 20061018 |
| Cannabinoid receptor-mediated inhibition of calcium signaling in rat retinal ganglion cells. | Molecular vision 20061006 |
| Biarylpyrazole inverse agonists at the cannabinoid CB1 receptor: importance of the C-3 carboxamide oxygen/lysine3.28(192) interaction. | Journal of medicinal chemistry 20061005 |
| [Successful treatment of obesity]. | MMW Fortschritte der Medizin 20061005 |
| Better strategies sought against obesity. | JAMA 20061004 |
| Protective activation of the endocannabinoid system during ischemia in dopamine neurons. | Neurobiology of disease 20061001 |
| The cannabinoid CB1 receptor antagonist rimonabant (SR141716) inhibits human breast cancer cell proliferation through a lipid raft-mediated mechanism. | Molecular pharmacology 20061001 |
| CB1 receptor antagonism increases hippocampal acetylcholine release: site and mechanism of action. | Molecular pharmacology 20061001 |
| Translation of nondopaminergic treatments for levodopa-induced dyskinesia from MPTP-lesioned nonhuman primates to phase IIa clinical studies: keys to success and roads to failure. | Movement disorders : official journal of the Movement Disorder Society 20061001 |
| Discriminative stimulus functions of AM-1346, a CB1R selective anandamide analog in rats trained with Delta9-THC or (R)-methanandamide (AM-356). | Psychopharmacology 20061001 |
| Effects of endocannabinoid neurotransmission modulators on brain stimulation reward. | Psychopharmacology 20061001 |
| Discriminative stimulus effects of the cannabinoid CB1 antagonist SR 141716A in rhesus monkeys pretreated with Delta9-tetrahydrocannabinol. | Psychopharmacology 20061001 |
| Involvement of cannabinoid receptors in inflammatory hypersensitivity to colonic distension in rats. | Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society 20061001 |
| Cannabinoid-serotonin interactions in alcohol-preferring vs. alcohol-avoiding mice. | Journal of neurochemistry 20061001 |
| 11C-JHU75528: a radiotracer for PET imaging of CB1 cannabinoid receptors. | Journal of nuclear medicine : official publication, Society of Nuclear Medicine 20061001 |
| Obesity drug development - CBI's 2nd Annual Summit. | IDrugs : the investigational drugs journal 20061001 |
| Neuropathic pain and the endocannabinoid system in the dorsal raphe: pharmacological treatment and interactions with the serotonergic system. | The European journal of neuroscience 20061001 |
| Pharmacotherapy of obesity. | Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association 20061001 |
| Non-cannabinoid CB1, non-cannabinoid CB2 antinociceptive effects of several novel compounds in the PPQ stretch test in mice. | European journal of pharmacology 20060928 |
| Analysis of the effects of cannabinoids on identified synaptic connections in the caudate-putamen by paired recordings in transgenic mice. | The Journal of physiology 20060915 |
| A cannabinoid receptor 1 mutation proximal to the DRY motif results in constitutive activity and reveals intramolecular interactions involved in receptor activation. | Brain research 20060907 |
| Effects of the cannabinoid CB1 receptor agonist CP55,940 and antagonist SR141716A on d-amphetamine-induced behaviours in Cebus monkeys. | Journal of psychopharmacology (Oxford, England) 20060901 |
| Antinociceptive activity of chemical congeners of improgan: optimization of side chain length leads to the discovery of a new, potent, non-opioid analgesic. | Neuropharmacology 20060901 |
| Interactions between CB1 cannabinoid and mu opioid receptors mediating inhibition of neurotransmitter release in rat nucleus accumbens core. | Neuropharmacology 20060901 |
| Neuroprotective cannabinoid receptor antagonist SR141716A prevents downregulation of excitotoxic NMDA receptors in the ischemic penumbra. | Acta neuropathologica 20060901 |
| SR 141716 (Rimonabant) precipitates withdrawal in marijuana-dependent mice. | Pharmacology, biochemistry, and behavior 20060901 |
| Effects of the CB1R agonist WIN-55,212-2 and the CB1R antagonists SR-141716 and AM-1387: open-field examination in rats. | Pharmacology, biochemistry, and behavior 20060901 |
| Critical appraisal of C-reactive protein throughout the spectrum of cardiovascular disease. | Vascular health and risk management 20060901 |
| Metabolic syndrome: the danger signal in atherosclerosis. | Vascular health and risk management 20060901 |
| [Cardiac metabolic risk factors. CB1-blocker corrects three with one stroke]. | MMW Fortschritte der Medizin 20060831 |
| Cannabinoid-1 receptor antagonist, rimonabant, for management of obesity and related risks. | Circulation 20060829 |
| Endogenous cannabinoid signaling through the CB1 receptor is essential for cerebellum-dependent discrete motor learning. | The Journal of neuroscience : the official journal of the Society for Neuroscience 20060823 |
| [Rimonabant improves cardiometabolic risk profile in obese or overweight subjects: overview of RIO studies]. | Revue medicale suisse 20060823 |
| Morphine reduces penile erection induced by the cannabinoid receptor antagonist SR 141617A in male rats: role of paraventricular glutamic acid and nitric oxide. | Neuroscience letters 20060814 |
| Effect of rimonabant on weight and cardiometabolic risk factors. | JAMA 20060809 |
| Early tolerance to the hypophagic effect of the cannabinoid receptor antagonist SR141716 does not impede blockade of an orexigenic stimulus. | European journal of pharmacology 20060807 |
| Evaluation of the in vivo receptor occupancy for the behavioral effects of cannabinoids using a radiolabeled cannabinoid receptor agonist, R-[125/131I]AM2233. | Synapse (New York, N.Y.) 20060801 |
| Antiobesity effects of the novel in vivo neutral cannabinoid receptor antagonist 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-3-hexyl-1H-1,2,4-triazole--LH 21. | Neuropharmacology 20060801 |
| Tolerance to cannabinoid response on the myenteric plexus of guinea-pig ileum and human small intestinal strips. | British journal of pharmacology 20060801 |
| Investigation on the relationship between cannabinoid CB1 and opioid receptors in gastrointestinal motility in mice. | British journal of pharmacology 20060801 |
| Characterization of the neuroprotective effect of the cannabinoid agonist WIN-55212 in an in vitro model of hypoxic-ischemic brain damage in newborn rats. | Pediatric research 20060801 |
| Fatty acid amide hydrolase deficiency limits early pregnancy events. | The Journal of clinical investigation 20060801 |
| Coming soon: the lose-weight-stop-smoking pill that's good for your heart. | Health news (Waltham, Mass.) 20060801 |
| Pharmacologic treatment for obesity. Options for today...and tomorrow. | Advance for nurse practitioners 20060801 |
| Rimonabant: new drug. Obesity: loss of a few kilos, many questions. | Prescrire international 20060801 |
| [Rimonabant--a panacea for patients with metabolic syndrome?]. | Polskie Archiwum Medycyny Wewnetrznej 20060801 |
| [Blockage of the CB1 cannabinoid receptor for the prevention of liver cirrhosis ]. | Revue medicale suisse 20060712 |
| Neural contractions in colonic strips from patients with diverticular disease: role of endocannabinoids and substance P. | Gut 20060701 |
| Synthesis and preliminary biological evaluation of [123I]Me2Pyr, a new potential ligand for imaging of central cannabinoid CB1 receptors. | Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine 20060701 |
| Pharmacological evaluation of cannabinoid receptor ligands in a mouse model of anxiety: further evidence for an anxiolytic role for endogenous cannabinoid signaling. | The Journal of pharmacology and experimental therapeutics 20060701 |
| Sphingosine and its analog, the immunosuppressant 2-amino-2-(2-[4-octylphenyl]ethyl)-1,3-propanediol, interact with the CB1 cannabinoid receptor. | Molecular pharmacology 20060701 |
| Evaluation of the role of nicotinic acetylcholine receptor subtypes and cannabinoid system in the discriminative stimulus effects of nicotine in rats. | European journal of pharmacology 20060701 |
| The obesity epidemic and its cardiovascular consequences. | Current opinion in cardiology 20060701 |
| Amygdala BDNF signaling is required for consolidation but not encoding of extinction. | Nature neuroscience 20060701 |
| Anandamide administration alone and after inhibition of fatty acid amide hydrolase (FAAH) increases dopamine levels in the nucleus accumbens shell in rats. | Journal of neurochemistry 20060701 |
| Is rimonabant a safe and effective therapy for sustained weight loss and improved cardiometabolic risk factors? | Nature clinical practice. Cardiovascular medicine 20060701 |
| SR147778, a CB1 cannabinoid receptor antagonist, suppresses ethanol preference in chronically alcoholized Wistar rats. | Alcohol (Fayetteville, N.Y.) 20060701 |
| [Smoking cessation intervention: 2006 update]. | Revue medicale suisse 20060628 |
| CB1 knockout mice display significant changes in striatal opioid peptide and D4 dopamine receptor gene expression. | Brain research 20060606 |
| Influence of the anabolic-androgenic steroid nandrolone on cannabinoid dependence. | Neuropharmacology 20060601 |
| Synthesis and structure-activity relationships (SARs) of 1,5-diarylpyrazole cannabinoid type-1 (CB(1)) receptor ligands for potential use in molecular imaging. | Bioorganic & medicinal chemistry 20060601 |
| Modulation of neuropathic and inflammatory pain by the endocannabinoid transport inhibitor AM404 [N-(4-hydroxyphenyl)-eicosa-5,8,11,14-tetraenamide]. | The Journal of pharmacology and experimental therapeutics 20060601 |
| CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis. | Nature medicine 20060601 |
| G protein-coupled receptors in regulation of body weight. | CNS & neurological disorders drug targets 20060601 |
| The cannabinoid CB1 receptor inverse agonist, rimonabant, modifies body weight and adiponectin function in diet-induced obese rats as a consequence of reduced food intake. | Pharmacology, biochemistry, and behavior 20060601 |
| Antipsychotics improve Delta9-tetrahydrocannabinol-induced impairment of the prepulse inhibition of the startle reflex in mice. | Pharmacology, biochemistry, and behavior 20060601 |
| [Impact of endocannabinoid system in modulation of cardiometabolic risk factors]. | Vnitrni lekarstvi 20060601 |
| Potential role of new therapies in modifying cardiovascular risk in overweight patients with metabolic risk factors. | Obesity (Silver Spring, Md.) 20060601 |
| Rimonabant: a cannabinoid receptor type 1 blocker for management of multiple cardiometabolic risk factors. | Journal of the American College of Cardiology 20060516 |
| The cannabinoid CB1 receptor antagonist SR 141716A induces penile erection by increasing extra-cellular glutamic acid in the paraventricular nucleus of male rats. | Behavioural brain research 20060515 |
| Treatments for metabolic syndrome may expand. | American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20060515 |
| Mutations of CB1 T210 produce active and inactive receptor forms: correlations with ligand affinity, receptor stability, and cellular localization. | Biochemistry 20060502 |
| Cannabinoid effects on behaviors maintained by ethanol or food: a within-subjects comparison. | Behavioural pharmacology 20060501 |
| Cannabinoid agonist WIN55,212-2 induces apoptosis in cerebellar granule cells via activation of the CB1 receptor and downregulation of bcl-xL gene expression. | Journal of neuroscience research 20060501 |
| Update on rimonabant--a selective cannabinoid CB1 antagonist. | The Annals of pharmacotherapy 20060501 |
| Noladin ether acts on trabecular meshwork cannabinoid (CB1) receptors to enhance aqueous humor outflow facility. | Investigative ophthalmology & visual science 20060501 |
| Cannabinoid modulation of electrically evoked pH and oxygen transients in the nucleus accumbens of awake rats. | Journal of neurochemistry 20060501 |
| Analysis of recent papers in hypertension: differences in central aortic blood pressure explain outcome differences in ASCOT: the CAFE substudy; and rimonabant improves multiple cardiometabolic parameters in overweight and obese individuals. | Journal of clinical hypertension (Greenwich, Conn.) 20060501 |
| Cannabinoids modulate spontaneous neuronal activity and evoked inhibition of locus coeruleus noradrenergic neurons. | The European journal of neuroscience 20060501 |
| 2-Arachidonylglycerol acting on CB1 cannabinoid receptors mediates delayed cardioprotection induced by nitric oxide in rat isolated hearts. | Journal of cardiovascular pharmacology 20060501 |
| Role of the basolateral nucleus of the amygdala in endocannabinoid-mediated stress-induced analgesia. | Neuroscience letters 20060424 |
| Cannabinoid modulation of opiate reinforcement through the ventral striatopallidal pathway. | Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20060401 |
| Involvement of the endocannabinoid system in drug addiction. | Trends in neurosciences 20060401 |
| Lack of tolerance to the suppressing effect of rimonabant on chocolate intake in rats. | Psychopharmacology 20060401 |
| Diabetes: assessing the pipeline. | Atherosclerosis. Supplements 20060401 |
| Optimal treatments for the metabolic syndrome. | Arteriosclerosis, thrombosis, and vascular biology 20060401 |
| The unfolding cannabinoid story on energy homeostasis: central or peripheral site of action? | International journal of obesity (2005) 20060401 |
| How many sites of action for endocannabinoids to control energy metabolism? | International journal of obesity (2005) 20060401 |
| Contribution of CB1 blockade to the management of high-risk abdominal obesity. | International journal of obesity (2005) 20060401 |
| Obesity drugs in clinical development. | Current opinion in investigational drugs (London, England : 2000) 20060401 |
| Role of TRPV1 and cannabinoid CB1 receptors in AM 404-evoked hypothermia in rats. | Pharmacology, biochemistry, and behavior 20060401 |
| Pharmacological treatment of obesity. | Arquivos brasileiros de endocrinologia e metabologia 20060401 |
| [The endocannabinoid system: a new paradigm in the metabolic syndrome treatment]. | Arquivos brasileiros de endocrinologia e metabologia 20060401 |
| The new cancer fighter (and other hot drugs on the way). | Time 20060320 |
| Systemic effect of cannabinoids on the spontaneous firing rate of locus coeruleus neurons in rats. | European journal of pharmacology 20060318 |
| The CB1 cannabinoid receptor is the major cannabinoid receptor at excitatory presynaptic sites in the hippocampus and cerebellum. | The Journal of neuroscience : the official journal of the Society for Neuroscience 20060315 |
| Metabolic risk factors, drugs, and obesity. | The New England journal of medicine 20060302 |
| [Pharmacotherapy in the treatment of obesity]. | MMW Fortschritte der Medizin 20060302 |
| Molecular mechanisms of cannabinoid protection from neuronal excitotoxicity. | Molecular pharmacology 20060301 |
| Endocannabinoids at the spinal level regulate, but do not mediate, nonopioid stress-induced analgesia. | Neuropharmacology 20060301 |
| Vasorelaxant effects of oleamide in rat small mesenteric artery indicate action at a novel cannabinoid receptor. | British journal of pharmacology 20060301 |
| Role of the cannabinoid system in the effects induced by nicotine on anxiety-like behaviour in mice. | Psychopharmacology 20060301 |
| Vanilloid VR1 receptor is involved in rimonabant-induced neuroprotection. | British journal of pharmacology 20060301 |
| Effects of castration on cannabinoid cb receptor expression and on the biological actions of cannabinoid in the parotid gland. | Clinical and experimental pharmacology & physiology 20060301 |
| Rimonabant: a cannabinoid receptor blocker for the treatment of metabolic and cardiovascular risk factors. | Nutrition, metabolism, and cardiovascular diseases : NMCD 20060301 |
| Rimonabant: a selective blocker of the cannabinoid CB1 receptors for the management of obesity, smoking cessation and cardiometabolic risk factors. | Expert opinion on investigational drugs 20060301 |
| The cannabinoid CB1 receptor antagonist rimonabant attenuates the hypotensive effect of smoked marijuana in male smokers. | American heart journal 20060301 |
| Pharmacologic interventions for smoking cessation. | Critical care nursing clinics of North America 20060301 |
| Effects of rimonabant, a selective cannabinoid CB1 receptor antagonist, in a rat model of Parkinson's disease. | Brain research 20060216 |
| Anandamide inhibits adhesion and migration of breast cancer cells. | Experimental cell research 20060215 |
| The analgesic activity of paracetamol is prevented by the blockade of cannabinoid CB1 receptors. | European journal of pharmacology 20060215 |
| Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. | JAMA 20060215 |
| Effects of exogenous and endogenous cannabinoids on GABAergic neurotransmission between the caudate-putamen and the globus pallidus in the mouse. | The Journal of pharmacology and experimental therapeutics 20060201 |
| New bicyclic cannabinoid receptor-1 (CB1-R) antagonists. | Bioorganic & medicinal chemistry letters 20060201 |
| The cannabinoid CB1 receptor antagonist rimonabant (SR141716) inhibits cell proliferation and increases markers of adipocyte maturation in cultured mouse 3T3 F442A preadipocytes. | Molecular pharmacology 20060201 |
| The cannabinoid receptor antagonist SR-141716A induces penile erection in male rats: involvement of paraventricular glutamic acid and nitric oxide. | Neuropharmacology 20060201 |
| Neuropharmacology and potential efficacy of new treatments for tobacco dependence. | Expert opinion on investigational drugs 20060201 |
| The endocannabinoid system: current pharmacological research and therapeutic possibilities. | Basic & clinical pharmacology & toxicology 20060201 |
| Cannabidiol is an allosteric modulator at mu- and delta-opioid receptors. | Naunyn-Schmiedeberg's archives of pharmacology 20060201 |
| Effects of cannabinoid receptor agonists on rat gastric acid secretion: discrepancy between in vitro and in vivo data. | Digestive diseases and sciences 20060201 |
| Cardiovascular risk management by blocking the endocannabinoid system. | Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association 20060201 |
| Drug development. Drugs inspired by a drug. | Science (New York, N.Y.) 20060120 |
| Suppression of feeding, drinking, and locomotion by a putative cannabinoid receptor 'silent antagonist'. | European journal of pharmacology 20060113 |
| Novel 4-oxo-1,4-dihydroquinoline-3-carboxamide derivatives as new CB2 cannabinoid receptors agonists: synthesis, pharmacological properties and molecular modeling. | Journal of medicinal chemistry 20060112 |
| [Drug treatment of obesity]. | Ugeskrift for laeger 20060109 |
| The effect of Delta9-tetrahydrocannabinol on sensorimotor gating in socially isolated rats. | Behavioural brain research 20060106 |
| [New obesity and metabolic syndrome treatment: rimonabant]. | Revue medicale suisse 20060104 |
| Endocannabinoids affect neurological and cognitive function in thioacetamide-induced hepatic encephalopathy in mice. | Neurobiology of disease 20060101 |
| Antinociceptive effect of spinally administered cannabinergic and 2-adrenoceptor drugs on the formalin test in rat: possible interactions. | Journal of psychopharmacology (Oxford, England) 20060101 |
| Pharmacological manipulation of CB1 receptor function alters development of tolerance to alcohol. | Alcohol and alcoholism (Oxford, Oxfordshire) 20060101 |
| Pharmacotherapy for obesity. | Appetite 20060101 |
| Effect of the cannabinoid CB1 receptor antagonist SR-141716A on ethanol self-administration and ethanol-seeking behaviour in rats. | Psychopharmacology 20060101 |
| Structural-activity relationship study on C-4 carbon atom of the CB1 antagonist SR141716: synthesis and pharmacological evaluation of 1,2,4-triazole-3-carboxamides. | European journal of medicinal chemistry 20060101 |
| Antagonism of discriminative stimulus effects of delta(9)-THC and (R)-methanandamide in rats. | Psychopharmacology 20060101 |
| The relationship of in vivo central CB1 receptor occupancy to changes in cortical monoamine release and feeding elicited by CB1 receptor antagonists in rats. | Psychopharmacology 20060101 |
| American Heart Association--scientific sessions 2005. Potential new drugs for various indications. 13-16 November 2005, Dallas, TX, USA. | IDrugs : the investigational drugs journal 20060101 |
| Rimonabant adds appetizing choice to slim obesity market. | Nature medicine 20060101 |
| Pharmacologic treatment of obesity. | Advances in psychosomatic medicine 20060101 |
| Cannabinoid receptor agonists inhibit Ca(2+) influx to synaptosomes from rat brain. | Pharmacology 20060101 |
| [Reducing obesity]. | Presse medicale (Paris, France : 1983) 20060101 |
| Developments in pharmacotherapy for tobacco dependence: past, present and future. | Drug and alcohol review 20060101 |
| Nicotine and non-nicotine smoking cessation pharmacotherapies. | Cardiology in review 20060101 |
| Methods evaluating cannabinoid and endocannabinoid effects on gastrointestinal functions. | Methods in molecular medicine 20060101 |
| Effect of N-arachidonoyl-(2-methyl-4-hydroxyphenyl) amine (VDM11), an anandamide transporter inhibitor, on capsaicin-induced cough in mice. | Cough (London, England) 20060101 |
| Therapeutic options in development for management of diabetes: pharmacologic agents and new technologies. | Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 20060101 |
| Contemporary strategies for managing cardiometabolic risk factors. | Journal of managed care pharmacy : JMCP 20060101 |
| Intra-abdominal obesity: an untreated risk factor for Type 2 diabetes and cardiovascular disease. | Journal of endocrinological investigation 20060101 |
| New approaches for the management of patients with multiple cardiometabolic risk factors. | Journal of endocrinological investigation 20060101 |
| Clinical outcomes in metabolic syndrome. | The Journal of cardiovascular nursing 20060101 |
| The endocannabinoid system and cardiovascular risk: pathophysiologic role and developing therapeutic interventions. | The American journal of geriatric cardiology 20060101 |
| Obesity. Rimonabant trials confirm benefit. | Reviews in cardiovascular medicine 20060101 |
| Obesity: new perspectives and pharmacotherapies. | Cardiology in review 20060101 |
| Emerging pharmacotherapy for treating obesity and associated cardiometabolic risk. | Asia Pacific journal of clinical nutrition 20060101 |
| Efficacy of rimonabant and other cannabinoid CB1 receptor antagonists in reducing food intake and body weight: preclinical and clinical data. | CNS drug reviews 20060101 |
| Therapeutic potential of targeting the endocannabinoids: implications for the treatment of obesity, metabolic syndrome, drug abuse and smoking cessation. | Current medicinal chemistry 20060101 |
| Rimonabant. | Drugs 20060101 |
| [Selective cannabinoid receptor antagonists]. | Pharmazie in unserer Zeit 20060101 |
| The relation of adipose tissue to cardiometabolic risk. | Clinical cornerstone 20060101 |
| The endocannabinoid system: body weight and metabolic regulation. | Clinical cornerstone 20060101 |
| Involvement of cannabinoid CB1 receptors in drug addiction: effects of rimonabant on behavioral responses induced by cocaine. | Pharmacological reports : PR 20060101 |
| In vitro effects of CB1 receptor ligands on lipid peroxidation and antioxidant defense systems in the rat brain. | Pharmacological reports : PR 20060101 |
| In vivo effects of CB1 receptor ligands on lipid peroxidation and antioxidant defense systems in the rat brain of healthy and ethanol-treated rats. | Pharmacological reports : PR 20060101 |
| Endocannabinoids--the brain's own marijuana--may be linked to the metabolic syndrome. | MedGenMed : Medscape general medicine 20060101 |
| Endocannabinoids and non-alcoholic steatohepatitis. | Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association 20060101 |
| The cannabinoid agonist WIN55,212-2 increases intracellular calcium via CB1 receptor coupling to Gq/11 G proteins. | Proceedings of the National Academy of Sciences of the United States of America 20051227 |
| Decrease in prostaglandin level is a prerequisite for the expression of cannabinoid withdrawal: a quasi abstinence approach. | Brain research 20051220 |
| Cannabinoid receptor ligands mediate growth inhibition and cell death in mantle cell lymphoma. | FEBS letters 20051219 |
| Dual Ca2+ modulation of glycinergic synaptic currents in rodent hypoglossal motoneurones. | The Journal of physiology 20051215 |
| Capsaicin evokes hypothermia independent of cannabinoid CB1 and CB2 receptors. | Brain research 20051214 |
| Paraventricular hypothalamic CB(1) cannabinoid receptors are involved in the feeding stimulatory effects of Delta(9)-tetrahydrocannabinol. | Neuropharmacology 20051201 |
| Inhibition of fatty-acid amide hydrolase enhances cannabinoid stress-induced analgesia: sites of action in the dorsolateral periaqueductal gray and rostral ventromedial medulla. | Neuropharmacology 20051201 |
| Involvement of the endogenous cannabinoid system in the effects of alcohol in the mesolimbic reward circuit: electrophysiological evidence in vivo. | Psychopharmacology 20051201 |
| Tackling obesity and nicotine dependence. | IDrugs : the investigational drugs journal 20051201 |
| Pharmacological properties and therapeutic possibilities for drugs acting upon endocannabinoid receptors. | Current drug targets. CNS and neurological disorders 20051201 |
| Endocannabinoid receptor antagonists and other emerging pharma-cological strategies for weight reduction. | Current drug targets. Cardiovascular & haematological disorders 20051201 |
| [The formidable virtue announced for rimonabant, alias Acomplia]. | Revue medicale suisse 20051130 |
| Tricyclic pyrazoles. 3. Synthesis, biological evaluation, and molecular modeling of analogues of the cannabinoid antagonist 8-chloro-1-(2',4'-dichlorophenyl)-N-piperidin-1-yl-1,4,5,6-tetrahydrobenzo[6,7]cyclohepta[1,2-c]pyrazole-3-carboxamide. | Journal of medicinal chemistry 20051117 |
| 1-Benzhydryl-3-phenylurea and 1-benzhydryl-3-phenylthiourea derivatives: new templates among the CB1 cannabinoid receptor inverse agonists. | Journal of medicinal chemistry 20051117 |
| Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. | The New England journal of medicine 20051117 |
| Pharmacotherapy for obesity--promise and uncertainty. | The New England journal of medicine 20051117 |
| Motivational effects of cannabinoids and opioids on food reinforcement depend on simultaneous activation of cannabinoid and opioid systems. | Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20051101 |
| Increasing treatment options for cannabis dependence: a review of potential pharmacotherapies. | Drug and alcohol dependence 20051101 |
| Effect of anandamide uptake inhibition in the production of nitric oxide and in the release of cytokines in astrocyte cultures. | Glia 20051101 |
| Allosteric modulation of the cannabinoid CB1 receptor. | Molecular pharmacology 20051101 |
| Novel 3,4-diarylpyrazolines as potent cannabinoid CB1 receptor antagonists with lower lipophilicity. | Bioorganic & medicinal chemistry letters 20051101 |
| Anandamide reduces infarct size in rat isolated hearts subjected to ischaemia-reperfusion by a novel cannabinoid mechanism. | British journal of pharmacology 20051101 |
| Safety of obesity drugs. | Expert opinion on drug safety 20051101 |
| Species and strain differences in the expression of a novel glutamate-modulating cannabinoid receptor in the rodent hippocampus. | The European journal of neuroscience 20051101 |
| [Medications in smoking cessation]. | Presse medicale (Paris, France : 1983) 20051022 |
| Anandamide elicits an acute release of nitric oxide through endothelial TRPV1 receptor activation in the rat arterial mesenteric bed. | The Journal of physiology 20051015 |
| Weeding out new drugs. | Drug discovery today 20051015 |
| Involvement of the cannabinoid CB1 receptor in the opioid inhibition of the response to cholecystokinin and acute withdrawal response. | Neurotoxicology 20051001 |
| Inhibition of cyclooxygenase-2 elicits a CB1-mediated decrease of excitatory transmission in rat CA1 hippocampus. | Neuropharmacology 20051001 |
| Cannabinoid CB1 receptors are involved in motivational effects of nicotine in rats. | Psychopharmacology 20051001 |
| Inhibitors of fatty acid amide hydrolase reduce carrageenan-induced hind paw inflammation in pentobarbital-treated mice: comparison with indomethacin and possible involvement of cannabinoid receptors. | British journal of pharmacology 20051001 |
| VR1-mediated depressor effects during high-salt intake: role of anandamide. | Hypertension (Dallas, Tex. : 1979) 20051001 |
| Endocannabinoids and liver disease--review. | Liver international : official journal of the International Association for the Study of the Liver 20051001 |
| Drugs on the horizon for diabesity. | Current diabetes reports 20051001 |
| Is the cannabinoid CB1 receptor antagonist rimonabant advancing the treatment of obesity? | Expert opinion on pharmacotherapy 20051001 |
| New drugs for prevention, relief. How you might benefit if 3 medications win FDA approval. | Heart advisor 20051001 |
| A new 'wonder drug'? | Diabetes forecast 20051001 |
| The G alpha(o/i)-coupled cannabinoid receptor-mediated neurite outgrowth involves Rap regulation of Src and Stat3. | The Journal of biological chemistry 20050930 |
| Appetite downer awaits approval. | Nature 20050929 |
| Rimonabant: the first therapeutically relevant cannabinoid antagonist. | Life sciences 20050923 |
| Synthesis of long-chain amide analogs of the cannabinoid CB1 receptor antagonist N-(piperidinyl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716) with unique binding selectivities and pharmacological activities. | Bioorganic & medicinal chemistry 20050915 |
| Retrograde endocannabinoid regulation of GABAergic inhibition in the rat dentate gyrus granule cell. | The Journal of physiology 20050915 |
| Mechanisms of HIV-1 inhibition by the lipid mediator N-arachidonoyldopamine. | Journal of immunology (Baltimore, Md. : 1950) 20050915 |
| Synthesis and structure-activity relationship of a novel series of aminoalkylindoles with potential for imaging the neuronal cannabinoid receptor by positron emission tomography. | Journal of medicinal chemistry 20050908 |
| FDA standards--good enough for government work? | The New England journal of medicine 20050908 |
| Lack of CB1 cannabinoid receptor impairs cocaine self-administration. | Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20050901 |
| The CB1 receptor antagonist rimonabant reverses the diet-induced obesity phenotype through the regulation of lipolysis and energy balance. | FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20050901 |
| Endogenous cannabinoid receptor agonists inhibit neurogenic inflammations in guinea pig airways. | International archives of allergy and immunology 20050901 |
| New options for drug treatment of obesity in patients with Type 2 diabetes. | Diabetic medicine : a journal of the British Diabetic Association 20050901 |
| Obesity Drug Development Summit. 21-22 July, 2005, Arlington, VA, USA. | IDrugs : the investigational drugs journal 20050901 |
| Fatty acid amide hydrolase controls mouse intestinal motility in vivo. | Gastroenterology 20050901 |
| Current evidence supporting a role of cannabinoid CB1 receptor (CB1R) antagonists as potential pharmacotherapies for drug abuse disorders. | Behavioural pharmacology 20050901 |
| SR 141716A differentially attenuates the behavioral effects of delta9-THC in rhesus monkeys. | Behavioural pharmacology 20050901 |
| Delta9-THC induced hyperphagia and tolerance assessment: interactions between the CB1 receptor agonist delta9-THC and the CB1 receptor antagonist SR-141716 (rimonabant) in rats. | Behavioural pharmacology 20050901 |
| The role of CB1 receptors in sweet versus fat reinforcement: effect of CB1 receptor deletion, CB1 receptor antagonism (SR141716A) and CB1 receptor agonism (CP-55940). | Behavioural pharmacology 20050901 |
| Anxiogenic profile of AM-251, a selective cannabinoid CB1 receptor antagonist, in plus-maze-naïve and plus-maze-experienced mice. | Behavioural pharmacology 20050901 |
| Long-term behavioural and neuroendocrine effects of perinatal activation or blockade of CB1 cannabinoid receptors. | Behavioural pharmacology 20050901 |
| Behaviorally relevant endocannabinoid action in hippocampus: dependence on temporal summation of multiple inputs. | Behavioural pharmacology 20050901 |
| [In diabetes cannabinoid antagonist kills two birds with one stone]. | MMW Fortschritte der Medizin 20050901 |
| [Innovative therapies in metabolic diseases: ezetimibe (Ezétrol), nicotinic acid (Niaspan), acids omega-3 (Omacor), rimonabant (Acomplia)]. | Revue medicale de Bruxelles 20050901 |
| New drug policy in childhood obesity. | International journal of obesity (2005) 20050901 |
| Cannabinoid CB1 receptors control conditioned drug seeking. | Trends in pharmacological sciences 20050801 |
| A role for endocannabinoids in viral-induced dyskinetic and convulsive phenomena. | Experimental neurology 20050801 |
| [Rimonabant reduced body weight and blood sugar]. | Medizinische Monatsschrift fur Pharmazeuten 20050801 |
| Cannabinoid CB1 receptor-mediated inhibition of noradrenaline release in guinea-pig vessels, but not in rat and mouse aorta. | Naunyn-Schmiedeberg's archives of pharmacology 20050801 |
| Rimonabant hydrochloride: an investigational agent for the management of cardiovascular risk factors. | Drugs of today (Barcelona, Spain : 1998) 20050801 |
| WIN 55,212-2-induced reduction of cocaine hyperlocomotion: possible inhibition of 5-HT(3) receptor function. | European journal of pharmacology 20050704 |
| Delta9-tetrahydrocannbinol accounts for the antinociceptive, hypothermic, and cataleptic effects of marijuana in mice. | The Journal of pharmacology and experimental therapeutics 20050701 |
| A role for endocannabinoids in the generation of parkinsonism and levodopa-induced dyskinesia in MPTP-lesioned non-human primate models of Parkinson's disease. | FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20050701 |
| Effect of the cannabinoid CB1 receptor antagonist, SR141716, on nociceptive response and nerve demyelination in rodents with chronic constriction injury of the sciatic nerve. | Pain 20050701 |
| Inhibitory effects of CB1 and CB2 receptor agonists on responses of DRG neurons and dorsal horn neurons in neuropathic rats. | The European journal of neuroscience 20050701 |
| Effect of rimonabant on weight reduction and cardiovascular risk. | Lancet (London, England) 20050701 |
| Effect of rimonabant on weight reduction and cardiovascular risk. | Lancet (London, England) 20050701 |
| Effect of rimonabant on weight reduction and cardiovascular risk. | Lancet (London, England) 20050701 |
| Effect of rimonabant on weight reduction and cardiovascular risk. | Lancet (London, England) 20050701 |
| [Medication for ending tobacco dependency. Current state]. | Atencion primaria 20050630 |
| Effect of delta9-tetrahydrocannabinol on phosphorylated CREB in rat cerebellum: an immunohistochemical study. | Brain research 20050628 |
| Cysteine residues in the human cannabinoid receptor: only C257 and C264 are required for a functional receptor, and steric bulk at C386 impairs antagonist SR141716A binding. | Biochemistry 20050621 |
| Abnormal sensitivity to cannabinoid receptor stimulation might contribute to altered gamma-aminobutyric acid transmission in the striatum of R6/2 Huntington's disease mice. | Biological psychiatry 20050615 |
| The endogenous cannabinoid anandamide and its synthetic analog R(+)-methanandamide are intravenously self-administered by squirrel monkeys. | The Journal of neuroscience : the official journal of the Society for Neuroscience 20050608 |
| Cannabinoid CB(1) receptors in the basal ganglia and motor response to activation or blockade of these receptors in parkin-null mice. | Brain research 20050607 |
| The cannabinoid antagonist SR141716A facilitates memory acquisition and consolidation in the mouse elevated T-maze. | Neuroscience letters 20050603 |
| Suppression of conditioned nicotine and sucrose seeking by the cannabinoid-1 receptor antagonist SR141716A. | Behavioural brain research 20050603 |
| Disruption of CB(1) receptor signaling impairs extinction of spatial memory in mice. | Psychopharmacology 20050601 |
| CB1 cannabinoid receptor-mediated modulation of food intake in mice. | British journal of pharmacology 20050601 |
| The effects of Delta9-tetrahydrocannabinol in rat mesenteric vasculature, and its interactions with the endocannabinoid anandamide. | British journal of pharmacology 20050601 |
| Endocannabinoid release from midbrain dopamine neurons: a potential substrate for cannabinoid receptor antagonist treatment of addiction. | Neuropharmacology 20050601 |
| Cannabinoids produce neuroprotection by reducing intracellular calcium release from ryanodine-sensitive stores. | Neuropharmacology 20050601 |
| Cannabinoid CB(1) antagonist SR 141716A attenuates reinstatement of heroin self-administration in heroin-abstinent rats. | Neuropharmacology 20050601 |
| Peripheral, but not central effects of cannabidiol derivatives: mediation by CB(1) and unidentified receptors. | Neuropharmacology 20050601 |
| Evidence that (-)-7-hydroxy-4'-dimethylheptyl-cannabidiol activates a non-CB(1), non-CB(2), non-TRPV1 target in the mouse vas deferens. | Neuropharmacology 20050601 |
| CB1 receptor antagonists for the treatment of nicotine addiction. | Pharmacology, biochemistry, and behavior 20050601 |
| Intention to lose weight, weight changes, and 18-y mortality in overweight individuals without co-morbidities. | PLoS medicine 20050601 |
| Keynote review: Medicinal chemistry strategies to CB1 cannabinoid receptor antagonists. | Drug discovery today 20050515 |
| Interaction between gamma-aminobutyric acid GABAB and cannabinoid CB1 receptors in spinal pain pathways in rat. | European journal of pharmacology 20050509 |
| [Highlights from the American College of Cardiology Annual Scientific Session 2005: March 5-9, 2005, Orlando, Florida]. | Revue medicale suisse 20050504 |
| Tricyclic pyrazoles. Part 2: Synthesis and biological evaluation of novel 4,5-dihydro-1H-benzo[g]indazole-based ligands for cannabinoid receptors. | Bioorganic & medicinal chemistry 20050502 |
| The cannabinoid CB1 receptor antagonist SR141716A reduces appetitive and consummatory responses for food. | Psychopharmacology 20050501 |
| CB1 cannabinoid receptor agonists increase intracranial self-stimulation thresholds in the rat. | Psychopharmacology 20050501 |
| Endocannabinoid control of food intake and energy balance. | Nature neuroscience 20050501 |
| Evidence for novel cannabinoid receptors. | Pharmacology & therapeutics 20050501 |
| The cannabinoid receptor agonist WIN 55212-2 inhibits neurogenic inflammations in airway tissues. | Journal of pharmacological sciences 20050501 |
| Cannabinoid receptor antagonists SR141716 and SR144528 exhibit properties of partial agonists in experiments on isolated perfused rat heart. | Bulletin of experimental biology and medicine 20050501 |
| Substituted 5,5'-diphenyl-2-thioxoimidazolidin-4-one as CB1 cannabinoid receptor ligands: synthesis and pharmacological evaluation. | Journal of medicinal chemistry 20050407 |
| Protective effects of Delta(9)-tetrahydrocannabinol against N-methyl-d-aspartate-induced AF5 cell death. | Brain research. Molecular brain research 20050404 |
| In vitro metabolism of diarylpyrazoles, a novel group of cannabinoid receptor ligands. | Drug metabolism and disposition: the biological fate of chemicals 20050401 |
| Involvement of protein kinase A in cannabinoid receptor-mediated protection from oxidative neuronal injury. | The Journal of pharmacology and experimental therapeutics 20050401 |
| Cannabinoid CB1 antagonists possess antiparkinsonian efficacy only in rats with very severe nigral lesion in experimental parkinsonism. | Neurobiology of disease 20050401 |
| Rimonabant--a selective CB1 antagonist. | The Annals of pharmacotherapy 20050401 |
| [Innovation instead of imitation -- news in drug therapy]. | Deutsche medizinische Wochenschrift (1946) 20050401 |
| Fighting obesity and associated risk factors by antagonising cannabinoid type 1 receptors. | Lancet (London, England) 20050401 |
| Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. | Lancet (London, England) 20050401 |
| Obesity and cardiovascular physiology: impact of some pharmacological agents. | Current vascular pharmacology 20050401 |
| Cannabinoid CB1 receptor antagonism reduces conditioned reinstatement of ethanol-seeking behavior in rats. | The European journal of neuroscience 20050401 |
| Bioisosteric replacements of the pyrazole moiety of rimonabant: synthesis, biological properties, and molecular modeling investigations of thiazoles, triazoles, and imidazoles as potent and selective CB1 cannabinoid receptor antagonists. | Journal of medicinal chemistry 20050324 |
| [Blocking the endocannabinoid system -- weight reduction and cardiovascular risk management]. | Deutsche medizinische Wochenschrift (1946) 20050324 |
| Involvement of cannabinoid receptors in the regulation of neurotransmitter release in the rodent striatum: a combined immunochemical and pharmacological analysis. | The Journal of neuroscience : the official journal of the Society for Neuroscience 20050316 |
| Effects of the endocannabinoid noladin ether on body weight, food consumption, locomotor activity, and cognitive index in mice. | Brain research bulletin 20050315 |
| Synergistic interactions between cannabinoids and environmental stress in the activation of the central amygdala. | Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20050301 |
| Cannabinoid CB1 receptor antagonists as promising new medications for drug dependence. | The Journal of pharmacology and experimental therapeutics 20050301 |
| Enhancing cannabinoid neurotransmission augments the extinction of conditioned fear. | Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20050301 |
| Pharmacological modulation of the endocannabinoid system in a viral model of multiple sclerosis. | Journal of neurochemistry 20050301 |
| Cannabinoid receptor as a novel target for the treatment of prostate cancer. | Cancer research 20050301 |
| Cannabinoids and the regulation of ingestive behaviour. | Current drug targets 20050301 |
| Will the new CB1 cannabinoid receptor antagonist SR-147778 have advantages over rimonabant? | Expert opinion on investigational drugs 20050301 |
| Inverse agonism and neutral antagonism at cannabinoid CB1 receptors. | Life sciences 20050204 |
| Effects of the cannabinoid CB1 receptor antagonist SR141716 on oxygen consumption and soleus muscle glucose uptake in Lep(ob)/Lep(ob) mice. | International journal of obesity (2005) 20050201 |
| Human sperm express cannabinoid receptor Cb1, the activation of which inhibits motility, acrosome reaction, and mitochondrial function. | The Journal of clinical endocrinology and metabolism 20050201 |
| 3,4 Methylenedioxymethamphetamine-induced conditioned place preference (CPP) is mediated by endocannabinoid system. | Pharmacological research 20050201 |
| The nonpsychoactive component of marijuana cannabidiol modulates chemotaxis and IL-10 and IL-12 production of murine macrophages both in vivo and in vitro. | Journal of neuroimmunology 20050201 |
| Synthesis and SAR of 5,6-diarylpyridines as human CB1 inverse agonists. | Bioorganic & medicinal chemistry letters 20050201 |
| Effects of the cannabinoid CB1 receptor antagonist rimonabant in models of emotional reactivity in rodents. | Biological psychiatry 20050201 |
| [Endocannabinoid and endocannabinoid receptor antagonists]. | Medizinische Monatsschrift fur Pharmazeuten 20050201 |
| Another pill for weight reduction. | Clinical cardiology 20050201 |
| Inhibition of restraint stress-induced neural and behavioural activation by endogenous cannabinoid signalling. | The European journal of neuroscience 20050201 |
| New diet drug stirs high hopes. But can the pill, rimonabant, liver up to large expectations? | Heart advisor 20050201 |
| Synthetic cannabinoid WIN55,212-2 inhibits generation of inflammatory mediators by IL-1beta-stimulated human astrocytes. | Glia 20050115 |
| [Nutrition--obesity]. | Revue medicale suisse 20050105 |
| Nicotine-associated cues maintain nicotine-seeking behavior in rats several weeks after nicotine withdrawal: reversal by the cannabinoid (CB1) receptor antagonist, rimonabant (SR141716). | Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20050101 |
| Role of the endocannabinoid system in the development of tolerance to alcohol. | Alcohol and alcoholism (Oxford, Oxfordshire) 20050101 |
| Interactions between cannabinoid and opioid receptor systems in the mediation of ethanol effects. | Alcohol and alcoholism (Oxford, Oxfordshire) 20050101 |
| Up-regulation of the endocannabinoid system in the uterus of leptin knockout (ob/ob) mice and implications for fertility. | Molecular human reproduction 20050101 |
| Endogenous cannabinoids are not involved in cocaine reinforcement and development of cocaine-induced behavioural sensitization. | European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology 20050101 |
| Suppressing effect of the cannabinoid CB1 receptor antagonist, SR147778, on alcohol intake and motivational properties of alcohol in alcohol-preferring sP rats. | Alcohol and alcoholism (Oxford, Oxfordshire) 20050101 |
| The anti-obesity effect of rimonabant is associated with an improved serum lipid profile. | Diabetes, obesity & metabolism 20050101 |
| Search for an endogenous cannabinoid-mediated effect in the sympathetic nervous system. | Naunyn-Schmiedeberg's archives of pharmacology 20050101 |
| Cannabis antagonists: a new era of social psychopharmacology? | Journal of psychopharmacology (Oxford, England) 20050101 |
| [The best of clinical pharmacology in 2004]. | Archives des maladies du coeur et des vaisseaux 20050101 |
| [Endocannabinoids--the new option in the treatment of metabolic syndrome and in smoking cessation]. | Casopis lekaru ceskych 20050101 |
| Cannabinoids depress excitatory neurotransmission between the subthalamic nucleus and the globus pallidus. | Neuroscience 20050101 |
| Periaqueductal grey CB1 cannabinoid and metabotropic glutamate subtype 5 receptors modulate changes in rostral ventromedial medulla neuronal activities induced by subcutaneous formalin in the rat. | Neuroscience 20050101 |
| Rimonabant: unique and promising. | Preventive cardiology 20050101 |
| [Obesity and type 2 diabetes]. | Revue medicale de Liege 20050101 |
| [The endocannabinoid system and the regulation of the metabolism]. | Revue medicale de Bruxelles 20050101 |
| [Rimonabant (Acomplia), specific inhibitor of the endocannabinoid system]. | Revue medicale de Bruxelles 20050101 |
| Cocaine- and amphetamine-related transcript is involved in the orexigenic effect of endogenous anandamide. | Neuroendocrinology 20050101 |
| Pharmacotherapy for nicotine dependence. | CA: a cancer journal for clinicians 20050101 |
| Prevalence, predisposition and prevention of type II diabetes. | Nutrition & metabolism 20050101 |
| [The endocannabinoid system and the regulation of the metabolism]. | Journal de pharmacie de Belgique 20050101 |
| [Rimonabant (Acomplia), specific inhibitor of the endocannabinoid system]. | Journal de pharmacie de Belgique 20050101 |
| The endocannabinoid system: a new approach to control cardiovascular disease. | Clinical cornerstone 20050101 |
| The metabolic basis of atherogenic dyslipidemia. | Clinical cornerstone 20050101 |
| Managing cardiovascular risk inpatients with metabolic syndrome. | Clinical cornerstone 20050101 |
| Pharmacotherapy to reduce visceral fat. | Clinical cornerstone 20050101 |
| Cannabinoid tolerance and dependence. | Handbook of experimental pharmacology 20050101 |
| Human brain endothelium: coexpression and function of vanilloid and endocannabinoid receptors. | Brain research. Molecular brain research 20041206 |
| Delta9-tetrahydrocannabinol-induced conditioned place preference and intracerebroventricular self-administration in rats. | European journal of pharmacology 20041203 |
| Discriminative stimulus effects in rats of SR-141716 (rimonabant), a cannabinoid CB1 receptor antagonist. | Psychopharmacology 20041201 |
| Activation of cannabinoid CB2 receptors suppresses C-fiber responses and windup in spinal wide dynamic range neurons in the absence and presence of inflammation. | Journal of neurophysiology 20041201 |
| Modulation of morphine-induced Fos-immunoreactivity by the cannabinoid receptor antagonist SR 141716. | Neuropharmacology 20041201 |
| The weight debate, continued. | Managed care (Langhorne, Pa.) 20041201 |
| (S)-AMPA inhibits electrically evoked calcitonin gene-related peptide (CGRP) release from the rat dorsal horn: reversal by cannabinoid receptor antagonist SR141716A. | Neuroscience letters 20041130 |
| Discriminative stimulus effects of the structurally novel cannabinoid CB1/CB2 receptor partial agonist BAY 59-3074 in the rat. | European journal of pharmacology 20041128 |
| A cannabinoid receptor antagonist attenuates conditioned place preference but not behavioural sensitization to morphine. | Brain research 20041112 |
| [Endocannabinoids receptor blocker lets tumble not only money. A drug against metabolic syndrome?]. | MMW Fortschritte der Medizin 20041104 |
| Endocannabinoids link feeding state and auditory perception-related gene expression. | The Journal of neuroscience : the official journal of the Society for Neuroscience 20041103 |
| Cannabinoid receptor agonists inhibit sensory nerve activation in guinea pig airways. | American journal of respiratory and critical care medicine 20041101 |
| The cannabinoid CB1 receptor antagonist SR141716 blocks the orexigenic effects of intrahypothalamic ghrelin. | British journal of pharmacology 20041101 |
| (-)-Adamantyl-delta8-tetrahydrocannabinol (AM-411), a selective cannabinoid CB1 receptor agonist: effects on open-field behaviors and antagonism by SR-141716 in rats. | Behavioural pharmacology 20041101 |
| Cannabinoid CB2 receptor activation inhibits mechanically evoked responses of wide dynamic range dorsal horn neurons in naïve rats and in rat models of inflammatory and neuropathic pain. | The European journal of neuroscience 20041101 |
| Potential modulation of plasma ghrelin and glucagon-like peptide-1 by anorexigenic cannabinoid compounds, SR141716A (rimonabant) and oleoylethanolamide. | The British journal of nutrition 20041101 |
| Cannabidiol prevents infarction via the non-CB1 cannabinoid receptor mechanism. | Neuroreport 20041025 |
| Cannabinoid inhibition improves memory in food-storing birds, but with a cost. | Proceedings. Biological sciences 20041007 |
| Cannabinoid receptor antagonist reduces heroin self-administration only in dependent rats. | European journal of pharmacology 20041006 |
| Endocannabinoids acting at cannabinoid-1 receptors regulate cardiovascular function in hypertension. | Circulation 20041005 |
| Characterization of cannabinoid modulation of sensory neurotransmission in the rat isolated mesenteric arterial bed. | The Journal of pharmacology and experimental therapeutics 20041001 |
| The THC-induced suppression of Th1 polarization in response to Legionella pneumophila infection is not mediated by increases in corticosterone and PGE2. | Journal of leukocyte biology 20041001 |
| A new strategy to block tumor growth by inhibiting endocannabinoid inactivation. | FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20041001 |
| CB1 receptor agonist and heroin, but not cocaine, reinstate cannabinoid-seeking behaviour in the rat. | British journal of pharmacology 20041001 |
| Changes in endocannabinoid levels in a rat model of behavioural sensitization to morphine. | The European journal of neuroscience 20041001 |
| Clinical pharmacotherapy for obesity: current drugs and those in advanced development. | Current drug targets 20041001 |
| Rimonabant, a CB1 antagonist, blocks nicotine-conditioned place preferences. | Neuroreport 20040915 |
| Suppressing effect of the cannabinoid CB1 receptor antagonist, SR 141716, on alcohol's motivational properties in alcohol-preferring rats. | European journal of pharmacology 20040913 |
| Analysis of the effects of cannabinoids on synaptic transmission between basket and Purkinje cells in the cerebellar cortex of the rat. | The Journal of pharmacology and experimental therapeutics 20040901 |
| Effect of low doses of delta9-tetrahydrocannabinol and cannabidiol on the extinction of cocaine-induced and amphetamine-induced conditioned place preference learning in rats. | Psychopharmacology 20040901 |
| Vanilloid TRPV1 receptor mediates the antihyperalgesic effect of the nonpsychoactive cannabinoid, cannabidiol, in a rat model of acute inflammation. | British journal of pharmacology 20040901 |
| 3-Morpholinylsydnonimine inhibits glutamatergic transmission in rat rostral ventrolateral medulla via peroxynitrite formation and adenosine release. | Molecular pharmacology 20040901 |
| Rats on the grog: novel pharmacotherapies for alcohol craving. | Addictive behaviors 20040901 |
| Evidence for an interaction between CB1 cannabinoid and oxytocin receptors in food and water intake. | Neuropharmacology 20040901 |
| Cannabinoids inhibit the vascular endothelial growth factor pathway in gliomas. | Cancer research 20040815 |
| Anandamide transport inhibitor AM404 and structurally related compounds inhibit synaptic transmission between rat hippocampal neurons in culture independent of cannabinoid CB1 receptors. | European journal of pharmacology 20040802 |
| Cannabinoid antagonist SR-141716 inhibits endotoxic hypotension by a cardiac mechanism not involving CB1 or CB2 receptors. | American journal of physiology. Heart and circulatory physiology 20040801 |
| Endocannabinoid system modulates relapse to methamphetamine seeking: possible mediation by the arachidonic acid cascade. | Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20040801 |
| Evidence for differential modulation of conditioned aversion and fear-conditioned analgesia by CB1 receptors. | The European journal of neuroscience 20040801 |
| Role of different brain structures in the behavioural expression of WIN 55,212-2 withdrawal in mice. | British journal of pharmacology 20040801 |
| A comparison of the discriminative stimulus effects of delta(9)-tetrahydrocannabinol and O-1812, a potent and metabolically stable anandamide analog, in rats. | Experimental and clinical psychopharmacology 20040801 |
| Genetic deletion and pharmacological blockade of CB1 receptors modulates anxiety in the shock-probe burying test. | The European journal of neuroscience 20040801 |
| Current and investigational antiobesity agents and obesity therapeutic treatment targets. | Obesity research 20040801 |
| Adolescent exposure to cannabinoids induces long-lasting changes in the response to drugs of abuse of rat midbrain dopamine neurons. | Biological psychiatry 20040715 |
| A comparative analysis of the potential of cannabinoids and ondansetron to suppress cisplatin-induced emesis in the Suncus murinus (house musk shrew). | Psychopharmacology 20040701 |
| Evidence for an interaction between CB1 cannabinoid and melanocortin MCR-4 receptors in regulating food intake. | Endocrinology 20040701 |
| Effects on turning of microinjections into basal ganglia of D(1) and D(2) dopamine receptors agonists and the cannabinoid CB(1) antagonist SR141716A in a rat Parkinson's model. | Neurobiology of disease 20040701 |
| Central effects of the cannabinoid receptor agonist WIN55212-2 on respiratory and cardiovascular regulation in anaesthetised rats. | British journal of pharmacology 20040701 |
| TRPV1 and CB(1) receptor-mediated effects of the endovanilloid/endocannabinoid N-arachidonoyl-dopamine on primary afferent fibre and spinal cord neuronal responses in the rat. | The European journal of neuroscience 20040701 |
| Inhibitory effect of the antidepressant St. John's wort (hypericum perforatum) on rat bladder contractility in vitro. | Urology 20040701 |
| CB1 cannabinoid receptors mediate anxiolytic effects: convergent genetic and pharmacological evidence with CB1-specific agents. | Behavioural pharmacology 20040701 |
| Recent advances in CB1 cannabinoid receptor antagonists. | Current opinion in drug discovery & development 20040701 |
| Comparison of anandamide transport in FAAH wild-type and knockout neurons: evidence for contributions by both FAAH and the CB1 receptor to anandamide uptake. | Biochemistry 20040629 |
| Rapid tolerance to the intestinal prokinetic effect of cannabinoid CB1 receptor antagonist, SR 141716 (Rimonabant). | European journal of pharmacology 20040628 |
| The antinociceptive effect of Delta9-tetrahydrocannabinol in the arthritic rat. | European journal of pharmacology 20040616 |
| Sex-linked differences in the vasorelaxant effects of anandamide in vascular mesenteric beds: role of oestrogens. | European journal of pharmacology 20040616 |
| Cannabinoid agonist-induced sensitisation to morphine place preference in mice. | Neuroreport 20040607 |
| Cannabinoids enhance N-methyl-D-aspartate-induced excitation of locus coeruleus neurons by CB1 receptors in rat brain slices. | Neuroscience letters 20040603 |
| Cannabinoids prevent the acute hyperthermia and partially protect against the 5-HT depleting effects of MDMA ('Ecstasy') in rats. | Neuropharmacology 20040601 |
| Presynaptic cannabinoid CB(1) receptors are involved in the inhibition of the neurogenic vasopressor response during septic shock in pithed rats. | British journal of pharmacology 20040601 |
| Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder. | The American journal of psychiatry 20040601 |
| Clinical trials update and cumulative meta-analyses from the American College of Cardiology: WATCH, SCD-HeFT, DINAMIT, CASINO, INSPIRE, STRATUS-US, RIO-Lipids and cardiac resynchronisation therapy in heart failure. | European journal of heart failure 20040601 |
| Multiple sclerosis following treatment with a cannabinoid receptor-1 antagonist. | Multiple sclerosis (Houndmills, Basingstoke, England) 20040601 |
| Memory reconsolidation and extinction have distinct temporal and biochemical signatures. | The Journal of neuroscience : the official journal of the Society for Neuroscience 20040519 |
| Behavioral and molecular changes elicited by acute administration of SR141716 to Delta9-tetrahydrocannabinol-tolerant rats: an experimental model of cannabinoid abstinence. | Drug and alcohol dependence 20040510 |
| Cannabinoids enhance subsecond dopamine release in the nucleus accumbens of awake rats. | The Journal of neuroscience : the official journal of the Society for Neuroscience 20040505 |
| Blockade by the cannabinoid CB1 receptor antagonist, rimonabant (SR141716), of the potentiation by quinelorane of food-primed reinstatement of food-seeking behavior. | Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20040501 |
| Cannabinoid receptor-mediated regulation of intracellular calcium by delta(9)-tetrahydrocannabinol in resting T cells. | Journal of leukocyte biology 20040501 |
| Retrograde activation of presynaptic NMDA receptors enhances GABA release at cerebellar interneuron-Purkinje cell synapses. | Nature neuroscience 20040501 |
| Advances in pharmacotherapy for tobacco dependence. | Expert opinion on emerging drugs 20040501 |
| The endogenous cannabinoid system protects against colonic inflammation. | The Journal of clinical investigation 20040415 |
| Antagonism of cannabinoid CB1 receptors in the paraventricular nucleus of male rats induces penile erection. | Neuroscience letters 20040408 |
| Combined low dose treatment with opioid and cannabinoid receptor antagonists synergistically reduces the motivation to consume alcohol in rats. | Psychopharmacology 20040401 |
| Differential effects of delta9-tetrahydrocannabinol and methanandamide in CB1 knockout and wild-type mice. | The Journal of pharmacology and experimental therapeutics 20040401 |
| CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity. | International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity 20040401 |
| Multiple actions of anandamide on neonatal rat cultured sensory neurones. | British journal of pharmacology 20040401 |
| Treating obesity: pharmacology of energy expenditure. | Current drug targets 20040401 |
| Involvement of brain-derived neurotrophic factor in cannabinoid receptor-dependent protection against excitotoxicity. | The European journal of neuroscience 20040401 |
| Very low doses of delta 8-THC increase food consumption and alter neurotransmitter levels following weight loss. | Pharmacology, biochemistry, and behavior 20040401 |
| The effect of SR 141716 and apomorphine on sensorimotor gating in Swiss mice. | Pharmacology, biochemistry, and behavior 20040401 |
| Cannabinoid receptor antagonists and obesity. | Current opinion in investigational drugs (London, England : 2000) 20040401 |
| Rimonabant Sanofi-Synthélabo. | Current opinion in investigational drugs (London, England : 2000) 20040401 |
| [A new pill for metabolic syndrome. Successful control of lipids, kilos and cigarettes]. | MMW Fortschritte der Medizin 20040325 |
| Central and peripheral mechanisms contribute to the antiemetic actions of delta-9-tetrahydrocannabinol against 5-hydroxytryptophan-induced emesis. | European journal of pharmacology 20040319 |
| Potent imidazole and triazole CB1 receptor antagonists related to SR141716. | Bioorganic & medicinal chemistry letters 20040308 |
| [Blocking cannabinoid receptors. Simultaneous control of overweight and nicotine addiction]. | MMW Fortschritte der Medizin 20040304 |
| Selective antagonist [3H]SR141716A binding to cannabinoid CB1 receptors is increased in the anterior cingulate cortex in schizophrenia. | Progress in neuro-psychopharmacology & biological psychiatry 20040301 |
| Massive accumulation of N-acylethanolamines after stroke. Cell signalling in acute cerebral ischemia? | Journal of neurochemistry 20040301 |
| Amyotrophic lateral sclerosis: delayed disease progression in mice by treatment with a cannabinoid. | Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases 20040301 |
| Disruption of endocannabinoid release and striatal long-term depression by postsynaptic blockade of endocannabinoid membrane transport. | The Journal of neuroscience : the official journal of the Society for Neuroscience 20040218 |
| Selective activation of cannabinoid CB2 receptors suppresses hyperalgesia evoked by intradermal capsaicin. | The Journal of pharmacology and experimental therapeutics 20040201 |
| Cannabinoids modulate ultrasound-induced aversive responses in rats. | Psychopharmacology 20040201 |
| Cannabinoid receptors and T helper cells. | Journal of neuroimmunology 20040201 |
| CB(1) receptor mediation of cannabinoid behavioral effects in male and female rats. | Psychopharmacology 20040201 |
| Partial agonist-like profile of the cannabinoid receptor antagonist SR141716A in a food-reinforced operant paradigm. | Behavioural pharmacology 20040201 |
| Differential effects of the sleep-inducing lipid oleamide and cannabinoids on the induction of long-term potentiation in the CA1 neurons of the rat hippocampus in vitro. | Brain research 20040130 |
| Synthesis, biological properties, and molecular modeling investigations of novel 3,4-diarylpyrazolines as potent and selective CB(1) cannabinoid receptor antagonists. | Journal of medicinal chemistry 20040129 |
| Consumption of high carbohydrate, high fat, and normal chow is equally suppressed by a cannabinoid receptor antagonist in non-deprived rats. | Neuroscience letters 20040116 |
| Cannabinoid receptor type 1 modulates excitatory and inhibitory neurotransmission in mouse colon. | American journal of physiology. Gastrointestinal and liver physiology 20040101 |
| Corticotropin-releasing hormone (CRH) mRNA expression in rat central amygdala in cannabinoid tolerance and withdrawal: evidence for an allostatic shift? | Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20040101 |
| Effect of cannabinoids on lithium-induced vomiting in the Suncus murinus (house musk shrew). | Psychopharmacology 20040101 |
| Behavioral mechanisms underlying inhibition of food-maintained responding by the cannabinoid receptor antagonist/inverse agonist SR141716A. | European journal of pharmacology 20040101 |
| Cannabinoids and the human uterus during pregnancy. | American journal of obstetrics and gynecology 20040101 |
| Long-term effects on cortical glutamate release induced by prenatal exposure to the cannabinoid receptor agonist (R)-(+)-[2,3-dihydro-5-methyl-3-(4-morpholinyl-methyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-naphthalenylmethanone: an in vivo microdialysis study in the awake rat. | Neuroscience 20040101 |
| Neurokinin B, neurotensin, and cannabinoid receptor antagonists and Parkinson disease. | Clinical neuropharmacology 20040101 |
| Molecule of the month. Rimonabant hydrochloride. | Drug news & perspectives 20040101 |
| Cannabinoid physiology and pharmacology: 30 years of progress. | Neuropharmacology 20040101 |
| Effects of CB1 cannabinoid receptor blockade on ethanol preference after chronic alcohol administration combined with repeated re-exposures and withdrawals. | Alcohol and alcoholism (Oxford, Oxfordshire) 20040101 |
| Anandamide content is increased and CB1 cannabinoid receptor blockade is protective during transient, focal cerebral ischemia. | Neuroscience 20040101 |
| Enhancement of androgen receptor expression induced by (R)-methanandamide in prostate LNCaP cells. | FEBS letters 20031218 |
| Cannabinoids decrease corticostriatal synaptic transmission via an effect on glutamate uptake. | The Journal of neuroscience : the official journal of the Society for Neuroscience 20031203 |
| An optimized approach to study endocannabinoid signaling: evidence against constitutive activity of rat brain adenosine A1 and cannabinoid CB1 receptors. | British journal of pharmacology 20031201 |
| A novel neuroimmune mechanism in cannabinoid-mediated attenuation of nerve growth factor-induced hyperalgesia. | Anesthesiology 20031201 |
| SR141716A reduces the reinforcing properties of heroin but not heroin-induced increases in nucleus accumbens dopamine in rats. | The European journal of neuroscience 20031201 |
| The cannabinoid CB1 antagonists SR 141716A and AM 251 suppress food intake and food-reinforced behavior in a variety of tasks in rats. | Behavioural pharmacology 20031201 |
| An aromatic microdomain at the cannabinoid CB(1) receptor constitutes an agonist/inverse agonist binding region. | Journal of medicinal chemistry 20031120 |
| Antagonism between the anti-inflammatory activity of the cannabinoid WIN 55212-2 and SR 141716A. | Pharmacology 20031101 |
| Discriminative stimulus effects of the cannabinoid antagonist, SR 141716A, in delta -sup-9-tetrahydrocannabinol-treated rhesus monkeys. | Experimental and clinical psychopharmacology 20031101 |
| Biphasic effects of cannabinoids on acetylcholine release in the hippocampus: site and mechanism of action. | The Journal of neuroscience : the official journal of the Society for Neuroscience 20031015 |
| CB1 cannabinoid receptors and on-demand defense against excitotoxicity. | Science (New York, N.Y.) 20031003 |
| Effects of direct periaqueductal grey administration of a cannabinoid receptor agonist on nociceptive and aversive responses in rats. | Neuropharmacology 20031001 |
| The endogenous cannabinoid system regulates seizure frequency and duration in a model of temporal lobe epilepsy. | The Journal of pharmacology and experimental therapeutics 20031001 |
| Hypotensive effect of anandamide through the activation of CB1 and VR1 spinal receptors in urethane-anesthetized rats. | Naunyn-Schmiedeberg's archives of pharmacology 20031001 |
| Activation of peripheral cannabinoid CB1 receptors inhibits mechanically evoked responses of spinal neurons in noninflamed rats and rats with hindpaw inflammation. | The European journal of neuroscience 20031001 |
| Cannabinoids inhibit the release of [3H]glutamate from rodent hippocampal synaptosomes via a novel CB1 receptor-independent action. | The European journal of neuroscience 20031001 |
| Antagonizing the cannabinoid receptor type 1: a dual way to fight obesity. | Journal of endocrinological investigation 20031001 |
| Potentiation of penile erection and yawning responses to apomorphine by cannabinoid receptor antagonist in rats. | Neuroscience letters 20030925 |
| SR141716A, a cannabinoid CB1 receptor antagonist, improves memory in a delayed radial maze task. | European journal of pharmacology 20030923 |
| Amnesia induced by beta-amyloid fragments is counteracted by cannabinoid CB1 receptor blockade. | European journal of pharmacology 20030923 |
| Inhibitory effect of anandamide on resiniferatoxin-induced sensory neuropeptide release in vivo and neuropathic hyperalgesia in the rat. | Life sciences 20030919 |
| Cannabinoid modulation of sensitivity to time. | Behavioural brain research 20030915 |
| Activation of phosphoinositide 3-kinase/PKB pathway by CB(1) and CB(2) cannabinoid receptors expressed in prostate PC-3 cells. Involvement in Raf-1 stimulation and NGF induction. | Cellular signalling 20030901 |
| Role of cannabinoid CB1 receptors and tumor necrosis factor-alpha in the gut and systemic anti-inflammatory activity of SR 141716 (rimonabant) in rodents. | British journal of pharmacology 20030901 |
| Lack of CB1 receptors increases noradrenaline release in vas deferens without affecting atrial noradrenaline release or cortical acetylcholine release. | British journal of pharmacology 20030901 |
| Inhibition of guinea-pig and human sensory nerve activity and the cough reflex in guinea-pigs by cannabinoid (CB2) receptor activation. | British journal of pharmacology 20030901 |
| Effects of levodopa on endocannabinoid levels in rat basal ganglia: implications for the treatment of levodopa-induced dyskinesias. | The European journal of neuroscience 20030901 |
| Effects of cannabinoids on non-adrenergic non-cholinergic-mediated relaxation in guinea-pig trachea. | European journal of pharmacology 20030815 |
| Arachidonylcyclopropylamide increases microglial cell migration through cannabinoid CB2 and abnormal-cannabidiol-sensitive receptors. | European journal of pharmacology 20030808 |
| Antitussive effect of WIN 55212-2, a cannabinoid receptor agonist. | European journal of pharmacology 20030808 |
| Functional localization of cannabinoid receptors and endogenous cannabinoid production in distinct neuron populations of the hippocampus. | The European journal of neuroscience 20030801 |
| Endogenous interleukin-1 receptor antagonist mediates anti-inflammatory and neuroprotective actions of cannabinoids in neurons and glia. | The Journal of neuroscience : the official journal of the Society for Neuroscience 20030723 |
| The effect of cannabinoid receptor antagonism with SR141716A on antinociception induced by cocaine and the NMDA receptor antagonist, MK-801. | Brain research bulletin 20030715 |
| The cannabinoid CB1 antagonist N-piperidinyl-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl) -4-methylpyrazole-3-carboxamide (SR-141716A) differentially alters the reinforcing effects of heroin under continuous reinforcement, fixed ratio, and progressive ratio schedules of drug self-administration in rats. | The Journal of pharmacology and experimental therapeutics 20030701 |
| Synthesis and characterization of NESS 0327: a novel putative antagonist of the CB1 cannabinoid receptor. | The Journal of pharmacology and experimental therapeutics 20030701 |
| The cannabinoid receptor antagonist SR 141716 attenuates overfeeding induced by systemic or intracranial morphine. | Psychopharmacology 20030701 |
| Anxiety does not affect the antinociceptive effect of Delta 9-THC in mice: participation of cannabinoid and opioid receptors. | Pharmacology, biochemistry, and behavior 20030701 |
| Behaviorally active doses of the CB1 receptor antagonist SR 141716A increase brain serotonin and dopamine levels and turnover. | Pharmacology, biochemistry, and behavior 20030701 |
| The cannabinoid receptor antagonist SR-141716 does not readily antagonize open-field effects induced by the cannabinoid receptor agonist (R)-methanandamide in rats. | Pharmacology, biochemistry, and behavior 20030701 |
| Hypersensitization of the Orexin 1 receptor by the CB1 receptor: evidence for cross-talk blocked by the specific CB1 antagonist, SR141716. | The Journal of biological chemistry 20030627 |
| Cannabinoid pharmacological properties common to other centrally acting drugs. | European journal of pharmacology 20030627 |
| Functional tolerance and blockade of long-term depression at synapses in the nucleus accumbens after chronic cannabinoid exposure. | The Journal of neuroscience : the official journal of the Society for Neuroscience 20030615 |
| Overeating, alcohol and sucrose consumption decrease in CB1 receptor deleted mice. | Neuroscience letters 20030612 |
| Neuroprotection by the cannabinoid agonist WIN-55212 in an in vivo newborn rat model of acute severe asphyxia. | Brain research. Molecular brain research 20030610 |
| Subversion and utilization of the host cell cyclic adenosine 5'-monophosphate/protein kinase A pathway by Brucella during macrophage infection. | Journal of immunology (Baltimore, Md. : 1950) 20030601 |
| Reduction of human monocytic cell neurotoxicity and cytokine secretion by ligands of the cannabinoid-type CB2 receptor. | British journal of pharmacology 20030601 |
| Endocannabinoids protect the rat isolated heart against ischaemia. | British journal of pharmacology 20030601 |
| Anandamide regulates neuropeptide release from capsaicin-sensitive primary sensory neurons by activating both the cannabinoid 1 receptor and the vanilloid receptor 1 in vitro. | The European journal of neuroscience 20030601 |
| WIN 55,212-2 decreases the reinforcing actions of cocaine through CB1 cannabinoid receptor stimulation. | Behavioural brain research 20030515 |
| Integrity of extracellular loop 1 of the human cannabinoid receptor 1 is critical for high-affinity binding of the ligand CP 55,940 but not SR 141716A. | Biochemical pharmacology 20030515 |
| Effects of cannabinoids in the rat model of Huntington's disease generated by an intrastriatal injection of malonate. | Neuroreport 20030506 |
| Microinjection of a cannabinoid receptor antagonist into the NTS increases baroreflex duration in dogs. | American journal of physiology. Heart and circulatory physiology 20030501 |
| The peripheral sympathetic nervous system is the major target of cannabinoids in eliciting cardiovascular depression. | Naunyn-Schmiedeberg's archives of pharmacology 20030501 |
| Cannabinoid receptor activation differentially modulates ion channels in photoreceptors of the tiger salamander. | Journal of neurophysiology 20030501 |
| A cannabinoid agonist differentially attenuates deep tissue hyperalgesia in animal models of cancer and inflammatory muscle pain. | Pain 20030501 |
| (R)-Methanandamide and delta9-tetrahydrocannabinol-induced operant rate decreases in rats are not readily antagonized by SR-141716A. | European journal of pharmacology 20030411 |
| Experimental drugs take aim at obesity. | JAMA 20030409 |
| Preferential effects of the cannabinoid CB1 receptor antagonist, SR 141716, on food intake and body weight gain of obese (fa/fa) compared to lean Zucker rats. | Psychopharmacology 20030401 |
| The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. | Molecular pharmacology 20030401 |
| Differential cannabinoid-induced electrophysiological effects in rat ventral tegmentum. | Neuropharmacology 20030401 |
| Vasodilator actions of abnormal-cannabidiol in rat isolated small mesenteric artery. | British journal of pharmacology 20030401 |
| Cannabinoid mechanism in reinstatement of heroin-seeking after a long period of abstinence in rats. | The European journal of neuroscience 20030401 |
| Pre-exposure to the cannabinoid receptor agonist CP 55940 enhances morphine behavioral sensitization and alters morphine self-administration in Lewis rats. | European journal of pharmacology 20030328 |
| Pharmacological characterisation of cannabinoid receptors inhibiting interleukin 2 release from human peripheral blood mononuclear cells. | European journal of pharmacology 20030319 |
| Regulation of extracellular signal-regulated kinase by cannabinoids in hippocampus. | The Journal of neuroscience : the official journal of the Society for Neuroscience 20030315 |
| Prostaglandin E2 attenuates SR141716A-precipitated withdrawal in tetrahydrocannabinol-dependent mice. | Brain research 20030314 |
| Cannabinoids inhibit gap junctional intercellular communication and activate ERK in a rat liver epithelial cell line. | International journal of cancer 20030310 |
| Contribution of endocannabinoids in the endothelial protection afforded by ischemic preconditioning in the isolated rat heart. | Life sciences 20030307 |
| Effects of cannabinoids on lithium-induced conditioned rejection reactions in a rat model of nausea. | Psychopharmacology 20030301 |
| Compounds acting at the endocannabinoid and/or endovanilloid systems reduce hyperkinesia in a rat model of Huntington's disease. | Journal of neurochemistry 20030301 |
| Anandamide-induced depressor effect in spontaneously hypertensive rats: role of the vanilloid receptor. | Hypertension (Dallas, Tex. : 1979) 20030301 |
| Cannabinoid receptor-independent inhibition by cannabinoid agonists of the peripheral 5-HT3 receptor-mediated von Bezold-Jarisch reflex. | British journal of pharmacology 20030301 |
| Direct and indirect interactions between cannabinoid CB1 receptor and group II metabotropic glutamate receptor signalling in layer V pyramidal neurons from the rat prefrontal cortex. | The European journal of neuroscience 20030301 |
| 'One-trial sensitization' to the anxiolytic-like effects of cannabinoid receptor antagonist SR141716A in the mouse elevated plus-maze. | The European journal of neuroscience 20030301 |
| Cannabinoid-induced Fos expression within A10 dopaminergic neurons. | Brain research 20030214 |
| Synthesis, structure-activity relationship, and evaluation of SR141716 analogues: development of central cannabinoid receptor ligands with lower lipophilicity. | Journal of medicinal chemistry 20030213 |
| Functional consequences of the acute administration of the cannabinoid receptor antagonist, SR141716A, in cannabinoid-naive and -tolerant animals: a quantitative 2-[14C]deoxyglucose study. | Brain research 20030207 |
| Milk intake and survival in newborn cannabinoid CB1 receptor knockout mice: evidence for a 'CB3' receptor. | European journal of pharmacology 20030207 |
| Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice. | American journal of physiology. Regulatory, integrative and comparative physiology 20030201 |
| Cannabinoid influences on palatability: microstructural analysis of sucrose drinking after delta(9)-tetrahydrocannabinol, anandamide, 2-arachidonoyl glycerol and SR141716. | Psychopharmacology 20030201 |
| Endogenous cannabinoids: a new target in the treatment of obesity. | American journal of physiology. Regulatory, integrative and comparative physiology 20030201 |
| Endocannabinoids induce ileitis in rats via the capsaicin receptor (VR1). | The Journal of pharmacology and experimental therapeutics 20030201 |
| Effects of CB1 cannabinoid receptor modulating compounds on the hyperkinesia induced by high-dose levodopa in the reserpine-treated rat model of Parkinson's disease. | Movement disorders : official journal of the Movement Disorder Society 20030201 |
| Activation of capsaicin-sensitive primary sensory neurones induces anandamide production and release. | Journal of neurochemistry 20030201 |
| The CB1 receptor antagonist SR141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: implications for therapeutic actions. | British journal of pharmacology 20030201 |
| Tricyclic pyrazoles. Part 1: synthesis and biological evaluation of novel 1,4-dihydroindeno[1,2-c]pyrazol-based ligands for CB1and CB2 cannabinoid receptors. | Bioorganic & medicinal chemistry 20030117 |
| The effects of delta9-tetrahydrocannabinol physical dependence on brain cannabinoid receptors. | European journal of pharmacology 20030117 |
| Concentration-dependent dual effect of anandamide on sensory neuropeptide release from isolated rat tracheae. | Neuroscience letters 20030116 |
| Cannabinoids ablate release of TNFalpha in rat microglial cells stimulated with lypopolysaccharide. | Glia 20030115 |
| R+-methanandamide inhibits tracheal response to endogenously released acetylcholine via capsazepine-sensitive receptors. | European journal of pharmacology 20030110 |
| Antiemetic and motor-depressive actions of CP55,940: cannabinoid CB1 receptor characterization, distribution, and G-protein activation. | European journal of pharmacology 20030110 |
| Differential distribution of functional cannabinoid CB1 receptors in the mouse gastroenteric tract. | European journal of pharmacology 20030110 |
| Effects of cannabinoid receptor ligands on psychosis-relevant behavior models in the rat. | Psychopharmacology 20030101 |
| Modulation of anxiety through blockade of anandamide hydrolysis. | Nature medicine 20030101 |
| Inhibition of interleukin-8 release in the human colonic epithelial cell line HT-29 by cannabinoids. | European journal of pharmacology 20030101 |
| A peripheral cannabinoid mechanism suppresses spinal fos protein expression and pain behavior in a rat model of inflammation. | Neuroscience 20030101 |
| Selective activation of cannabinoid CB(2) receptors suppresses spinal fos protein expression and pain behavior in a rat model of inflammation. | Neuroscience 20030101 |
| Pharmacophores for ligand recognition and activation/inactivation of the cannabinoid receptors. | Current pharmaceutical design 20030101 |
| Modulation of electrically evoked acetylcholine release through cannabinoid CB1 receptors: evidence for an endocannabinoid tone in the human neocortex. | Neuroscience 20030101 |
| Potential role of the cannabinoid receptor CB1 in rapid eye movement sleep rebound. | Neuroscience 20030101 |
| Tolerance to the memory disruptive effects of cannabinoids involves adaptation by hippocampal neurons. | Hippocampus 20030101 |
| Cannabinoid agonists and antagonists modulate lithium-induced conditioned gaping in rats. | Integrative physiological and behavioral science : the official journal of the Pavlovian Society 20030101 |
| In vivo imaging of the brain cannabinoid receptor. | Chemistry and physics of lipids 20021231 |
| Discriminative stimulus effects of BAY 38-7271, a novel cannabinoid receptor agonist. | European journal of pharmacology 20021220 |
| Endogenous cannabinoid, anandamide, acts as a noncompetitive inhibitor on 5-HT3 receptor-mediated responses in Xenopus oocytes. | Synapse (New York, N.Y.) 20021201 |
| SR-141716A-induced stimulation of locomotor activity. A structure-activity relationship study. | Pharmacology, biochemistry, and behavior 20021201 |
| Tolerance to the disruptive effects of Delta(9)-THC on learning in rats. | Pharmacology, biochemistry, and behavior 20021201 |
| The endocannabinoid system and the molecular basis of paralytic ileus in mice. | FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20021201 |
| N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716A) interaction with LYS 3.28(192) is crucial for its inverse agonism at the cannabinoid CB1 receptor. | Molecular pharmacology 20021201 |
| Design, expression, and characterization of a synthetic human cannabinoid receptor and cannabinoid receptor/ G-protein fusion protein. | The journal of peptide research : official journal of the American Peptide Society 20021201 |
| Effects of pharmacological manipulations of cannabinoid receptors on severity of dystonia in a genetic model of paroxysmal dyskinesia. | European journal of pharmacology 20021115 |
| Interactions between the CB1 receptor agonist Delta 9-THC and the CB1 receptor antagonist SR-141716 in rats: open-field revisited. | Pharmacology, biochemistry, and behavior 20021101 |
| Anandamide induces cough in conscious guinea-pigs through VR1 receptors. | British journal of pharmacology 20021101 |
| A peripheral mechanism for CB1 cannabinoid receptor-dependent modulation of feeding. | The Journal of neuroscience : the official journal of the Society for Neuroscience 20021101 |
| Evidence for a physiological role of endocannabinoids in the modulation of seizure threshold and severity. | European journal of pharmacology 20021011 |
| Effect of chronic administration of R-(+)-[2,3-Dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone mesylate (WIN55,212-2) or delta(9)-tetrahydrocannabinol on cannabinoid receptor adaptation in mice. | The Journal of pharmacology and experimental therapeutics 20021001 |
| Inhibition of improgan antinociception by the cannabinoid (CB)(1) antagonist N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716A): lack of obligatory role for endocannabinoids acting at CB(1) receptors. | The Journal of pharmacology and experimental therapeutics 20021001 |
| Cannabinoid receptor agonism inhibits transient lower esophageal sphincter relaxations and reflux in dogs. | Gastroenterology 20021001 |
| The effects of genetic and pharmacological blockade of the CB1 cannabinoid receptor on anxiety. | The European journal of neuroscience 20021001 |
| Delta(9)-tetrahydrocannabinol decreases extracellular GABA and increases extracellular glutamate and dopamine levels in the rat prefrontal cortex: an in vivo microdialysis study. | Brain research 20020906 |
| SR141716, a central cannabinoid (CB(1)) receptor antagonist, blocks the motivational and dopamine-releasing effects of nicotine in rats. | Behavioural pharmacology 20020901 |
| Effects of anandamide on embryo implantation in the mouse. | Life sciences 20020823 |
| Modulation of gastric emptying and gastrointestinal transit in rats through intestinal cannabinoid CB(1) receptors. | European journal of pharmacology 20020816 |
| Endocannabinoids are implicated in the infarct size-reducing effect conferred by heat stress preconditioning in isolated rat hearts. | Cardiovascular research 20020815 |
| Contrasting effects of WIN 55212-2 on motility of the rat bladder and uterus. | The Journal of neuroscience : the official journal of the Society for Neuroscience 20020815 |
| Memory impairment following combined exposure to delta(9)-tetrahydrocannabinol and ethanol in rats. | European journal of pharmacology 20020809 |
| Dose-dependent effects of Delta9-tetrahydrocannabinol on rates of local cerebral glucose utilization in rat. | Synapse (New York, N.Y.) 20020801 |
| Delta(9)-tetrahydrocannabinol-induced apoptosis in the thymus and spleen as a mechanism of immunosuppression in vitro and in vivo. | The Journal of pharmacology and experimental therapeutics 20020801 |
| The endogenous cannabinoid system controls extinction of aversive memories. | Nature 20020801 |
| Evidence for functional CB1 cannabinoid receptor expressed in the rat thyroid. | European journal of endocrinology 20020801 |
| The role of gap junctions in mediating endothelium-dependent responses to bradykinin in myometrial small arteries isolated from pregnant women. | British journal of pharmacology 20020801 |
| Role of the endocannabinoid system in MDMA intracerebral self-administration in rats. | British journal of pharmacology 20020801 |
| Involvement of the opioid system in the anxiolytic-like effects induced by Delta(9)-tetrahydrocannabinol. | Psychopharmacology 20020801 |
| Pharmacological activity of fatty acid amides is regulated, but not mediated, by fatty acid amide hydrolase in vivo. | The Journal of pharmacology and experimental therapeutics 20020701 |
| Characterization of the diarylether sulfonylester (-)-(R)-3-(2-hydroxymethylindanyl-4-oxy)phenyl-4,4,4-trifluoro-1-sulfonate (BAY 38-7271) as a potent cannabinoid receptor agonist with neuroprotective properties. | The Journal of pharmacology and experimental therapeutics 20020701 |
| Blockade of cannabinoid CB(1) receptor function protects against in vivo disseminating brain damage following NMDA-induced excitotoxicity. | Journal of neurochemistry 20020701 |
| Antinociceptive, behavioural and neuroendocrine effects of CP 55,940 in young rats. | Brain research. Developmental brain research 20020630 |
| Synthesis and structure-activity relationships of amide and hydrazide analogues of the cannabinoid CB(1) receptor antagonist N-(piperidinyl)- 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716). | Journal of medicinal chemistry 20020620 |
| Boosting effect of morphine on alcohol drinking is suppressed not only by naloxone but also by the cannabinoid CB1 receptor antagonist, SR 141716. | European journal of pharmacology 20020607 |
| Anandamide-induced vasorelaxation in rabbit aortic rings has two components: G protein dependent and independent. | American journal of physiology. Heart and circulatory physiology 20020601 |
| Evaluation of CB1 receptor knockout mice in the Morris water maze. | The Journal of pharmacology and experimental therapeutics 20020601 |
| The effect of cannabinoids on capsaicin-evoked calcitonin gene-related peptide (CGRP) release from the isolated paw skin of diabetic and non-diabetic rats. | Neuropharmacology 20020601 |
| Reversal of cannabinoids (delta9-THC) by the benzoflavone moiety from methanol extract of Passiflora incarnata Linneaus in mice: a possible therapy for cannabinoid addiction. | The Journal of pharmacy and pharmacology 20020601 |
| Cannabinoids inhibit excitatory inputs to neurons in the shell of the nucleus accumbens: an in vivo electrophysiological study. | The European journal of neuroscience 20020601 |
| Inhibition of GABAergic neurotransmission in the ventral tegmental area by cannabinoids. | The European journal of neuroscience 20020601 |
| The cannabinoid agonist DALN positively modulates L-type voltage-dependent calcium-channels in N18TG2 neuroblastoma cells. | Brain research. Molecular brain research 20020530 |
| Cannabinoid receptor antagonism and inverse agonism in response to SR141716A on cAMP production in human and rat brain. | European journal of pharmacology 20020517 |
| Blockade by the cannabinoid CB(1) receptor antagonist, SR 141716, of alcohol deprivation effect in alcohol-preferring rats. | European journal of pharmacology 20020517 |
| Delta(9)-tetrahydrocannabinol increases endogenous extracellular glutamate levels in primary cultures of rat cerebral cortex neurons: involvement of CB(1) receptors. | Journal of neuroscience research 20020515 |
| Presynaptic cannabinoid sensitivity is a major determinant of depolarization-induced retrograde suppression at hippocampal synapses. | The Journal of neuroscience : the official journal of the Society for Neuroscience 20020515 |
| Effect of opioid and cannabinoid receptor antagonism on orphanin FQ-induced hyperphagia in rats. | European journal of pharmacology 20020510 |
| Attenuation of nerve growth factor-induced visceral hyperalgesia via cannabinoid CB(1) and CB(2)-like receptors. | Pain 20020501 |
| [Increase of the heart arrhythmogenic resistance and decrease of the myocardial necrosis zone during activation of cannabinoid receptors]. | Rossiiskii fiziologicheskii zhurnal imeni I.M. Sechenova 20020501 |
| Cannabinoid CB(1) receptor blockade enhances the protective effect of melanocortins in hemorrhagic shock in the rat. | European journal of pharmacology 20020419 |
| Interaction between vanilloid and glutamate receptors in the central modulation of nociception. | European journal of pharmacology 20020329 |
| Arvanil-induced inhibition of spasticity and persistent pain: evidence for therapeutic sites of action different from the vanilloid VR1 receptor and cannabinoid CB(1)/CB(2) receptors. | European journal of pharmacology 20020329 |
| Molecular interaction of the antagonist N-(piperidin-1-yl)-5-(4-chlorophenyl)-1- (2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide with the CB1 cannabinoid receptor. | Journal of medicinal chemistry 20020328 |
| Role of CB1 and CB2 receptors in the inhibitory effects of cannabinoids on lipopolysaccharide-induced nitric oxide release in astrocyte cultures. | Journal of neuroscience research 20020315 |
| The cannabinoid CB1 receptor mediates retrograde signals for depolarization-induced suppression of inhibition in cerebellar Purkinje cells. | The Journal of neuroscience : the official journal of the Society for Neuroscience 20020301 |
| Effect of the cannabinoid receptor ligand, WIN 55,212-2, on superoxide anion and TNF-alpha production by human mononuclear cells. | International immunopharmacology 20020301 |
| SR 141716A prevents delta 9-tetrahydrocannabinol-induced spatial learning deficit in a Morris-type water maze in mice. | Progress in neuro-psychopharmacology & biological psychiatry 20020201 |
| Effect of the enzyme inhibitor, phenylmethylsulfonyl fluoride, on the IOP profiles of topical anandamides. | Investigative ophthalmology & visual science 20020201 |
| Motivational effects of cannabinoids are mediated by mu-opioid and kappa-opioid receptors. | The Journal of neuroscience : the official journal of the Society for Neuroscience 20020201 |
| CB(1) receptor antagonist SR141716A inhibits Ca(2+)-induced relaxation in CB(1) receptor-deficient mice. | Hypertension (Dallas, Tex. : 1979) 20020201 |
| Evaluation of the reinforcing effects of the cannabinoid CB1 receptor antagonist, SR141716, in rhesus monkeys. | European journal of pharmacology 20020125 |
| The potent emetogenic effects of the endocannabinoid, 2-AG (2-arachidonoylglycerol) are blocked by delta(9)-tetrahydrocannabinol and other cannnabinoids. | The Journal of pharmacology and experimental therapeutics 20020101 |
| Endogenous cannabinoids: a new system involved in the homeostasis of arterial pressure in experimental cirrhosis in the rat. | Gastroenterology 20020101 |
| CB(1) receptor antagonist SR141716A increases capsaicin-evoked release of Substance P from the adult mouse spinal cord. | British journal of pharmacology 20020101 |
| Reversal of SR 141716A-induced head-twitch and ear-scratch responses in mice by delta 9-THC and other cannabinoids. | Pharmacology, biochemistry, and behavior 20020101 |
| Reversal of delta 9-THC hyperphagia by SR141716 and naloxone but not dexfenfluramine. | Pharmacology, biochemistry, and behavior 20020101 |
| Rimonabant. SR 141716, SR 141716a. | Drugs in R&D 20020101 |
| Cannabinoids attenuate depolarization-dependent Ca2+ influx in intermediate-size primary afferent neurons of adult rats. | Neuroscience 20020101 |
| Control by the endogenous cannabinoid system of ras oncogene-dependent tumor growth. | FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20011201 |
| Inhibition of rat C6 glioma cell proliferation by endogenous and synthetic cannabinoids. Relative involvement of cannabinoid and vanilloid receptors. | The Journal of pharmacology and experimental therapeutics 20011201 |
| Selective cannabinoid CB1 receptor activation inhibits spinal nociceptive transmission in vivo. | Journal of neurophysiology 20011201 |
| Effects of the cannabinoid receptor antagonist SR 141716, alone and in combination with dexfenfluramine or naloxone, on food intake in rats. | Psychopharmacology 20011201 |
| Characteristics of learning and memory impairment induced by delta9-tetrahydrocannabinol in rats. | Japanese journal of pharmacology 20011201 |
| Activity of SR141716 on post-reinforcement pauses in operant responding for sucrose reward in rats. | Behavioural pharmacology 20011201 |
| Cannabinoid CB(1) receptor expression, activation and detection of endogenous ligand in trabecular meshwork and ciliary process tissues. | European journal of pharmacology 20011123 |
| Effects of the cannabinoid receptor agonist CP 55,940 and the cannabinoid receptor antagonist SR 141716 on intracranial self-stimulation in Lewis rats. | Life sciences 20011121 |
| Rapid tolerance to Delta(9)-tetrahydrocannabinol and cross-tolerance between ethanol and Delta(9)-tetrahydrocannabinol in mice. | European journal of pharmacology 20011116 |
| Exogenous anandamide protects rat brain against acute neuronal injury in vivo. | The Journal of neuroscience : the official journal of the Society for Neuroscience 20011115 |
| The cannabinoid receptor antagonist SR 141716 prevents acquisition of drinking behavior in alcohol-preferring rats. | European journal of pharmacology 20011102 |
| Inhibitory effect of palmitoylethanolamide on gastrointestinal motility in mice. | British journal of pharmacology 20011101 |
| Anandamide-induced relaxation of sheep coronary arteries: the role of the vascular endothelium, arachidonic acid metabolites and potassium channels. | British journal of pharmacology 20011101 |
| Anandamide administration into the ventromedial hypothalamus stimulates appetite in rats. | British journal of pharmacology 20011101 |
| Effects of cannabinoids on adrenaline release from adrenal medullary cells. | British journal of pharmacology 20011101 |
| The cannabinoid CB1 receptor antagonist SR 141716A reverses the antiemetic and motor depressant actions of WIN 55, 212-2. | European journal of pharmacology 20011026 |
| Cannabinoid receptor agonist WIN 55,212-2 inhibits rat cortical dialysate gamma-aminobutyric acid levels. | Journal of neuroscience research 20011015 |
| Interaction of anandamide with the M(1) and M(4) muscarinic acetylcholine receptors. | Brain research 20011005 |
| Cannabinoids inhibit nitric oxide production in bone marrow derived feline macrophages. | Veterinary immunology and immunopathology 20011001 |
| Cannabinoid CB1-receptor mediated regulation of gastrointestinal motility in mice in a model of intestinal inflammation. | British journal of pharmacology 20011001 |
| Cannabinoid activity curtails cocaine craving. | Nature medicine 20011001 |
| A cannabinoid mechanism in relapse to cocaine seeking. | Nature medicine 20011001 |
| Mechanisms of anandamide-induced vasorelaxation in rat isolated coronary arteries. | British journal of pharmacology 20011001 |
| Assessment of the role of CB1 receptors in cannabinoid anticonvulsant effects. | European journal of pharmacology 20010928 |
| Opioid and cannabinoid modulation of precipitated withdrawal in delta(9)-tetrahydrocannabinol and morphine-dependent mice. | The Journal of pharmacology and experimental therapeutics 20010901 |
| Cannabinoids attenuate capsaicin-evoked hyperalgesia through spinal and peripheral mechanisms. | Pain 20010901 |
| Neuroprotection by Delta9-tetrahydrocannabinol, the main active compound in marijuana, against ouabain-induced in vivo excitotoxicity. | The Journal of neuroscience : the official journal of the Society for Neuroscience 20010901 |
| Effects of chronic Delta(9)-tetrahydrocannabinol treatment on hippocampal extracellular acetylcholine concentration and alternation performance in the T-maze. | Neuropharmacology 20010901 |
| A possible role of lipoxygenase in the activation of vanilloid receptors by anandamide in the guinea-pig bronchus. | British journal of pharmacology 20010901 |
| Differential effects of anandamide on acetylcholine release in the guinea-pig ileum mediated via vanilloid and non-CB1 cannabinoid receptors. | British journal of pharmacology 20010901 |
| Cannabinoid effects on anxiety-related behaviours and hypothalamic neurotransmitters. | Pharmacology, biochemistry, and behavior 20010901 |
| Effects of CB1 cannabinoid receptor blockade on ethanol preference after chronic ethanol administration. | Alcoholism, clinical and experimental research 20010901 |
| SR141716, a CB1 receptor antagonist, decreases the sensitivity to the reinforcing effects of electrical brain stimulation in rats. | Psychopharmacology 20010901 |
| Activation of the CB1 cannabinoid receptor protects cultured mouse spinal neurons against excitotoxicity. | Neuroscience letters 20010831 |
| The cannabinoid CB(1) receptor antagonist SR141716A increases norepinephrine outflow in the rat anterior hypothalamus. | European journal of pharmacology 20010831 |
| Modulation of cytokine responses in Corynebacterium parvum-primed endotoxemic mice by centrally administered cannabinoid ligands. | European journal of pharmacology 20010803 |
| The cannabinoid receptor agonist WIN 55,212-2 regulates glutamate transmission in rat cerebral cortex: an in vivo and in vitro study. | Cerebral cortex (New York, N.Y. : 1991) 20010801 |
| Inhibition of glioma growth in vivo by selective activation of the CB(2) cannabinoid receptor. | Cancer research 20010801 |
| (R)-methanandamide and Delta 9-THC as discriminative stimuli in rats: tests with the cannabinoid antagonist SR-141716 and the endogenous ligand anandamide. | Psychopharmacology 20010801 |
| Intravenous self-administration of the cannabinoid CB1 receptor agonist WIN 55,212-2 in rats. | Psychopharmacology 20010801 |
| Anandamide-induced sleep is blocked by SR141716A, a CB1 receptor antagonist and by U73122, a phospholipase C inhibitor. | Neuroreport 20010720 |
| CB1 receptor mediated analgesia from the Nucleus Reticularis Gigantocellularis pars alpha is activated in an animal model of neuropathic pain. | Brain research 20010720 |
| Functional interaction between opioid and cannabinoid receptors in drug self-administration. | The Journal of neuroscience : the official journal of the Society for Neuroscience 20010715 |
| Endogenously produced cannabinoids and liver cirrhosis. | Lancet (London, England) 20010707 |
| Hemodynamic effects of cannabinoids: coronary and cerebral vasodilation mediated by cannabinoid CB(1) receptors. | European journal of pharmacology 20010706 |
| Comparative characterization in the rat of the interaction between cannabinoids and opiates for their immunosuppressive and analgesic effects. | Journal of neuroimmunology 20010702 |
| Mechanisms of endocannabinoid inactivation: biochemistry and pharmacology. | The Journal of pharmacology and experimental therapeutics 20010701 |
| Endocannabinoids acting at vascular CB1 receptors mediate the vasodilated state in advanced liver cirrhosis. | Nature medicine 20010701 |
| Identification of two distinct vasodilator pathways activated by ATP in the mesenteric bed of the rat. | British journal of pharmacology 20010701 |
| Effects of cannabinoids on prefrontal neuronal responses to ventral tegmental area stimulation. | The European journal of neuroscience 20010701 |
| Delta 9-tetrahydrocannabinol-induced MAPK/ERK and Elk-1 activation in vivo depends on dopaminergic transmission. | The European journal of neuroscience 20010701 |
| The central cannabinoid receptor inactivation suppresses endocrine reproductive functions. | Biochemical and biophysical research communications 20010608 |
| The synthetic cannabinoid WIN55,212-2 attenuates hyperalgesia and allodynia in a rat model of neuropathic pain. | British journal of pharmacology 20010601 |
| Cannabinoid receptor agonist and antagonist effects on motor function in normal and 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP)-treated non-human primates. | Psychopharmacology 20010601 |
| Inhibition of peristaltic activity by cannabinoids in the isolated distal colon of mouse. | Life sciences 20010525 |
| Cannabinoids inhibit the formation of new synapses between hippocampal neurons in culture. | The Journal of neuroscience : the official journal of the Society for Neuroscience 20010515 |
| Cannabinoid receptor agonist-stimulated [35S]guanosine triphosphate gammaS binding in the brain of C57BL/6 and DBA/2 mice. | Journal of neuroscience research 20010515 |
| Delta9-tetrahydrocannabinol enhances cortical and hippocampal acetylcholine release in vivo: a microdialysis study. | European journal of pharmacology 20010511 |
| Critical role of the endogenous cannabinoid system in mouse pup suckling and growth. | European journal of pharmacology 20010511 |
| Cannabinoid CB(1) receptor agonists produce cerebellar dysfunction in mice. | The Journal of pharmacology and experimental therapeutics 20010501 |
| Presynaptic mechanisms underlying cannabinoid inhibition of excitatory synaptic transmission in rat striatal neurons. | The Journal of physiology 20010501 |
| The role of central and peripheral Cannabinoid1 receptors in the antihyperalgesic activity of cannabinoids in a model of neuropathic pain. | Pain 20010501 |
| The activity of anandamide at vanilloid VR1 receptors requires facilitated transport across the cell membrane and is limited by intracellular metabolism. | The Journal of biological chemistry 20010420 |
| Cannabinoid inhibition of capsaicin-sensitive sensory neurotransmission in the rat mesenteric arterial bed. | European journal of pharmacology 20010420 |
| Leptin-regulated endocannabinoids are involved in maintaining food intake. | Nature 20010412 |
| Effect of vanilloid drugs on gastrointestinal transit in mice. | British journal of pharmacology 20010401 |
| Blockade of effects of smoked marijuana by the CB1-selective cannabinoid receptor antagonist SR141716. | Archives of general psychiatry 20010401 |
| Cannabinoid antagonists: a treatment in search of an illness. | Archives of general psychiatry 20010401 |
| Reduction of opioid dependence by the CB(1) antagonist SR141716A in mice: evaluation of the interest in pharmacotherapy of opioid addiction. | British journal of pharmacology 20010401 |
| Pharmacological properties of cannabinoid receptors in the avian brain: similarity of rat and chicken cannabinoid1 receptor recognition sites and expression of cannabinoid2 receptor-like immunoreactivity in the embryonic chick brain. | Pharmacology & toxicology 20010401 |
| Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses. | Nature 20010329 |
| Spontaneous and precipitated withdrawal with a synthetic cannabinoid, WIN 55212-2. | European journal of pharmacology 20010323 |
| Inhibitory effects of SR141716A on G-protein activation in rat brain. | European journal of pharmacology 20010302 |
| Metabotropic and NMDA glutamate receptors participate in the cannabinoid-induced antinociception. | Neuropharmacology 20010301 |
| Novel pyrazole cannabinoids: insights into CB(1) receptor recognition and activation. | The Journal of pharmacology and experimental therapeutics 20010301 |
| Cannabinoid inhibition of the capsaicin-induced calcium response in rat dorsal root ganglion neurones. | British journal of pharmacology 20010301 |
| Cannabinoidergic and opioidergic inhibition of spinal reflexes in the decerebrated, spinalized rabbit. | Neuropharmacology 20010301 |
| Enhanced acetylcholine release in the hippocampus of cannabinoid CB(1) receptor-deficient mice. | British journal of pharmacology 20010301 |
| Pharmacological analysis of cannabinoid receptor activity in the rat vas deferens. | British journal of pharmacology 20010301 |
| 2-Arachidonoylglycerol, a candidate of endothelium-derived hyperpolarizing factor. | European journal of pharmacology 20010301 |
| Endogenous cannabinoid anandamide increases heart resistance to arrhythmogenic effects of epinephrine: role of CB(1) and CB(2) receptors. | Bulletin of experimental biology and medicine 20010301 |
| Cannabinoids and pain. | Current opinion in investigational drugs (London, England : 2000) 20010301 |
| Intracerebral self-administration of the cannabinoid receptor agonist CP 55,940 in the rat: interaction with the opioid system. | European journal of pharmacology 20010216 |
| Delta(9)-tetrahydrocannabinol and synthetic cannabinoids prevent emesis produced by the cannabinoid CB(1) receptor antagonist/inverse agonist SR 141716A. | Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20010201 |
| Endocannabinoids control spasticity in a multiple sclerosis model. | FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20010201 |
| Structure-activity relationship for the endogenous cannabinoid, anandamide, and certain of its analogues at vanilloid receptors in transfected cells and vas deferens. | British journal of pharmacology 20010201 |
| Regional differences in anandamide- and methanandamide-induced membrane potential changes in rat mesenteric arteries. | The Journal of pharmacology and experimental therapeutics 20010201 |
| delta(9)-Tetrahydrocannabinol increases nerve growth factor production by prostate PC-3 cells. Involvement of CB1 cannabinoid receptor and Raf-1. | European journal of biochemistry 20010201 |
| Human platelets bind and degrade 2-arachidonoylglycerol, which activates these cells through a cannabinoid receptor. | European journal of biochemistry 20010201 |
| Involvement of cannabinoids in the cardioprotection induced by lipopolysaccharide. | British journal of pharmacology 20010201 |
| Cannabinoid CB1-mediated inhibition of stress-induced gastric ulcers in rats. | Naunyn-Schmiedeberg's archives of pharmacology 20010201 |
| Effects of SR141716A on ethanol and sucrose self-administration. | Alcoholism, clinical and experimental research 20010201 |
| The endocannabinoid anandamide is a direct and selective blocker of the background K(+) channel TASK-1. | The EMBO journal 20010115 |
| Systemic and portal hemodynamic effects of anandamide. | American journal of physiology. Gastrointestinal and liver physiology 20010101 |
| CB1 cannabinoid receptor inhibits synaptic release of glutamate in rat dorsolateral striatum. | Journal of neurophysiology 20010101 |
| Cannabinoid CB1 receptor-mediated inhibition of acetylcholine release in the brain of NMRI, CD-1 and C57BL/6J mice. | Naunyn-Schmiedeberg's archives of pharmacology 20010101 |
| Synergistic efects of opioid and cannabinoid antagonists on food intake. | Psychopharmacology 20010101 |
| Precipitated cannabinoid withdrawal is reversed by Delta(9)-tetrahydrocannabinol or clonidine. | Pharmacology, biochemistry, and behavior 20010101 |
| Delta-9-tetrahydrocannabinol differentially suppresses cisplatin-induced emesis and indices of motor function via cannabinoid CB(1) receptors in the least shrew. | Pharmacology, biochemistry, and behavior 20010101 |
| Cannabinoid-induced motor incoordination through the cerebellar CB(1) receptor in mice. | Pharmacology, biochemistry, and behavior 20010101 |
| Conditioned place preference induced by the cannabinoid agonist CP 55,940: interaction with the opioid system. | Neuroscience 20010101 |
| [Antiarrhythmic properties of a cannabinoid (CB) receptor agonist]. | Eksperimental'naia i klinicheskaia farmakologiia 20010101 |
| Novel cannabinoid-sensitive receptor mediates inhibition of glutamatergic synaptic transmission in the hippocampus. | Neuroscience 20010101 |
| Cannabinoid-mediated inhibition of inducible nitric oxide production by rat microglial cells: evidence for CB1 receptor participation. | Advances in experimental medicine and biology 20010101 |
| Involvement of central and peripheral cannabinoid receptors in the regulation of heart resistance to arrhythmogenic effects of epinephrine. | Bulletin of experimental biology and medicine 20001101 |
| CB1 cannabinoid receptor-mediated cell migration. | The Journal of pharmacology and experimental therapeutics 20000701 |
| The anandamide transport inhibitor AM404 activates vanilloid receptors. | European journal of pharmacology 20000512 |
| Cannabinoid CB(1) receptors colocalize with tyrosine hydroxylase in cultured fetal mesencephalic neurons and their activation increases the levels of this enzyme. | Brain research 20000227 |
| Evidence that 2-arachidonoylglycerol but not N-palmitoylethanolamine or anandamide is the physiological ligand for the cannabinoid CB2 receptor. Comparison of the agonistic activities of various cannabinoid receptor ligands in HL-60 cells. | The Journal of biological chemistry 20000107 |
| HU-308: a specific agonist for CB(2), a peripheral cannabinoid receptor. | Proceedings of the National Academy of Sciences of the United States of America 19991207 |
| Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors. | Proceedings of the National Academy of Sciences of the United States of America 19991123 |
| The role of cannabinoid receptors in intestinal motility, defaecation and diarrhoea in rats. | European journal of pharmacology 19991112 |
| CB1 cannabinoid receptor agonist WIN 55,212-2 decreases intravenous cocaine self-administration in rats. | Behavioural brain research 19991001 |
| Dual intracellular signaling pathways mediated by the human cannabinoid CB1 receptor. | European journal of pharmacology 19990625 |
| The central cannabinoid receptor (CB1) mediates inhibition of nitric oxide production by rat microglial cells. | The Journal of pharmacology and experimental therapeutics 19990301 |
| Structure-activity relationships of pyrazole derivatives as cannabinoid receptor antagonists. | Journal of medicinal chemistry 19990225 |
| Effects of cannabinoids on prolactin and gonadotrophin secretion: involvement of changes in hypothalamic gamma-aminobutyric acid (GABA) inputs. | Biochemical pharmacology 19981115 |
| Delta9-tetrahydrocannabinol increases sequence-specific AP-1 DNA-binding activity and Fos-related antigens in the rat brain. | The European journal of neuroscience 19980501 |
| Comparative receptor binding analyses of cannabinoid agonists and antagonists. | The Journal of pharmacology and experimental therapeutics 19980401 |
| LY320135, a novel cannabinoid CB1 receptor antagonist, unmasks coupling of the CB1 receptor to stimulation of cAMP accumulation. | The Journal of pharmacology and experimental therapeutics 19980101 |
| Regulation of delta opioid receptors by delta9-tetrahydrocannabinol in NG108-15 hybrid cells. | Life sciences 19980101 |
| The cannabinoid receptor agonist WIN 55,212-2 reduces D2, but not D1, dopamine receptor-mediated alleviation of akinesia in the reserpine-treated rat model of Parkinson's disease. | Experimental neurology 19971101 |
| Regional differences in cannabinoid receptor/G-protein coupling in rat brain. | The Journal of pharmacology and experimental therapeutics 19970901 |
| Cannabinoid-induced hypotension and bradycardia in rats mediated by CB1-like cannabinoid receptors. | The Journal of pharmacology and experimental therapeutics 19970601 |
| delta 9-Tetrahydrocannabinol increases activity of tyrosine hydroxylase in cultured fetal mesencephalic neurons. | Journal of molecular neuroscience : MN 19970401 |
| Characterization of CB1 receptors on rat neuronal cell cultures: binding and functional studies using the selective receptor antagonist SR 141716A. | Journal of neurochemistry 19970101 |
| Characterisation of the rat cerebella CB1 receptor using SR141716A, a central cannabinoid receptor antagonist. | Neuroscience letters 19961213 |
| Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands. | The Journal of pharmacology and experimental therapeutics 19960901 |
| Structural features of the central cannabinoid CB1 receptor involved in the binding of the specific CB1 antagonist SR 141716A. | The Journal of biological chemistry 19960322 |
| Biochemical and pharmacological characterization of cannabinoid binding sites using [3H]SR141716A. | Neuroreport 19960227 |
| Characterization and distribution of binding sites for [3H]-SR 141716A, a selective brain (CB1) cannabinoid receptor antagonist, in rodent brain. | Life sciences 19960101 |
| Anandamide, an endogenous cannabinoid, inhibits Shaker-related voltage-gated K+ channels. | Neuropharmacology 19960101 |
| Activation of mitogen-activated protein kinases by stimulation of the central cannabinoid receptor CB1. | The Biochemical journal 19951201 |
| Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. | Molecular pharmacology 19950901 |
| SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. | FEBS letters 19940822 |
| Fasting induces CART down-regulation in the zebrafish nervous system in a cannabinoid receptor 1-dependent manner. | Molecular endocrinology (Baltimore, Md.) |